var title_f26_22_26976="Myelomeningocele";
var content_f26_22_26976=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Myelomeningocele at 36",
"    <sup>",
"     5/7th",
"    </sup>",
"    weeks of gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 201px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADJAgIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UpcUCvSvgx8Mf+Fiz6qbjVF0u0skjRZmTcJJ5W2xx9R1weRk9OOaAPNgpNOWJmUkY44xVq/s5rO8ntriJop4GMciH+FlOCPzFQjG0MjEt/EtK4hsVu0jhSyoCcbn4ANPns5oJljlUAt905yD9DUglEqMhGeMhj/WmkiRNqnaF5wxzz7UXGQmFwWHHy8GkEbk4xzVuURunmwsRLnDRnnn1pbRWluXPKkDGT2NFwIYrKSQgKUwepzwPrUx0q5Cbzs2ZwDnrVuPzIfMzETKRg7R8pH0qSWXzESMo5Bxnb29/ai4jPXS7hgSuwgd80Npdwqlm2BR3JrSQOUljt3MioQyAjBY9+amtZw8Tjyi7k5IJxj2ouBkjSbgsFLRAnkZbFOg0W5mchWiAH8TNgfyrRYNOwDqu9T8gB6/Wrhn3RKAhe5jGCByUH070XC5gro9yf4owewJOT+lLHot0+MGMZOOWxW9FKiYnEuJD8pyvP5dqhlCPdARyO6n5jz0NFwMQaVOXkXdGChwck8/TinDR7gjO+Hb/e3cfyrYkO7DIr7JGwA3XIp0sUaCQSmRcLww6A0rhcwv7LuCCQUOOOppX0q5SEysF8sHbuycZrWiuiCRlWI5Ynp9abNd4iWKR26ngfdwe9O4XMg6bOoBbYoIzkntTBZS+WrkoA3QE8mtF5A8ew7lGMKzf0phkOCj5AC7d2MkUXYFFLORw5UoQvU5oaykUMSycDJ5rRtojKMRfIw4DHhcVv6H4fi1CTfqd0LZQQTF3kUdxQBycOm3Eyhk27D0Ynip59CvIIhJJ5YBIAG7nmvVbaLS53ZbOB5YYlKbQMY/2se1ct4hl2YhT95s6ybcMaAOPOkXAkCFot3TG49fyp02i3MRAZos9wGPH14rWiZvO8wgsM5z71cDiUlfnODlnYdBSuFzmhpVwSdpjOOCcn/CpBol2SNvltn0bp9a6KPyRvljLLajgbj8xNSWBdJ0lboOUUfxfWmmBzMmiXccZdgmB6E5/lVS7sp7RkE6bd43L7iuwiuZDM6tkOxJA255+lQX9n9uhFsxzOuWRm4+b0ouM47FFPkRo3ZJFKupwQexptMBMUYpQMkCuy+GPg+Dxv8AETTfDX22S0iuzKDcCMOV2RO/TIznZjr3oA4zFFej/FD4d23g/RdE1O2vdRI1J5U+xapYGzuovLIG4puPynPHT8e3nOKAEoxS0YoATFGKWigBMUYpaMUAJijFLiigBMUUtFACYoxS44ooATFGKWigBKMUtHNACUUtFACYopaKAExRilooATFGKWigBMUUuKD0oAbRRRQAo616V4K+KWp+EfCUOi+H7Gyjn/tD7fNdXEazmVgAEAVlwu3aCCDnPIxXmy9atWciJKBMMxnr7UhHQ/ELXYvFPjDVNagsPsIvpfOMKuXCuQNxzgZy2T+Nc27B2O5fLkHHFaUV3HhobhQ0WcCReoHY1E4gjupEudxPZxzkdjQBRJQjKAo4HI7GhWUhWZeFPOD1qW6QPIzIwfaOoHUetVwpwcjGOfegY9GxLkBtxPArT09QZLrzmZUx8wx3+lZ0s3mohP8ArlOMjjipVuZGR3lwScKT3pAXWuZ92XYsIhgvjnbQsiC0aW3dxJ/FuOCagnmLwtEj5QAfdPX60/dG8MAkcIufm4yCKBFpUeePKuqBRkqp2sD7URMs0YZmJ2na2Dgg+tVb2LzJB5B+VVyOeD9KdHOY7QJKrKSPlYAcn0NIC1PCYpImG5kJyppsDSxGWVl+aU43rzio5b2dREfmO0ckjqPSpYocStunYRkb1UdvrTAfAyiJgSPOc43Z7VHc/uwFIYY6E9/eooYWlll3sSeSpXjJ+lPUmOzRW/ec5Ixlh7UATIXeyLSFpFJzkdqbHczTviY4RBwG9PYVLBMI4mXq5HykcY9iKr3EeZVYkAAc4NDEiskrRo0MYPyktkdT7UCZrlwxXdJjoRjaPao4hliUbYFPysKsMdtwFjkByMnaMc0DI3aPOD8+0c5HGPSljJcOoyS33R6D3o81jI8rIu9cDbng0QBnHlhQod88dW9vpQBZgjRn8vzVUdCwOcewrS1K4lhliijYjCBM7eQP8au+D/DrXN1vlcW9lHKC87cqD6YroLi90pL6aJVWXMu15WGQfQj/AApgZdpNdadpguTujzlY8d/UmueeRiu5mZ8nk9TXVeLTJa2iW6TK0Od0bDqAa5S3TZKwRuMHPpSATa0OHh5C9/Wt1YEh0Xz543WWRuDjgrWZHultUiAxzzjkiun1Rzp3hlbS4jkeWXDI7/wj0UU7AcpFGHjWPziYw2dvrU8iSeaZ0+RgMhR0Aotoja4xgrkEtjOKJ52OoSMT+62Y5PFACW2YHllYuHHzBzyfwoEu5Wk+YFjkP3pwuWngMMpCxxjhx1PsKrzglY1UjYOAKQGXr9uGb7XGOpxL9fWsU11LBEjlEp/dn5MYzuzXO3tu1rO0T9uQfUU0CIom2uDx0xzXTfDPxbJ4G8cab4jitFvXsvMxA0mwPvieP72DjG/PTtXLGl7UxnoPjr4jDxH4WsvDthpH9naZb3ZvW869lvJXlK7OJJOVXB+6OM815/SClpAFJmil7UAGKKSgUALSUUtAAOlJmiigAo9aMe1ByKAD60UoBbAAJNaunaRJOwZxx6YqZSUVdlRi5OyK9jpz3QyDgV0Fh4cDEBiOfUVuaVpgjhUsAAOea1onjhOMjHpXmV8Y9onp0MGrXkcfrHhkwRF1YZHoK5Z4HRyhHNetT3ENxEVlOBXH39ijXLMuKMNi5bTKxGEja8Tk0hZ2I6EVPBZMzHd2rYhtgs5JI9+KkCLHvYMOe2K65V+xyLDrqYTWjbzjpStZMOhyK1yV55HNWI1UpxjNJ15IfsIs5mSFkJBFR4roLqIE9BWXcWxUkg1tCqpbmU6Ntil0oqRo2Hao8VruYNNbi0hpc0hoENooopgOTrTqavWnHpSEx6SFAMYyOn+FI0rkgk/d6D0pAfl7UirnPI49aARKzI3zITGD1HWg4dVLEsVGBjvTYmIk524PBzSRsqqwwcnofSgYgKjBPI7inFCy5B/4DRvzAAFUFTye5pqAZyWH0oAkiwSSzYYCpExOYvuhgcY6ZqOORllDHBPTpmpAFVSAF3kc57GkBJcNMgAlfgHA29RU6EsonkZXK/8ALPOD9frVRc7xnkkVYWBmRWbbjPHXOaBEglcW5jd9+87kGORT3V/NBLDyscsB932pIomO9EH7wHn0H0Nb2jeH77VDCLaIt23Lz+dAjJYQjyHjfk8Fqj2NbBWEpOXOBj7wr1bTPhsIdRtrTXJlgjuCFzGMmM+p7V2kvwRt20976HXLa6t4m8spxux/sn1oGfPu/wAuRCFILnGCvAps1mSjsJUM6HO3OOK9w1/4Z2+l2oc3LNZoM+ZKBx78VVsPh/basIZLaF2soCEublAFLg9xmm0B4j5IDhlKqQO3c0xUKRsFH73qSf5CvZ9a+FMdvd7dKmkuInfbEj4Dqff2rhPE/hHUfDt0qakgKEnaY/mBpBc5EAJcDzh8hGTgcVZgiWS5jWNSUc5XJxtqZ7Ygh/lMXRVJyQamQMpRgcFfvYHP5UAW9Uuy+2ODeka8Mm7gkd6bYRG41CCKIGTzHBJ7A+5rS0rShql5JI7KABkc4BHf8a7nQF0vSfD2sGCFvPQCS2lKZCt6GmGxxPi6xubfUIvtLw7gMeXH2HvWdFCm4L5YbcctzU1/PcXVzK87o0gGRjpmobWeKPBnBI7YNAHUfD/RVv8AxEgvPlhT5ii/eKD0o+IniK31vVZIbWM/Z4CY488+WBxyR1qA3txY6UbxlXEgKRshxge9c413J9jCIsawZ3Mw6uaACCSaK3HmSbY923J/iFCJDGczyAxyPzgcke1MUN5eNjMDzj+7RZExAo6xuzgjaf4aAH3UZtmeCNlEA6YGSPrQ1siybkyAqjJI4JpBG0jB4PnROHZ+Bmn3m5AtqJlm43tjt7UtgKeoN5Ug+zgFeCB2J9zWffqbu2+YqGjyUI5z6irnlOTNLIcRKMAdh9KqrHi+iZn3hRuKdhRcOpgnpRWnrke6c3KIiLIeVToDWZTGLSUE0UALSH0ooFABjilpOtHagAo7UUc0AFFKqs3QE/hVyzsZJHBZSAKUpKO41Ft2Q+ztmkwOfyrU/sxWAJ5qxbqsS993Sr0G5hhRXBUrO+h6FKirakNjoyF1IwAO+K6aGC2s49zMCR2FVLa3lMW7BFKbd5FIIOK4alWUtGzup0ow1SGXmptIdqAKtVoJWeX5icCrD2GwqW70yWEqdqjHvUrlWxbUnuF4V+UKeetZTliSQT+Vaot2Iy2SaFtMnpVRkokyg2YnkljnmnfZGYDg4+ldB9h2FWwdp74rSjsRKDgYxTliEthLD3ONOnurDKnnpxSNbtC2On4V3J07LqjqR6YqvqGhkx78H64qVi03qN4V9Dh5M85/lULRqc8/hit64050zuBFZs8YTOM11Qqp7HNOm1uZTQjB7Vn3MRVuM+9bLJzxmkNuJUAOd3piuqNXl3OeVNSRz5BA5Bpprbks/kOQeKzLqLyxn1NdEKikcs6TirlaiiitDIVetPAzn1pqjJpSCKQgxg0uRyCKSg0ALjgkUYPHv0oPHFJQA4Dkg4zmkAAIyOh5FIeefzoAyOBk0DJnCtKEiA+bGCTUgjbzHQ7Wkxt57/SoI9u7Dfd7e1TQh5GZUI3dcnigRPE4CxoVAZDyT3q+EaQsm4SMSCMVSkaThpYwM/KWBGDXS+FLNr+6t440jVA43F+mPekB0HhjwtJqWnSNLEIZQdylzjzR6A9M17ppdtoXh/RrZJIxFdmIStHtCbgPf1rivG1haaQNJ1PTLoNpwcR+Qj5G/vioviU/+m6dbxyqhlhEgV+Rz/WqA61PGujPqq3Ma20hWMkRvyAO+fetmz/sS+s4b77UrBnJhSJtvzHswHYV84SLbwTzxiUsyjd6Hd6Yqx4VhuZdcsUubiWztbmT/j4LYC/WkB9H65bWyWsNrqQFwl0h8uNCWBb0BrkvD2vw+FtP1k6wtwkZf93ZA7nGBweeoram03TLDQTFqmvG4s4v+Pa5H8DeoIryb4l3d/rN7YwRX8VykKcOo27l9TQIry/FG9kW7UWsHmXD7WlOQ4XPAGK1dO8S6dqUUOm6nFOIycs3BZj9TXmE9oFu1WBgxT5gW6E+9akMbi6iuZECAjbhDlT70bjPQvFPw3tYPDVvrWmTM9rdZaJgnQ9w1ecpYqrhTsEjA8g8E19SfB/wvquo+DUj193j0/zPMtYjzuU9/oa2b34P6NdrKBCkG9sK0QxtXuR70bAfJemNJCGEZVH2nezH730q+t/L/Z7Kshw427Qa+kH+AugGWBFmuDDHzuY/Mfas5vgRDJJfIkywwSMPLIGWUD0oA+W3gkMkgKkqpy5A6H096fZwGa4PmBVtlIO9xn9K+hfEPwjh0OwUXDfbJrpwgIO3Yo/izWjafA6IzBrS4eOxMQYiUZ3HHWgZ84a3JPK2xDm3HyjJ4x7Cs+CDMfmDd5UfyqOxNe++IPgU9tavfWOqxXFsqndvH8XoBXJ6j8JfE9hBbwTQwyQyruXY4G0HpmgR5ZBLLPKY1fajL91ehqyJAiBViGenXJz710eq+DdT0vUI7V7OZZsfNIBkEexqjdaNcQXAV4X8s4b5V4HuTQgMCbzfnMiZ24+RTwPwqeGECR3kJ3OMqh6gfSr4s2MkkigtA77VI65qZbB5BLOEHlxNtLt1PtSsBj3Vq4wruPJb5mQNk1WezuRIFghwXHy7uSBXeeG/DT31woMf7qUfI0gxn6CuusvCH2k28cFqZmVyZXLcBRTsB4fqFkIdPnJV5JFA3P2XkVz1fRnjXwfDbeAPE+p3SRq0UKG1hh4WMeagLH1OCa+cxQAUYpaTtQMWjNJSgZ46mgBKUAnoM1f07TpLmQblYJWv/ZcMQAw1ZTrRhoawoynqc2kTuQFU5rZ03QJrs/NlRV6O0RGHB4rSsrh4ceXuzXPUxLt7p0U8Kr+8Pt/DsNuAJGxioru2SJgkJyKvzPPIgZgeaksYo2lVZc8964HVm9ZM9BUYJWijKSzkyrEEA1rWlsEI4I9TWjKYYvkz0qMzR5wpyPU1jKs5bG0aKWpqhI1j9Biqc1xGEYJ1z1qo9xJ5oRWytEEbAEN1Y5rC3Vm6fRCSFpcBunapoIWkGCDgVeSzBdGAOMVpW1qFIBU4NRKokUoXMlbUfwg+tTw6cXXIBwK3lsfkHHPp7Vfs7MiIgg7awlXtsaqmc/Dp+VKEE45q5FZBCAoOTW79kCx7jkZOKjkiCjIJOKydZsrksVntomVBjLDvTLxQYDHjp3q3GUGeuaiutrRO2Du71HM7hY4fXIGDHAIGK5e4hbnIP1r0PV4POj3AduMVy13bFSRtP0r0sPWsrHJXp3OYkjI5weKauRzyGPWtae3yrEZ47VReHB716MaiaOGVOxDgMjAk1kazFstlbn74H6GtkxlSOuKzdfXFinX/AFg/ka3ov30c9aPuM5+iiivSPNHL1pf601etONIQvWkoHpS+vNACGikp204zQMCpyeMH0pwBA757AUoG/G5uMdaeUAIUbunQ9qAEhjbcGHI7gGpVtmVWkIYwjg4PIqRAiMY9jlsZyO1WIMwbRjzFbOMd/Y0hEMalmAjTcJBgKDkg/Suy0iM2Nq+5403py7cc+hHatbw34NjbRIdWcypfl8RRKvyke9YeqAfbZQsTo6/6yNxnn1poDb0vURJpzvqG8WgOVjAzhh3FVNU+26xay6msp3RceV1KKO9VoJCbNIvMEaSkDB6A/SuntLaJPDOtxGIPJhQGJ4X3yKBnO2EM+p2rX8rwTGCP5pehGOxqPT9R1W3sn1SxiUWG4xMXUNgn+6DXV/B/w7Z6mdRXULmARiFsWxyXkOOq461jeGtA1vUYLyz0+zZ9PtZy8nPUA9KBGhLqf2jwXb2d20zFpvMSPdtUfhVKea7mtFitm2wHiTegDf4163/Zdh4h0KW0utEFjeJEoRyQGAHcVveBfAGiaXO114hkS8VCjW7DnGOzepzQB5P4R+FOv6/9qMWlvAm0CKSbKLz355NfQngb4PaBomkWQ1SzjvNSjId5GJK7vYelW9f8cXtpCz2VlFHEkoVFZvmlHoB2rp9FudSvbZL29gNvHJGW8jPzD2xQBuIqpGFRVVFGABwAKz7vW9NsxKbq9gjEYyRuzgV5/wCL/GVnHHHBcPd6fbxEo6EY8w+nritvR18MzeSkLrL9rjC7X53e31oC50N1r1nBZR3ab5oXXcCi8AepPasDSPGUuoKpksxbN8x2sd25e2K1r1BplnFYwWEk1hJmNjHyUB9q43V/F76ZfzWek6VCzwJ8h2ZZVA6H0NAGV4w8Y6u+oQxvaR20cLF/JdNxlX1J7V0OmfFjw5PB5c1yttfJHk27HK8Ds3SuI1PxDqniHTnmvdOSGST5ZYejGMelT+BtF8G6ffi4uvLcou4I6ZVX9D6mgR6fpmpaLqOhhXuonjmHmyDlcHrU+h6xouvwyfYXilUHyyrDkgcflXiXjvxlcavrVzFo1i1tbwxGMFlx5w9BWF4b1S8sYfMedo5Y08yQxKSE9FJpDPpC+0qAWkkcFtHJPL8itIu7bnv9K5TxLo+hnQhbwQR3dxHKqbIx1fPTiuJ8F/ETxd4n8TQadptvAY41/fNIpIjT+8x9T2Fbuo64mj69f2MV+jM5E0ssSAIjf3R707MVyvb/AA/s5L+S3XS4BK22SWIfciJ6EnuadrPgnSopRZXixrbquWwME+wrRi1qTbIkUroLllkeY8szdhmotQ1FZfE25SbqdIt0sr8CNfRR0zQBRbSLmK2t3ewgsbWP5IEIy5HrViLSLLTtPuNrmJJAWdg3Pv8ASovEer3UOnQw3AaQzqXVYz87egzVd9Z0v+yoEdI2umjw1uXzs92oBnB+ObiKb4T+L3hk/wBGWFI1dhy7efHwDXyqK95+LGrXcmhanYxRJDppUGNR/F8684rwbtQhoKXFJS0DJIYWlIwDtrb03TBlS6nnnFRabEAmSp6Vswg5HXA71x1qzWiOyhRT1ZpwfZbOP7vbtVA5mmZgDjPFDRs2OuDV+ztsNjHNcLdtWz0FG+iI4LXeeRxV5bIIAQtXFtyigYrQdUW2CkfNiuadV9DohS7mc6KEUNwO1Zt2RGcqe9LqF3sk2joOMelUA0lx2JzThBvVkzklohzTuz85PpT4y5wAcGp7ax8zBYZFXYLD97tA4z1qpTitAjCT3JLCPeycZc1qW9vvYg/eBq3p1gomj/djGME1e+wNHN93k+9cFSqrnZThoMtFXZsI+bOK0/s4kxsBGD2qrZQhNxkHz54qzAzI2WPeuSbubpWLeCm044+tWopAUyOOaqySI+cDHHrUYmPArJ6lJGhcSCV1KggYwareWC7AHt0qFZSDgHmlVsuTzkcUkrAxj5V24qGdwHCHkEcipZCGJxms5yVJJBLGtIkjpVDoQAcds1mXlmrRlhnf35rSjJIz0NMuFCvkjg9R71vF2JaucncWToWLKRmsye354HNdsDC0TLJjPSsG8tlWQ7V4NddOqzmnTMCW2IHSsLxMu2xjGP8AloP5GuwMf7ogrg1zPjGLZp0R/wCmoH6GvQw071EjgxMLU2zj6KKK9s8QVetOpF606kIDzk55pKWkoACacWO3aTkdRTTx9algI3bWYAH1GaBj0jcKrjaQRzzV1pW+zwgAF1+8oXnHtUVtGskqrGpkIGDGB1rqPB3hXUNXuy1uhLxA4jfgke1IRTgMNyBGsPmyEfMVGGX6jvXaeCvDNlHdq2r29zOCuYggyPxHUCtTTtCt4JvIhQC4YbnJGXRhXdWt1fTWY1eApDcW48j97GEVx9femgJbXSb3VdFkeytPOab91apHIADjqpHrXlvjHwvqOj6oU1C2ubVyMkyLnj/e717D4fuLeyvNNuorpILoyl/IQHKsep9CK7PXb/SfEWlyWniWGdyuTHIifNn047UAfJ8MEa3qxTvvUAfOPevTv+EPuLDTHWxmWY3kHzc5UDGcGugTwRGumT/Y47e8iuzh2bG+AD0Ndb4Q8FebpEUljqmy9j+U283zKQKAPAfBdtNaa1bxRWsz4kMUnknDY7kele5+E9Jt7HQ54dMjna8kn/eSOmDtzyGNaVp4Fi0LxCdWB/d3BwcYALn09q6S53afEzI9vEkqnz4/M4f049aQHJX8aPqZu7dxiICJl2Zc+wPpS6TYapp199r1vS7ufSbh9lpaKw3LIf4n9qPD0NraeIJtXhlcGFd3kyjg+vH9a7OfxBpeuaba3t7c/Z7WRmEPlyZwy5++B344piOJe1tdc+J2maLfz+XDCpuzbg4w68hM969vaRfNEZO1uq5ON30r5rtPDWsax4rsdZ023liu1mMkUz5IKg4BP1rf8YfFTWdO1CTTZ9Gghu4SYDfqSwjJHJA9aBnq3jLwrZ+J9OMFyBHMudkqjkV4NYx2Phnxnp8V5dXrMt4kZkOdqnPGT0FdPoPxOupnj0ObdI8cQYXkWcv/ALx6V61aaXp2p6Ekd1p8JhuEDSRuoO4+po2Dc2Cy/KQSQ5wCOc1iXPh2zn1l9Q5zKoSVFOAcdzXmHxH8T6h4N8XW1np195Fk8IlIf51RRxtx2rE8N+MdWTVJr63lkhsJ9zKZjuWVvYHpQDOp+J/g+707T7zWfDf2i51Bl8tbfI2gevtgVzXghLWHwR/xMIhca5v3G1jIZyc9TWnpHxIn8S6hEslrcshVoPsCHiQ93Yj+Vc94m0pvCNlNqun2LpqLvlTyPKU/zoWojvdQ0Kz1LVdPtdJQeZNAXm3crBx0+uax/F9pZ+A4rdbgPdrcja820AJzjB7VlfB3X7m11FrjVSnmag4DyyNg7O2B2rvvHvibwxc6be6TqUsF0pXc7LhhERypJ/vZGaGMx7Szt/APh26FlbBb3V13q6nJBxxuPoM1ieFPDkGo3Nra30hnmtwZp5pPlTJ5/Gsrwr4kfX8f2lLJJPbSCMMejRDozenHavXrTQ9K1J/Pgz/Z7LtYZ2h2/wAKAPKdXPneIZtNgv1uDK2yBYSBFER3Y12vhY6P4d0+aPWL+C/1NnI2jB3H0Wsvxl4X0fQtSQwrFDBPG8k2eoA6YrzjWExaQo4EKxESQXKD5pM9F+tAHod/fWVwnlukMcgd33s/+pB7L6mvHNKe5PiySxheWSIMxBVMuwz0wOpNdebe70d49Qm0yOXVZU+UXchCxr6ketdN4L1Cw8Ksr3lmLjxRqQMryMoVEXsq+goCxxPxq8PW2m/Du8vr+1ktbqWJBbxsctnzFzux04zXy1X0p8fvGV5reh3NlqEUcO1MqAcsx3jt2FfNigsQB1oGIKv2VmzlWIzS2entIwJrpNNsTkDArnrVlFaHRRouTIbW3IUDHWtK2h+ZQRxV6GwYA9OKnW0fbuOMDrXlVK1z1adGxHHbrLKEVfrWjFaKrjAwRSaehjlB65PWtVyrR5IAbpXJOozrhDuVZSsEWWAJrF1O/EhOw8jrUms3bINoOKyLOMzSfMeKulTuuZk1J2fKhEiMz7iDg9TVmGBoycD6VpR26ouFwa0rSxE2CAMinOtYIUblPTY2PyFfmPatOCzdJgQpwa2LPSiE3hVz61q29kWYDAI71w1K6vodUKdlYz9Picw7lQlgcV0I07CRtty5GatabbJCCu0E5rXhjLRkKBkdK8+rW7G6VjnINJMrEr1zVi70E7QIwA4963LK3ZN7ZGc1dKgxmQgB+3vWDrMqx5hqyS2chVunt61USZjtbPI5rpfEdsZJGUrn+lchK5tztP0rroy51qS9DTSQ5DdQanR85wTms23uAy9RipEn2biSMmtHERZmm2k461TllOAD165pJ9xKknr1qvOSM569qqMRMtpJ84x3p18jeSX7HvWak21hk5q3cXYeIj0q2n0JuZzoyr0zmoWRmUgjmp2dmToAKRHRWGQDxzW8b2MmZs8I28HjPNcx45TbpMPH/LYD/wAdaunLAyP/AHQelcz48kVtMiC/89wf/HWrtwjftYnHi0vZSOFooor6I+dFWnCkXrTqQhKKXvR3oAF6Hb261d06xluyG2FoRwzAH5abY2jSuo6bzjP+NeqeBtG1KBEutM+zzxxv+/h2hsL7j0oGYfhnRBayxTQHdJn5gwyCPUGuun1KRmWKCU20sTApMjYwR6ird1qFvHqU1zp9utoucNCB8m7+8p7fSpJNLvHu0nvIVkhkG7ESBhIPqO9AjstM0g3XhKbVfs8g1bdvM8QwXI9R6GsWF1vNKu3uLyW3nf5XsGTAf12+9N0+/u1DWk13HFswIYGJAI9DWRr2txpqFu8QmVUbY0aru2H+960mB2fh2HStMazl0i6eScD547lTvTjkDNXtU13ZcLHbk295OdxFw2FA9RXDfa9RXWIbu6ljIIO05xvGOhHrVa6mj+xRxLua7lcsTNktGuaYWPUvC+sCPV5o55khlZRgbh5Uue4Har2rTJ4d1m2WOU2QLeb9pjG+MZ6g1wKpYNp9xIsHnvYIquxfbuz3BrU0fSrjWI9JtbqR00ydtyAtkE56MaAN7xdrF1f3iRPqyrb43o0kJTPuKtf2Hp/ivwnZWT6nJBcSyZt/KUl3Yf3j6VJ8SNOu7G9hgmiNxYNDtTbjdGR3HtV7wJ4pstJtiJ1je1RQgdcbkYdetAGb4y8OaxommwzLqRubgRBGiWLbgeu7oa4DwFf20OqHTl+03IaQvKu3AB9ga958X+M/DkXheWeTU7f98hEGRuO/HGRXzP4c8Q3R8Yw3lx5LT8+YF+VCPagLH2DHd2Vnp0Msk0cMIiBBkIU4x6V83/Gfxdo3ieeP7Lbp/okrKkoPMoIwWOO3pmsXx744uZ76E2ikxFTEdx3hc+lcfrLpZJBayyxXDgbwY2z17MBQM7Gx1nTHj0fTUYQwWjrJNJnJuBnJUkV69rXxj023srkaNayTfZwq+YcbB7Ad6+XYLqeG+W6trdESH5m3fcB9BVifxC/mJPCNsbf8fCxfdbNIR6Tr+vQeINYTWlMZ1GdPLjgbofqOlcxqMtxclbO5t2hu0cBESTCDPU1zLatJCkcEEDOeXAI+ZQfeqNndCOZrm4ldpd3MTE9KYH0T8NLqPwPp8quLS6knfJbzASp9Aa0vE/j1dWW40uaCCC72kx7xnI9R/wDXrxrwzr9vZ77i5s4Y7dmyBuJb8BXN6nrIutcnv18wRyMSF3YI9jmgLHXa+zadbRXjSxKnRYHfJbHfiuOWeS71K1vfNMVszfPCDyazNZ8Qz3jqk5UwxD5ERep9zVbStVa4kQxR4Yn7hGOPagD2HTrKG+eO+aeSwsllVbieNcZX0Hqa9H8bfEnR9PtrXR9HR5EhAkZx1XHQY9Sa880kSW3gi5vLmNnuLo7LeAgny/8Aax2rjp9d0ux0mWJ7OV79htkvJskA+oFAGpe+M73xRqfl6rdyNtmDyMV4CD+EDvXrfhO1ub/XoNRS2ju7eJB9nWcbUiwOoHr7186Wl0sd1Bcszm0xgTMNrflXoukXPiO8RLvTjNBp54HmSkNN747CgVj1DxVK2pR3Mlykct3FJudwQI4lXvn0FeP+JriXUpI9QtdRla8JJ88rj5R/dHYUnifxHM+mXGm28q7jlrqUE7BjsD3rlba9nv7S3ECOiImzz3bbkewoGV/FEv2nwrqMrI812EAlmmbkDevQepriLHT4/Ljcryygmux8Sq1p4T1GKBfOSXbucEnYAwP86rafY7obf5RzChH5CsMTPkhc6cLT552KlnYrnhRitrT7UDBwKu20AVMBRz1PpU0arCrZGa8KpWcj3adBRIvJ2ueMDNWVtg8blccjioXkJxnnJrTtgFiycYrmlJ7nQkZar5bhQMkcVLECwZTgsT1NOvFIkVl7mpI1DE8AE9DS5rq4zA8SweW8fAxj1rHsn2HB6dK6zWbMvAHY54rk9u12GBXZQmpQsclaLU7mxbMwYYPvXY6G0TQHdjNcFHLsCk1r2F8Ythzj2rCtBtaG9Oa6nqVjbLJEuenQCtWHTQxCpwp65rjtK1cuU2ntjGa7axuCzRuW+XAyK8atGUWdkWjYtLFI413qu/1p8sKIMKACaiS9TPLcA06W6SUA5AC1xN3L1IC370KgA9ab9lnd95Pyg9KmQoZAFALGt21RfJwwGaIq5M58quc1dWKeQ3nKCxHWvLfEUQjkcHAOcCvbNXt827sMDivCfGE7f2mynoDgGuvCxbqWIlUTjcz4XK8ZNXyfkBxxjisa2Jc9fatmJcRcnkCvSnGxMGX7cRvbDzOGFUL9gCxA4J4NWIIpGVWHK1UvlKZDjBHasktSnsZ7SAA9M0z7RiTn071G+SWI70y4OSMADArqijFstTT7YtoAxnNUjcfvMnmopJCI8dzx9KqknNaxgZSn2LDync5wMEYxXNeMH3abGPSYf+gtW7nK1zvi0/6FGBjHmj+RrswsbVYnJin+6kcpRRRXungjl606mr1pTSEL+NW7awllwWXah6E8ZqqowwyoPtmuj054TCgSRSDw0L9j/SkB0/g6zt55IbPUkRGc7Vk24Dfj2NdJeG30C4mh0x3S8UFTLGSCy/7Q/rWB4c1OMSNp19blJQd0bnv7Vv63oGtHZrVvGzQRr1GDt9j7UASaTbqbNZ9RQ3dlKD5ssUmHT3x3ps/ia6/swafphIigb926D5nX39DWNo2kajrEN3LbMkd23Hk7tvPqO1XNN0vUdJZob7TJZ72JfMBjOSB746imBHqLajcWi34aPC8nJ2vkVRa9uJwL6MzAHiRzxtNbl/PqVy8A+yGMTpkRGPj8PWrPh2xvdTn2izWezg5uY0XJA+nWgCjoesyW89xLehLzzE2oJhyPcGtvQdBt9cf7QL+Y30aFo4ydufbB61q6jp3hqHyZgkwgJ2pE8TYU+9dFY/8ACMNoMtrqim2dVJjuY859sGgDH8DWMGrTvZLIBcX26AySj90WHUH3r13RvhcyaTDbapqUpkg4i+zEoij6V4B5L6NYi2tbqQLLMJYgrcdfvg+tda3xG16yWJv7VmvrI4QySLtaIjr060ARfEe/8RaF4jl0lNRe4SHDIzj5vLPbJ/nXLXU1pBaefbyzmcsDc28pyk3vntSeMvFsms65m4eR4wnE7Jhif8K5aEsbieF5RlxksvpQB1Wta1ol7piRW9i8c8JBYx8BB/WuYu7R7FV1GFlurNz68j8KhtIrhrm4KyERKMExpkke4pZftlvDHdpPF5Aby8KAVx649aEMZrup2l4tv9gj8mPbhwSc59qz7eW/i1NG0+2y6j5jIAcCrGqLHc3JaZjJsTIaMBNvtjvVCO8VfLi+aF3OCSecfWgRc1e7mjuIYCG2ScyBumfwrMuZJhbvENixK3IHXH1puqmNbkqkrSZHBPrVaGMQ7ZFUzTY+dSeF96VwNS9vlSC1ktzJ5ifKrZx+Z71Wvo7neJ3nQofmbB5H0rPuYi4JclmzuDluF/Cn38oltEeRsS/dx0B96ANVLgR2Bltw+CP9Y7ZKmqdrNcahP5bhZinXA6e9PWMT2MTTOtvaRj5ueXP0qP7VcB1RMRWxHG3gfiaAHXVvM1wzwwkxx9cng0kNy1rchzD5Up6KRjI9q0rC8WzRmn8qVQPlHv8A1rJvb+AtNczEveg/u1I+VfpQB6DaeKLqC3hgRmiLjiMHt61y3iDULp5f9KC+Ru+RD8uffFYKX9w0sdy1w0bsPnbHJ+ntV26hM8i3LssqEcheWx680wL9ne2TyhHZi4Hyq33R9K7e31y5CQWEQmkh25KIcgD/AGjXl95dWsFyk0KssIGNndjUthrF5EjiJ/JhmOG57fzoA9DtraTX5pbSCJ5o4D5kzKAscYHq1ZEcws7iW5u5Xki3bYoE5AX69hWZpOu3MFvcWNv5vlt/yxU4VvdvWtuS506KzWS5Ri6r0UcFvTNAFvX4bX/hAtfu/Lm8yWBBFEgxHGPNTLE9z2qDRYS1pbtxjyI//QRXP63q8l74a1CGOZmQIN4z0G9eMVLZa29vHbrjKiJB/wCOiuPHJunZHdgGlU1Or+VBIn5VUuWAQj8TVNdYhuCpDBW75NSSSCQNllII9a+f5Wnqe+pJ7CwDzWHpWtEA0ew8Ed6zLZcEANWpCoWLNRNlxGzx7YDwCc5zipLWIMu48HFWfLDwrkYGKakZidRu4NZcxdhbu1/0dVfGAM1wmsweTcFhjBNek36ebDhOCBzXIalp7TAkdfcVeHq8stTOvDmjoc2nzSKD3H5VdiAWVVByarXdrLbtlhxSW0padST0Neg1zK6OOL5XZnR6RLJEwX3rutPvZFVVZvlIzXAW9wvnAAcV0lleoyBiwx0rzMRG530n2Ov+0jyyc5Ge1XrK48xvJdgFxnntXLrdqrL84Aq5BeKG3kjPrXnSpnSmjubcpuUqy4ArYinRccjGOtefw6jsIw3J6Cp21gkYLADp1rDkaehMoc25veJdYWG2chhgZyK8I8RXv2vUGZSOua7HxRq4Nsybhub3rzln3ys2frXp4Ck9Zs5azUUoI07EBih4xmughVZRsPUCsLTEJdQCMZrrrS3U3Kg45HNbVnY0hsaOn6cJLVGFYHiG3CXbLjtXeRKIbVYlxtPeue8StbQtvlZc4xiuKNR8xo1ocIIioIHUmmzwEJnv3qWS7DXIYY56e1PuJf3MgOM4r0U2YaGHONsmM1A+M5qQlpn461ItnIzds4rrWm5y7vQqtjacHtXO+KB/oMZ9ZB/I10tzbuoA461zvisAafEAf+Wo/ka6sK/3iObFL93I5SiiivbPDFXrUyRlhv27kH3gOoptunmShC23PetGC3MbSQzblkXlSoz+B9qTALe3juVjVlOAeXU8ge4rdsLDarQny5JAuY36MR6Ed6m0yDT76zY3DeTcgYBXj86pRTsjeRNgohyrbSCR6ilcRPa3Mck/2a7kNrMo/dyk5UV3WneM9X07R2tRew3agYlVk+8teZrceTdFrj9/bSH/AFinkVLPqojI8hmeMHG0jkj60wOlj1K7tr97rTmMan5klQFl+jCvVPD3jj7Po6atey28k6r5bbB19jXlHgjWX0+WeGGNJo5lJMc39M1VutYWKKe3NuySSScAfdA9x2oQztr/AMXSXOoNItw0tssnnRRov+qb/CussvHFnpsMV5bILi7uf+Pkx4jaP8OhryK9k0+SwhlgbZdRH5wnytj+tUGd7zZO6Si2B+ZkGMD3FAj2vWvHDmJYSYmtCd7SSRDJB9D61ysnilYbu6ihuGmtZuA/lBiQewHauWuIPtdujafexysnKxyHG4ehHrSwQXUsKm1XDL94EgKPpQBuTX9ilqIrGRjeIdwjlbI/Adqz4daS6SNZmVG58wrwFNYs0cEF4LhGK3GcNE/J+oNWFigmlmSO2uFaTmQKflPvQBJ/as8d8ZUWMRLwd53Fh/s1PearKu7ypUwfukRjkelP0OXSo9SSC/tRNCOAAORVrxZqPh9IfsulaZNayjkSlsg0AVtHt7hpZJZbxYHdPlVmxv8ArVWWefTLV5XeJH34LIdy/XFZWm6l9kvytyDM23OSN22opT9tEwtkfa5yfM4U/wCFAF1rxZ7kyS+XIdvzv0z74qoxtZZY1lVzs6FD0PqTVTUPtEUkETlN23pnoP60iuWfMSOsSDkg8N9aQGnrMEcFzBJHvYOnLsvy/h6VmSyqlztgRzHty5B5q4t1PqYWK5nk8kD5YwMdKqX8gjs2hiCRITg5X52/GgCFsTWTpFKuCctvGGFSWdpHcKs975jJwoZTwo9az4CLacK65QjoBVmK8DXMUcs0giHVF4H0oA2tUk0yztvL00tKX++zjd+VYovop5IxLxbx/wABPOaW6aOSUeQrxRH0WqJAgkZpFcRNwhIAY0ATSLJLMJZHVIA2QrHtSx745HeSPdD/AA54JqO0kHmJHIvysf4Vyx/GtTUZSn7iOPjbkALls+5oAyJpPJdZTnzyeEznaKvqWLbi0jSOv+qj4P8A9YVkAukvmS5Jz19KuQ3M1t5skBJZxjeT0oAmvkSGKNUR2lzuctzj2qW0aJonld90gPyRLxt+pqlbyMHb7QXCP1I5ZjTJGjjiaNVOc5yetAGtp91DZGeSbdJcHlUzgE/4Van1a6vI4IFcOH6hVwq/T1rnjLAEUYdmI+Yn+VWIb0IwkhUmbG1R2UUAjX1COW30W6VAyROoLkn7x3Dir81sY1th03Qxn/x0VzFxdBrKZZppJJmAAUH5V5r0TUrTf9jKZJ+yxZ/74FcuLlywOzBR5pnOfZnZvlJ/CrS2l2IxtdiPStOGExyDcvXit/T442UA+teRPEWR7EKCbOUguNRtZN5jZ0Xrx2rT/wCEmxGqPEAc16HY6XDcI0e35COuKyNW8ERurNGT+VcjxVGTtNWN1RqRXuMzbbXoLuJIg6owHNatrJFK6ASA4GTXDaj4dnsyXi3jHtWdb3l7YyZy5qvq0KivSkL28oO1RHrtqokfGfvcCqt5ZgSDac+oxXKaL4sKyIs3AHc+tddaatBcMXypZhXDVpVKT1R1QqRmtGYeoaetzG6njb3xXHTWv2e5O7IAPJxXo8rAwuVYZ71janYI/LdxmtqGIcNHsZ1qKnqtzj3mCSlkapIdQdMYbIJ6VLfab85aPOCazntpEcrtJI616MeSaOJ88GdDDqrEfe59K0rTVmBw2CDXEhpEIyDmr0N2yYypJrGphV0NoYh9TuP7VwiljjNVrrWQv8XFcpNqDbeM0js9wAx6e1YrCJayNXib6RJtSv5Lq4JUkr2os4xn5vqc0kFqVOT+VaVvAAAV4J9a1lKMI8sTOEHJ80i1YqNpHOc9cV3WhWRlRXw2F6nFc1plntw79R2xXeaDdBYymAIwK86vPsdcUadzEkelkg42ivIfEs0lxdsdxye1dn4r1xBbNBE2G9q4K5ugwG7iSs8JCXNzsVRpqxSWFty54NSXDYDBj1HWnTToMHdyKzri5L8KevWvUinJnPJqKI4nEb7hzmrjXalRt6jris0ZJxSOJMcA1s43MYyaJp7gENz06Vy3idt1mh/6aj+RrXk39DnmsjxKuLCP180fyNdmGiozRyYluUGczRRRXsnil3S8+dJiMSDYdyeoyK6LR3aC785Ua5hUYZG4dB/WsnwtCtxqZjLKpMZ2ljgZyK7n+xrnyTPAyR3MY/1btjcP9lqTEZmrWdtdqdQ0eZ4ZsfPG645rHGsvfZs70RjjCyEYIb1q7fXdzJAwlAE68eYnBB9xXMTyO7/6UMkfxDvSAn2+VuikcrJnhhyrVXMpBwq5fpkcUjzNIgSTGUHyt3xTVMmQ4wSvcHmgDTtr9jbjBZZo+NwGcioB5txJ5v7x5c8nPUVXguFAkZ495bqAcUQsccM0a+o6H60DNvUZ90cZEocgYYAYZfrTrK+u4opIfNVlYYwD1rElBkdxlfMAyGB6irMc6x+XKSryrxnGOPrQI02RBbNuYK/r0ZfpjrTrC7nXajyeamcYY4zVGW682RZo1EeP4iwIPtim293iThC5zkccCgDYiiS5u5hJK0ZUZEbensa0LLWjZwlAplLfKOOfpmsuS/ut8cckEEkpHyuCMEVCpmgu/wB/AzRv1jPy49waYGnq91EkUS2lqUvHOTuOQPxqlqb3WI5ZVYyAdT0qtdh01JWnYrCfuKzc/nUV07zXYMd0ojToC2aQDS1yM3HBLcbQtSWVy8fmPKzICMbGG4flSyXEyyiW7njRRwhVc1Qu5vPmJaZvn6lVwKAJkZpiZpWwV+6hGcj2qS8naQK7sIQByAcFvw7VDam7AEVq6eX1GcU24ZGyQf3qjrnJNAGpDLP5ULxSLIcdc4x9ajvZZJIXklgdiOrKahU2q2se6R1kIyAO596liu7q3sX2TRIr9c96AMieWWSLzBFtTpkGmp5QQfOwbHQDrTZpD5pkBBYjJ7A/hURBcg7wQeSfSgZchA2eZK756gGmO7J852vu+7uOSoqETt3JbHCim7mRTyFJ7HkmgCWC4eGTdBKQ3diOn0rSh1N/sjwxAvIesmOayFYwycDjvnvV1ZXezLLNHCAchFXBoAgZHdRGV2Z5ZmPWnxQ7p0SAee54x2H1qvLtyHMpdzU1pNcZaKKQRhvvHoAKANK7tjZDfd3cPnEYWOMbiKzbqSFo1EYJJPzMRyanP2SGQYYzP1JHQ1Xvrrz5htVVQDAVaBDZGQxYiyX6c9cUSu8bJgopx91f61DCCWJHX19KTIDfPyD1NAxzENExVcHv9K9dtZSfspUE7raID/vgV5JJuaJn3gLjAXvivYNOiIsrKQj71tHj/vkVxY/+Ed+X/wAUS7UK4AGa2dDsHmiVgjEg+lM0vTzeXarJkpnk16Jo1hb2reUfu46181WrKCPooxuRWCxwQxhuGarly6MhUce9QawqRKrRH7vOKxn1CR5Aq5ya8xt1Hc3SSRNe2kMysjLz61jX3hCCaEsik8frWzK8jSLgEDGT71NaX0iybSvyjsauM5w+Fg4qW55Hrfhma0LMisVB6Vjx3V3ZsNrMMdq9uv7eK6TaFyWFcxf+D/tGWWMqfSvRoZgmuWqcdTCNPmp6HK6VrquCs784rZGow3QRHbnGM1ian4Ou7WYFUfB7isqS0vrFtxV/l9RW7pUausJEKrVp6TR0+oQsikR5I65rOVGWUcZyKjsNcwojnOARg57VqrNbMhO9dxxgZqHGVLRo1TjPVMpi2hlI+Q5HNS/Y4S4zGQPWruxIyNjD5uSavCNCPm/D3rJ1WjRU11ObmsE8wbUIHf3p1rEkTFMfLWzco02/aNpXt61WgtVdiJMjPSqVVtasn2aTukLDAmFJB5FXbGwbz8lSVHPSpdPskZsSsdq/drpNJWEO6ZyfU1jOpY0USK2tXcKVXg9fpT7ppLSOVt2FAyK2FKk4j44rlvFt2ILKSIOfMGeDXNFuckin7qucve3fnSPKWyR2rHdpJbgMT09KZAZZBznaTmrSBYFYupGK9aMFT0ONyc9Subd3Vm5yTxVWdCkmxDz3rTa/VYyEXtxmsslprgbQc962hfqZTsti3p6bn5BOO9Wn8sS+WBu9ajgjeBCxzyKyzeSRyuw6mlyub0HzKC1LGoSQqNsY+bpXN+Jx/wASuM5584fyatSPdNLznPU1V8XwbdEjlAx/pCr/AOOt/hXXh1yVIo5cQ+anJnF0UUV7Z4ZteFADqMmZBH+6PzMMgfMvWuqa7mtSLeRk2sOHVso4/oa8+jd4yTGxUkYyDWjDqr+UIrmNZUHTsRSYFq5eSWa5KuSkfGDyazllV0ZHG0HofQ0M483dDISvTDcN/wDXpvlfaJsIQjHorHA/OkIagAIfcFZfUdaR2DPujG0n+EClKuXMbIdy9QOop0kmUUKoDrxuHGfwoGR/NuCjv2qwrCE/NtkUduhquh2uGOD9aWRsylsZoAto0kUOF8tg5ypHJHtSfOsoeRcZHzBk4NU16cEgdcCtCCdXiCTK7Y755oAPkguWnhaER4yoYZBPpipTNJqFzGPOS3kPUH5R+lUrvylYGDzMjqG5qMuhgYBec/eI6UAbYCW8ssYzI6jcVByD7g1Il1C9rukZtueVOdymsqxunhIwPMyMewq3NeWhjwwPmn+72oEWtMv1tryRpRFOmMgOMn9elFxq9vJJIkVvGJG6ZUYzWIlx5d0WR8oeu4VYKJOBLFAiqepLYoAi8p5p90sqZB+7SLgwyquSwORjoKryYViq8kHGSaar7ABnHPagZetyn2Zi6hZuzEkUzIjbcJth7kc5qIM0qtgjHoTTo4lZ9pbAAyD6UAWWaGeRZJH4UcjpupsohYZbhOwHWoYlRpSFCk+pPWo2ZVLIc4J5OaAGzKVkwMEkcc5wKVXCYX5WHf3pmVGQgJPqaUIQPlxu/PNAEq3G3duRCe2R0ptvC04O0KW6lmOMU1ow2WGSB1Io5IPkggd+KAEJVQdyZbpnPFIXYDYGBB64FJ90rlcg84PejbsfJXP9KYEhUYAGQR0z0FRqrHJzhe56Zq3EnnN5cMZye5qO8g8khC2SOvOcUkA+yRpJNqmOJf7xoubNoWZg6kd2Pc+1NtJYYX37N5H3d/TP0qK7n859xJJ60wEijYkhcZPcngUx12uRkEj0pu7rg8GkoAe8jEEdB3xXu9lblNG09gDn7LEcf8BH+favBDXutpeZs7Jc8C1iAGf9gVwZj/CPQy3+KdL4d8mG3d2OX6n2pr6u6TttZvTr2rDFwUQsuR9DUM04ZwVJyeor5eVPmep9JF2Ogm1SSUg7iQOvNMF4vnqw4rBiuG6MParTSoiLj731qHSS2GpHRC+YsfU9qhFw0kgcEjBxWRbXqEHcx3dqspMrMcZxjmsnCxadzqdPxuRmBPNdDb+W7MpTAHI964qC6ZWjwSEAxVy21Mo+3eeeBmuWpFstHYS2VrdICUDAVnah4YtLkN+7GCKq2OpOGCKCwz1roob2MqORkjkVknKL3Jlc831j4bwyuDAuGPoa53UPh9eWrBYg5bHrXtiXkLZYjJHSoJbqMI8jr06V1Qx1aGidzJ0YSesTwO90PV7H5mUtt7VRbVLu3GyWNhjua9u1KS1mRsICx65rn7/QrK7jLtEuPauqnj1L+JEl4dr4HY84/tsfIy53d60YNQiZS5+8elX9V8IRIwaEYyM1y15pl3avtCHAPFdcHRq/C7GLdWn8SuddbTFzE4B2E1uWDrHeE8hSOlef2OpzQKIphtCnjNdTo2oJPKRnr0zWFWi4m0KikdFPqnkQyMBgr3rgdbvn1K/+Y4H866HXZxFA4YggiuAFx/pRbJxnpVYWje8iK9S1kdLpemoCrycR55qDxMtrHuWBie2KpjUykeFJx9azr66E0nQ10xpycrsynOKjZEQVmVVA5q9pEINwSw5FUIpG+VhW7pqAyYPGRk1vNtIyhFNk17s+zuEBzniuYu4Ch56muhvX8tNvYHrWNdSJKx2n5qii2ncqskQ2MGZPTjj3qPx8hj8O26lSP9IX/wBBat7w9ZGZ1ZlyBVH4rxiPRYMdftK/+gPW9GpfERXmY1o/uJPyPLKKKK+hPnhR1paQUtABQCR0NFFAEpl3kM5YMO4oV2b5ThhnvUVJSAmX5WI2gjPGacwjyApLA9sYNQZNOVgPvLmiwD2BjbPlkH3qxC0s4MSANnpu7fjVQuWxuJI+tOUjJbJx6A80CJi0tsdpXDDtSSSOHDeUqg9scGoyCRuJLDp1pdwxhQxPY5pDJSrpEGT5d3p0phZ/vfKe3HUU9spF5jKwLdz0P4VHJKHUALhhQBEct0FPXeqk7fl756U1WxkDIz1pcqh5y3tTAe6hScbGBoEZLhSu3d0waa+w4KjBPYHNJgkeuPfpSAmnhMCDIwx980xkKwhivB5znFRlg2eoP50+MM/B57ZPamA5Zhs2yIpPZj1FKFjaPcF+Ydc96jGxWHmAsO+KkDAnEOVJ7daQELAg4A2+1PCMMMxwKW5UI4HOcc5qInPUmgRNDJIGIjOPfHNNZ35HJxUeeB+dG45OCRTsMkjwuWk5x2961bW3W2j+1XoBQ8rGDWJk055Hf77FvqaLAarahCgkaFCZG4Xd/DWZJK0h3Pyx71F3paLCDJooopjEpaSloAQ161YsRDbjn/UR/wDoIryU19EaX4aeS0sH2DY1pA3T1QGuDMZKNK7O/Lot1dDn42f7p6dqTcRya7aTwwRCcoNw6YrC1HSvIOMcivmlXg2fR8jMUyHk9u9RTXOAvNS3EBiBJ6VmvmWQrjgdK2glLUznJrQv2rtK3FdJZwt5CkjJJwaxdFty8uAOAOa7SC38i2Upgk9Qa5cRJLY2pIjMRUxqoyCvNSx2gKeZ1PpWlaQoyljgnGcZp8VpIxUImfX6V58p6nRZEenSeUcEZzxWvuXy9ynDdKWPTHKbhGqk8dearT2stsoRiCCc1hJpjLVou1+W69BU1yVVdmM7uazV81c4xjtTpbhkQOw7c81NgsVzbN520dD61cFniMrgkH0qlNqfzY2DgcYog1gxoTJHkDtVq9tAsyy1orwsCMkVn3OnW8joHiBYjipX1iPDDY2WPFU/t4aUuQ2R0q48wjD17wzG/KxgMfSuRms7vSJxydh6V6edSBYGSPtjmsDXHt5U3PGDzn6V3UMROPuvVHPUpReq0ZwGparJNlXZsVmQHdJ71ravawb3cnCnkYrEB8rO09a9ujyuHuo82o5KXvFt32EA04hWY9zjrVASk8YzUqyhSM1bg0SpJmvYQxsCGI455pJ79Y2+Q8rxWWlwcttOc8YqSPTrmdxtTg1Hs1e82X7R2tFCXN/JK3U0WqH7zdTW1p3hS6lAkZcAnFdXZeCSjxNNtK9xmoqV6dNWRUKU5O7OZsNWitEAxgKP1rmvH2sf2jpcUe3kThs/8BYf1r0G98MLHJM21dm7AFcP8RtNjs9EgkjUAm4VTj/db/Clg50p14tbixcaioyvsec0UUV9MfNi0ZpKKAFzRmkooAXNGaSigBc0ZpKKAFzRmkooAXNKHYdCabRQA9nZvvMT9aHkL43c4GKZRQA4NzyM0pbIxgfWmUUAODEdKNxByOtNooAeshU9j9aA7AkqcZ9KZRQA9pCzZPWhXZWypwfamUUAOZ2Y5JyaTNJRQAuaM0lFAC5ozSUUALmjNJRQAuaM0lFAC5ozSUUALmvWLf43avBb20KaPpe2CGOFciTJCLtBPzdeOa8morKrRhWjy1FdGlOrOk+aDsz19/jtrLrj+x9KH4Sf/FViX/xU1K8Yl9OsEz/dD/8AxVed0VyrK8ItVBG/1/EfznXT+Ob2YYa1tsf8C/xqEeMboNu+y22f+Bf41y9FarBUFooi+u19+Y7K38fXsHKWdpn33f41pp8VtTRAo0+x47/P/jXnVFRLLsNLeA1j8QtpnpC/FnVFxjT7Af8Aff8A8VV63+NesQcrpmmn6h//AIqvKaKh5XhH/wAu0P8AtDE/zs9dPx11w4/4lemZHfD/APxVQP8AGzWX+/pmmt9Q/wD8VXlNFL+ycH/z7X4h9fxH856q3xq1gjH9mab0x0f/AOKqrP8AF7V5Tk2FgOOwf/GvNKKP7Jwf/PtD/tHE/wA7PRk+LGqqoH2CxOPUP/jSn4s6pz/xLrDn2f8Axrziiq/svCfyIP7QxP8AOz0Q/FXUywP9nWH5P/jTv+Fsap/0D7D8n/xrzmin/ZmF/kQv7QxP856JN8VdTlYE6fYg+wf/ABqrc/EjULhCrWVmPoG/xrhaKay7DLaCE8fiH9s6G68U3Vz96CFR6DP+NQPr8zD/AI94R9M/41i0VssNSWiiZvE1XvI2BrswORDF+v8AjTTrcx/5ZR/rWTRVewp9he3qdzZg1+eJwwhhOOxz/jW7ZfEO9tECrYWTf7wb/GuJoqJYWlP4olRxVWO0j0+H4w6nDGqLpOmYHs//AMVTpfjNrLqR/Z2njPoH4/8AHq8uorF5bhXvAv69iF9s7+6+KGq3ClWtLNQfTd/jWB4g8UXet2iW9zFEiLIJAUznIBHc+9c/RWlPBUKbUoRsyZ4ytNOMpXQUUUV1HMf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Lumbo-sacral myelomeningocele. Please note the bulging neural tissue into the amniotic cavity. B) Three-dimensional reconstruction of the same defect demonstrating a bulge, which corresponds to the spinal lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26976=[""].join("\n");
var outline_f26_22_26976=null;
var title_f26_22_26977="Strongyloides in stool";
var content_f26_22_26977=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strongyloides stercoralis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wet mount of stool (x100) shows the diagnostic larval form of Strongyloides stercoralis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26977=[""].join("\n");
var outline_f26_22_26977=null;
var title_f26_22_26978="Gangrene of breast";
var content_f26_22_26978=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gangrene of breast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gangrene of the breast is rare but can occur in women with diabetes and renal failure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26978=[""].join("\n");
var outline_f26_22_26978=null;
var title_f26_22_26979="Nephrology pattern 18 answer";
var content_f26_22_26979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 18 answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Type 2 membranoproliferative glomerulonphritis. Electron micrograph in type 2 MPGN (dense-deposit disease) showing dense, ribbon-like appearance of subendothelial and intramembranous material (arrow) and narrowing of the capillary lumen due to proliferation of cells (double arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26979=[""].join("\n");
var outline_f26_22_26979=null;
var title_f26_22_26980="Tinea pedis moccasin";
var content_f26_22_26980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea pedis, moccasin distribution",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse scale on the plantar surface is present in this patient with tinea pedis in the \"moccasin\" distribution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26980=[""].join("\n");
var outline_f26_22_26980=null;
var title_f26_22_26981="Hip effusion US";
var content_f26_22_26981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Ultrasonography left hip effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anechoic fluid collection at the lateral aspect of the left hip adjacent to the femoral neck is a joint effusion (Panel A). The effusion causes lateral bowing of the gluteus minimus muscle, which can sometimes be seen on plain film as displacement of the gluteal fat pad. Ultrasound of the right hip shows no such collection (Panel B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Rosenthal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26981=[""].join("\n");
var outline_f26_22_26981=null;
var title_f26_22_26982="Tiagabine: Drug information";
var content_f26_22_26982=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tiagabine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/29/20949?source=see_link\">",
"    see \"Tiagabine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/40/39558?source=see_link\">",
"    see \"Tiagabine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F227535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gabitril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F227562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F227539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Partial seizures (adjunct):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients receiving enzyme-inducing AED regimens: 4 mg once daily for 1 week; may increase by 4-8 mg weekly to response or up to 56 mg daily in 2-4 divided doses; usual maintenance: 32-56 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients",
"     <b>",
"      not",
"     </b>",
"     receiving enzyme-inducing AED regimens: The estimated plasma concentrations of tiagabine in patients not taking enzyme-inducing medications is twice that of patients receiving enzyme-inducing AEDs. Lower doses are required; slower titration may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F227551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/40/39558?source=see_link\">",
"      see \"Tiagabine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Partial seizures:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients receiving enzyme-inducing AED regimens: Children 12-18 years: 4 mg once daily for 1 week; may increase to 8 mg daily in 2 divided doses for 1 week; then may increase by 4-8 mg weekly to response or up to 32 mg daily in 2-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients",
"     <b>",
"      not",
"     </b>",
"     receiving enzyme-inducing AED regimens: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F227540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F227513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 2 mg, 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gabitril&reg;: 2 mg, 4 mg, 12 mg, 16 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F227499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10913264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM229203.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM229203.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F227517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy in adults and children &ge;12 years of age in the treatment of partial seizures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F227569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       TiaGABine may be confused with tiZANidine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F227560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Concentration decreased, dizziness, nervousness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, hypertension, palpitation, peripheral edema, syncope, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, ataxia, chills, confusion, difficulty with memory, confusion, depersonalization, depression, euphoria, hallucination, hostility, insomnia, malaise, migraine, paranoid reaction, personality disorder, speech disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, bruising, dry skin, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, gingivitis, increased appetite, mouth ulceration, stomatitis, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait, arthralgia, dysarthria, hyper-/hypokinesia, hyper-/hypotonia, myasthenia, myalgia, myoclonus, neck pain, paresthesia, reflexes decreased, stupor, twitching, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision, amblyopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear pain, hearing impairment, otitis media, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea, epistaxis, pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, cyst, diaphoresis, flu-like syndrome, lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abortion, abscess, anemia, angina, apnea, asthma, blepharitis, blindness, cellulitis, cerebral ischemia, cholelithiasis, CNS neoplasm, coma, deafness, dehydration, dysphagia, dystonia, electrocardiogram abnormal, encephalopathy, hemorrhage, erythrocytes abnormal, leukopenia, fecal incontinence, herpes simplex/zoster, glossitis, goiter, hematuria, hemoptysis, hepatomegaly, hypercholesteremia, hyper-/hypoglycemia, hyperlipemia, hypokalemia, hyponatremia, hypotension, hypothyroidism, impotence, kidney failure, liver function tests abnormal, MI, neoplasm, peripheral vascular disorder, paralysis, photophobia, psychosis, petechia, photosensitivity, seizure (when used for unlabeled uses), sepsis, spasm, suicide attempt, thrombocytopenia, thrombophlebitis, urinary retention, urinary urgency, urticaria, visual field defect",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F227520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tiagabine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F227503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Severe reactions, including toxic epidermal necrolysis and Stevens-Johnson syndromes, although rarely reported, have resulted in fatalities; drug should be discontinued if there are any signs of hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Enzyme-inducing drugs: Experience in patients not receiving enzyme-inducing drugs has been limited; caution should be used in treating any patient who is not receiving one of these medications (decreased dose and slower titration may be required).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Unlabeled use: New-onset seizures and status epilepticus have been associated with tiagabine use when taken for unlabeled indications; often these seizures have occurred shortly after the initiation of treatment or shortly after a dosage increase. Seizures have also occurred with very low doses or after several months of therapy. In most cases, patients were using concomitant medications (eg, antidepressants, antipsychotics, stimulants, narcotics). In these instances, the discontinuation of tiagabine, followed by an evaluation for an underlying seizure disorder, is suggested. Use for unapproved indications, however, has not been proven to be safe or effective and is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F227556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F227508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F227532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food reduces the rate but not the extent of absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease tiagabine levels. Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F227509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7793146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     Patients exposed to tiagabine during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F227543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F227523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F227522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Gabitril Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (30): $223.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $223.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg (30): $288.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16 mg (30): $376.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (TiaGABine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (30): $200.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $200.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F227511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A reduction in seizure frequency is indicative of therapeutic response to tiagabine in patients with partial seizures; complete blood counts, renal function tests, liver function tests, and routine blood chemistry should be monitored periodically during therapy; suicidality (eg, suicidal thoughts, depression, behavioral changes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F227514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maximal plasma level after a 24 mg/dose: 552 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gabitril (AT, AU, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IT, NO, PL, PT);",
"     </li>",
"     <li>",
"      Tiabine (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F227502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The exact mechanism by which tiagabine exerts antiseizure activity is not definitively known; however,",
"     <i>",
"      in vitro",
"     </i>",
"     experiments demonstrate that it enhances the activity of gamma aminobutyric acid (GABA), the major neuroinhibitory transmitter in the nervous system; it is thought that binding to the GABA uptake carrier inhibits the uptake of GABA into presynaptic neurons, allowing an increased amount of GABA to be available to postsynaptic neurons; based on",
"     <i>",
"      in vitro",
"     </i>",
"     studies, tiagabine does not inhibit the uptake of dopamine, norepinephrine, serotonin, glutamate, or choline",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F227519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid (45 minutes); prolonged with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 96%, primarily to albumin and &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP (primarily 3A4)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Absolute: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-5 hours when administered with enzyme inducers; 7-9 hours when administered without enzyme inducers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (63%); urine (25%); 2% as unchanged drug; primarily as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adkins JC and Noble S, &ldquo;Tiagabine. A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in the Management of Epilepsy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998, 55(3):437-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/22/26982/abstract-text/9530548/pubmed\" id=\"9530548\" target=\"_blank\">",
"        9530548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dodrill CB, Arnett JL, Sommerville KW, et al, &ldquo;Cognitive and Quality of Life Effects of Differing Dosages of Tiagabine in Epilepsy,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 48(4):1025-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/22/26982/abstract-text/9109894/pubmed\" id=\"9109894\" target=\"_blank\">",
"        9109894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gustavson LE, Boellner SW, Granneman GR, et al, &ldquo;A Single-Dose Study to Define Tiagabine Pharmacokinetics in Pediatric Patients With Complex Partial Seizures,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 48(4):1032-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/22/26982/abstract-text/9109895/pubmed\" id=\"9109895\" target=\"_blank\">",
"        9109895",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kalviainen R, Brodie MJ, Duncan J, et al, &ldquo;A Double-Blind, Placebo-Controlled Trial of Tiagabine Given Three-Times Daily as Add-On Therapy for Refractory Partial Seizures. Northern European Tiagabine Study Group,&rdquo;",
"      <i>",
"       Epilepsy Res",
"      </i>",
"      , 1998, 30(1):31-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/22/26982/abstract-text/9551842/pubmed\" id=\"9551842\" target=\"_blank\">",
"        9551842",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leach JP and Brodie MJ, &ldquo;Tiagabine,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 351(9097):203-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/22/26982/abstract-text/9449883/pubmed\" id=\"9449883\" target=\"_blank\">",
"        9449883",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patsalos PN and Sander JW, &ldquo;Newer Antiepileptic Drugs: Towards an Improved Risk-Benefit Ratio,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1994, 11(1):37-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/22/26982/abstract-text/7917080/pubmed\" id=\"7917080\" target=\"_blank\">",
"        7917080",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Samara EE, Gustavson LE, El-Shourbagy T, et al, &ldquo;Population Analysis of the Pharmacokinetics of Tiagabine in Patients With Epilepsy,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1998, 39(8):868-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/22/26982/abstract-text/9701378/pubmed\" id=\"9701378\" target=\"_blank\">",
"        9701378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Uthman BM, Rowan AJ, Ahmann PA, et al, &ldquo;Tiagabine for Complex Partial Seizures: A Randomized, Add-On, Dose-Response Trial,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 1998, 55(1):56-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/22/26982/abstract-text/9443711/pubmed\" id=\"9443711\" target=\"_blank\">",
"        9443711",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10144 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26982=[""].join("\n");
var outline_f26_22_26982=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227535\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227562\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227539\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227551\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227540\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227513\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227499\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10913264\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227517\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227569\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227560\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227520\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227503\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227556\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227508\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227532\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227509\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7793146\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227543\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227523\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227522\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227511\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227514\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038845\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227502\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227519\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10144\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10144|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/29/20949?source=related_link\">",
"      Tiagabine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/40/39558?source=related_link\">",
"      Tiagabine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_22_26983="Paraneoplastic cerebellar degeneration";
var content_f26_22_26983=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paraneoplastic cerebellar degeneration",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/22/26983/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26983/contributors\">",
"     Josep Dalmau, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26983/contributors\">",
"     Myrna R Rosenfeld, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/22/26983/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26983/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/22/26983/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26983/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/22/26983/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15807611\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic neurologic syndromes are a heterogeneous group of neurologic disorders associated with systemic cancer and caused by mechanisms other than metastases, metabolic and nutritional deficits, infections, coagulopathy, or side effects of cancer treatment.",
"   </p>",
"   <p>",
"    Paraneoplastic cerebellar degeneration is an uncommon disorder that can be associated with any cancer; the most commonly associated are lung cancer (particularly small cell lung cancer (SCLC)), gynecologic and breast cancer, and lymphoma (particularly Hodgkin disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/1\">",
"     1",
"    </a>",
"    ]. The neurologic symptoms frequently precede the diagnosis of cancer, sometimes by an interval of years.",
"   </p>",
"   <p>",
"    This topic discusses paraneoplastic cerebellar degeneration (PCD). An overview of paraneoplastic syndromes and other paraneoplastic disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=see_link\">",
"     \"Paraneoplastic syndromes affecting peripheral nerve and muscle\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=see_link\">",
"     \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=see_link\">",
"     \"Paraneoplastic and autoimmune encephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15805935\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cerebellum is a frequent target of paraneoplastic autoimmunity. All paraneoplastic antibodies have been reported in association with PCD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/2-17\">",
"     2-17",
"    </a>",
"    ]. Some of these autoantibodies are associated with specific clinical settings (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"UTD.htm?31/60/32717\">",
"     table 1",
"    </a>",
"    ) that may help focus the search for an underlying occult malignancy. Only two antibodies, anti-Yo and anti-Tr, predominantly associate with cerebellar dysfunction; the other paraneoplastic antibodies often associate with symptoms involving other areas of the nervous system.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common among the associated antibodies, anti-Yo antibodies (also called Purkinje cell antibody type 1 or PCA-1) primarily occur in patients with PCD who have breast cancer or tumors of the ovary, endometrium, and fallopian tube (",
"      <a class=\"graphic graphic_picture graphicRef60259 \" href=\"UTD.htm?42/22/43367\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/4,5,18-20\">",
"       4,5,18-20",
"      </a>",
"      ]. Rare cases of anti-Yo associated PCD have been described in men with adenocarcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/21-25\">",
"       21-25",
"      </a>",
"      ]. The target antigens of anti-Yo antibodies are the cdr proteins that are expressed by Purkinje cells and ovarian and breast cancers [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/6,7,26\">",
"       6,7,26",
"      </a>",
"      ]. A cytotoxic T cell response against cdr2 has also been identified in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-Hu antibodies (also called antineuronal nuclear antibody, type 1 or ANNA-1) are prevalent in patients with small cell lung cancer (SCLC) and PCD. In one report of 57 such patients, 44 percent had a high titer of anti-Hu antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/2\">",
"       2",
"      </a>",
"      ]. These patients are more likely to have multifocal neurologic disease and severe disability than other patient groups [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Anti-P/Q",
"      </span>",
"      type calcium channel antibodies were the second most commonly associated antibody (seen in 24 percent) in the above series of patients with SCLC and PCD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/2\">",
"       2",
"      </a>",
"      ]. These antibodies were present in all patients who also had Lambert-Eaton myasthenic syndrome (LEMS), as well as in some patients with cerebellar dysfunction without LEMS [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/3,28,29\">",
"       3,28,29",
"      </a>",
"      ]. Antitumor treatment did not alter the course of the cerebellar degeneration, but it did improve the myasthenic symptoms. Lambert-Easton myasthenic syndrome is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=see_link\">",
"       \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anti-Tr antibodies, directed against a cytoplasmic antigen of Purkinje cells, appear to be specific for cerebellar degeneration associated with Hodgkin disease (HD) and less commonly non-Hodgkin lymphoma (",
"      <a class=\"graphic graphic_picture graphicRef65517 \" href=\"UTD.htm?31/56/32647\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/8,9,30-32\">",
"       8,9,30-32",
"      </a>",
"      ]. In some patients, these antibodies are detectable in the CSF but not in serum. In contrast to other clinical settings, PCD often develops after the diagnosis of HD or when the patient is in remission [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-Ri (ANNA-2) antibodies have been associated with PCD, primarily in patients with breast, gynecologic cancers, and SCLC [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/27,33\">",
"       27,33",
"      </a>",
"      ]. Multifocal disease also occurs in this group with associated encephalitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      opsoclonus myoclonus occurring in more than half.",
"     </li>",
"     <li>",
"      Anti-CV2 antibodies, directed against a cytoplasmic antigen in some glial cells, and against peripheral nerve antigens [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/10\">",
"       10",
"      </a>",
"      ], have been associated with several syndromes, including PCD as well as limbic encephalitis, encephalomyelitis, peripheral neuropathy, and optic neuritis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/10-12,34\">",
"       10-12,34",
"      </a>",
"      ]. The most common tumors are SCLC and thymoma. Anti-CV2 antibodies are probably the same as CRMP5 antibodies found in patients with a variety of neurologic disorders associated with thymoma and SCLC [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies to Ma proteins, which are selectively expressed in brain, testis, and some tumors can occur in patients with paraneoplastic brainstem and cerebellar dysfunction associated with a variety of tumors arising in the testes (germ-cell tumors), breast, colon, and parotid gland, among others [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies to the Zic4 have been described in patients with neurologic disorders including cerebellar dysfunction and SCLC. These patients often have concurrent anti-Hu or CRMP5 antibodies. Patients with isolated Zic4 antibodies are more likely to develop cerebellar dysfunction than those with concurrent immunities [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/13,38\">",
"       13,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other, less well characterized antibodies have been reported in patients with PCD. PCA-2 and ANNA-3 are not syndrome specific and have unknown autoantigens [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Antibodies to a glutamate receptor in the brain, designated anti-mGluR1, have only been identified in two patients with PCD and Hodgkin lymphoma as well as one patient without cancer (",
"      <a class=\"graphic graphic_table graphicRef77919 \" href=\"UTD.htm?31/60/32717\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/16,39\">",
"       16,39",
"      </a>",
"      ]. Antibodies against the carbonic anhydrase related protein VIII (CARP VIII) were identified in a patient with PCD and melanoma [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/17\">",
"       17",
"      </a>",
"      ]. In one patient with nonSCLC and PCD, immunoreactivity was observed to protein kinase C, a protein highly expressed in the Purkinje cells of the cerebellum [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/40\">",
"       40",
"      </a>",
"      ]. Other antibodies remain to be characterized [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to antibody-mediated immune responses, cytotoxic T-cell responses appear to be important in the pathogenesis of PCD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/7,42,43\">",
"     7,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologic examination shows marked degeneration of the Purkinje cells with minimal involvement of the molecular or granular cell layers along with inflammation, depending on the stage of the disease, in the cerebellar cortex, deep cerebellar nuclei, and inferior olivary nuclei (",
"    <a class=\"graphic graphic_picture graphicRef60259 \" href=\"UTD.htm?42/22/43367\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In patients who have PCD coexisting with Lambert-Eaton myasthenic syndrome (LEMS), the immunologic target of the antibodies appears to be the",
"    <span class=\"nowrap\">",
"     P/Q",
"    </span>",
"    type voltage-gated calcium channel of the cerebellar molecular layer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=see_link&amp;anchor=H14#H14\">",
"     \"Paraneoplastic syndromes affecting peripheral nerve and muscle\", section on 'Lambert-Eaton myasthenic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15807251\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with paraneoplastic cerebellar degeneration (PCD) typically present with dizziness, nausea, and vomiting, often beginning acutely, and followed several days later by gait instability, oscillopsia, diplopia, both truncal and appendicular ataxia, dysarthria, and dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/18,19,27,44\">",
"     18,19,27,44",
"    </a>",
"    ]. Symptoms typically continue to worsen for weeks to months before stabilizing. Severe disability with inability to walk or even sit unsupported, inability to write or feed oneself, and limited communication secondary to dysarthria are common, with some patients having a somewhat better outcome.",
"   </p>",
"   <p>",
"    Many of these patients with paraneoplastic syndromes develop cerebellar dysfunction along with other neurologic signs. As an example, when cerebellar degeneration occurs with encephalomyelitis, the underlying tumor is SCLC in approximately 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/2\">",
"     2",
"    </a>",
"    ]. LEMS can occur with PCD in patients with SCLC who have",
"    <span class=\"nowrap\">",
"     anti-P/Q",
"    </span>",
"    type calcium channel antibodies. Even patients with anti-Yo antibodies and relatively isolated PCD have detectable cognitive deficits approximately 20 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/18,45\">",
"     18,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients (60 to 70 percent) with PCD do not have a cancer diagnosis at the onset of their neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/18,19,27\">",
"     18,19,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15807258\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to patients with PCD includes considering and ruling out other diagnoses, confirming and characterizing the paraneoplastic syndrome, and identifying the underlying neoplasm, if this is not previously known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15807265\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of cerebellar ataxia includes cerebellar and brainstem metastases, toxic and metabolic causes, and neurodegenerative causes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/45\">",
"     45",
"    </a>",
"    ]. Alcoholism, vitamin deficiency (thiamine, vitamin E, cobalamin), hypothyroidism, cerebrovascular disease, demyelination, infectious or postinfectious cerebellitis, Miller-Fisher syndrome, anti-glutamic acid decarboxylase (GAD)-associated cerebellar ataxia, Creutzfeldt Jakob disease, HIV, and celiac disease should be specifically considered. Medication lists should also be reviewed for possible contributors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/12/9417?source=see_link&amp;anchor=H12#H12\">",
"     \"Gait disorders of elderly patients\", section on 'Cerebellar ataxia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15807406\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic evaluation typically begins with neuroimaging and laboratory testing to exclude other conditions.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) is usually not helpful for positive diagnosis of PCD but is important to exclude metastatic and cerebrovascular disease. In rare instances of PCD, contrast enhancement in the cerebellar folia can be found in acute phases of the disease, and positron emission tomography (PET) may reveal hypermetabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/46\">",
"     46",
"    </a>",
"    ]. Diffuse cerebellar atrophy develops subsequently [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/18,34,47\">",
"     18,34,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory testing may include thyroid function tests, vitamin levels, and other testing (anti-gliadin, anti-GAD antibodies, HIV serology) in the appropriate clinical setting.",
"   </p>",
"   <p>",
"    As with other paraneoplastic syndromes involving the nervous system, cerebrospinal fluid (CSF) examination can show inflammatory changes, at least in the early stages of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/18\">",
"     18",
"    </a>",
"    ]. A mild pleocytosis (10-50 lymphocytes) and a mild elevation of protein are characteristic. Some patients with PCD or extensive encephalitis have the 14-3-3 protein characteristic of Creutzfeldt-Jakob disease (CJD) in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/48\">",
"     48",
"    </a>",
"    ]. This might create some diagnostic confusion if a tumor is not evident because of symptom overlap between paraneoplastic disease and CJD. It is likely that the 14-3-3 protein in this setting reflects extensive CNS damage rather than CJD. Immunoblotting reveals the 14-3-3 protein as a double band (similar to other false positive results) rather than the single band in CJD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=see_link\">",
"     \"Creutzfeldt-Jakob disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paraneoplastic biomarkers should be sought in the patient&rsquo;s serum (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"UTD.htm?31/60/32717\">",
"     table 1",
"    </a>",
"    ). Not all biomarkers have commercially available testing, and some antigens remain to be characterized. Thus, negative results do not exclude a paraneoplastic or autoimmune disorder. A sample of a patient&rsquo;s CSF and serum should be sent to a research laboratory for examination in these cases. Other caveats regarding antibody screening are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\", section on 'Antibody screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient does not have a known cancer diagnosis, evaluation for occult malignancy should also ensue. The presence of paraneoplastic biomarkers may help direct further evaluation if initial screening is negative (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"UTD.htm?31/60/32717\">",
"     table 1",
"    </a>",
"    ). Tumors may be small; in some cases FDG-PET or exploratory laparotomy was the only means of identifying the underlying lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/18,49\">",
"     18,49",
"    </a>",
"    ]. In a minority of patients with PCD, no tumor is identified despite vigorous investigations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/18,19,27\">",
"     18,19,27",
"    </a>",
"    ]. In such cases, serial investigations are advised. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\", section on 'Occult malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15807413\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic outcome is often poor, most patients (75 to 80 percent) become and remain nonambulatory [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/27\">",
"     27",
"    </a>",
"    ]. Treatment of the underlying tumor is considered essential for neurologic stabilization; clinical improvement is less likely but can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/1,2,18,27\">",
"     1,2,18,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunotherapy is often used, but does not clearly affect neurologic outcome. In one larger case series, immunotherapy was not significantly associated with recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/27\">",
"     27",
"    </a>",
"    ]. However, there are anecdotal reports of neurologic improvement in patients tried on various immunological therapies, including plasma exchange, intravenous immune globulin, corticosteroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , given individually or in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/9,27,30,50-60\">",
"     9,27,30,50-60",
"    </a>",
"    ]. One literature review of 15 cases found that treatment with intravenous immune globulin was more likely to be associated with a good outcome if it was administered between within three months of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/61\">",
"     61",
"    </a>",
"    ]. There are also rare reports of spontaneous improvement. Given the overall poor prognosis with substantial neurologic disability, a trial of immunotherapy seems reasonable.",
"   </p>",
"   <p>",
"    The type of antibody appears to affect neurologic prognosis. Patients with PCD associated with anti-Hu or anti-Yo antibodies are less likely to recover, while those with anti-Tr, anti-Ri, or anti-CV2 antibodies may have a somewhat better chance of neurologic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/2,12,32,62\">",
"     2,12,32,62",
"    </a>",
"    ]. In some reports, younger age and less severe disability at diagnosis and intervention appear to favorably affect prognosis.",
"   </p>",
"   <p>",
"    Survival also varies with the type of associated antibody as well as the underlying neoplasm. In one series, survival was worse in patients with anti-Hu antibodies (median seven months) and those with anti-Yo antibodies (median 13 months) compared with patients who had anti-Tr or anti-Ri antibodies (median survival 113 and 69 months, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/27\">",
"     27",
"    </a>",
"    ]. In another series, median survival was 11 months in patients with anti-Hu antibodies compared with 48 months in those with anti-CV2 antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/63\">",
"     63",
"    </a>",
"    ]. Advanced age has a negative impact on survival. While some reports find that neurologic morbidity contributes most substantively to mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/18,27\">",
"     18,27",
"    </a>",
"    ], others have found that cancer progression was more important [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26983/abstract/19,50\">",
"     19,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15807562\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic cerebellar degeneration (PCD) is an uncommon disorder that can be associated with any cancer; the most commonly associated are lung cancer (particularly small cell lung cancer (SCLC)), gynecologic and breast cancer, and lymphoma (particularly Hodgkin disease).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of autoantibodies associated with PCD have been characterized. Individual autoantibodies are often linked to specific cancer types",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      clinical syndromes. As an example, patients with PCD and anti-Yo antibodies typically have breast or gynecologic cancer and isolated cerebellar deficits and pathology. Other antibodies along with their associated tumors and characteristic clinical features are outlined. (See",
"      <a class=\"local\" href=\"#H15805935\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with PCD typically present with dizziness, nausea, and vomiting, often beginning acutely, and followed several days later by gait instability and other cerebellar signs. Many patients with PCD develop cerebellar dysfunction along with other paraneoplastic neurologic disorders such as Lambert Eaton myasthenic syndrome and encephalomyelitis. (See",
"      <a class=\"local\" href=\"#H15807251\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuroimaging and cerebrospinal fluid analysis are important to exclude other conditions; findings in PCD may be normal or nonspecifically abnormal. Paraneoplastic biomarkers provide supporting evidence for the diagnosis. If the patient does not have a known cancer diagnosis, evaluation for occult malignancy should ensue. (See",
"      <a class=\"local\" href=\"#H15807258\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depending on the type of underlying antibody and associated neoplasm, patients&rsquo; neurologic symptoms may stabilize or rarely improve with antitumor treatment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immunotherapy. (See",
"      <a class=\"local\" href=\"#H15807413\">",
"       'Treatment and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/1\">",
"      Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/2\">",
"      Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120 ( Pt 8):1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/3\">",
"      Fukuda T, Motomura M, Nakao Y, et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003; 53:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/4\">",
"      Furneaux HM, Rosenblum MK, Dalmau J, et al. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990; 322:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/5\">",
"      Rojas-Marcos I, Rousseau A, Keime-Guibert F, et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) 2003; 82:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/6\">",
"      Fathallah-Shaykh H, Wolf S, Wong E, et al. Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A 1991; 88:3451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/7\">",
"      Albert ML, Darnell JC, Bender A, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/8\">",
"      Graus F, Gultekin SH, Ferrer I, et al. Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system. Acta Neuropathol 1998; 96:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/9\">",
"      Bernal F, Shams'ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/10\">",
"      Antoine JC, Honnorat J, Camdessanch&eacute; JP, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001; 49:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/11\">",
"      Honnorat J, Antoine JC, Derrington E, et al. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996; 61:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/12\">",
"      de la Sayette V, Bertran F, Honnorat J, et al. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol 1998; 55:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/13\">",
"      Bataller L, Wade DF, Graus F, et al. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 2004; 62:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/14\">",
"      Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000; 47:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/15\">",
"      Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 2001; 50:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/16\">",
"      Sillevis Smitt P, Kinoshita A, De Leeuw B, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000; 342:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/17\">",
"      Bataller L, Sabater L, Saiz A, et al. Carbonic anhydrase-related protein VIII: autoantigen in paraneoplastic cerebellar degeneration. Ann Neurol 2004; 56:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/18\">",
"      Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/19\">",
"      Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/20\">",
"      McKeon A, Tracy JA, Pittock SJ, et al. Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond. Arch Neurol 2011; 68:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/21\">",
"      Sutton IJ, Fursdon Davis CJ, Esiri MM, et al. Anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus. Ann Neurol 2001; 49:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/22\">",
"      Meglic B, Graus F, Grad A. Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with gastric adenocarcinoma. J Neurol Sci 2001; 185:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/23\">",
"      Krakauer J, Balmaceda C, Gluck JT, et al. Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of unknown origin. Neurology 1996; 46:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/24\">",
"      Matschke J, Kromminga A, Erbersdobler A, et al. Paraneoplastic cerebellar degeneration and anti-Yo antibodies in a man with prostatic adenocarcinoma. J Neurol Neurosurg Psychiatry 2007; 78:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/25\">",
"      Debes JD, Lagarde SM, Hulsenboom E, et al. Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of the gastroesophageal junction. Dig Surg 2007; 24:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/26\">",
"      Totland C, Aarskog NK, Eichler TW, et al. CDR2 antigen and Yo antibodies. Cancer Immunol Immunother 2011; 60:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/27\">",
"      Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/28\">",
"      Clouston PD, Saper CB, Arbizu T, et al. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology 1992; 42:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/29\">",
"      Graus F, Lang B, Pozo-Rosich P, et al. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002; 59:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/30\">",
"      Hammack J, Kotanides H, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease. Neurology 1992; 42:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/31\">",
"      Geromin A, Candoni A, Marcon G, et al. Paraneoplastic cerebellar degeneration associated with anti-neuronal anti-Tr antibodies in a patient with Hodgkin's disease. Leuk Lymphoma 2006; 47:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/32\">",
"      Briani C, Vitaliani R, Grisold W, et al. Spectrum of paraneoplastic disease associated with lymphoma. Neurology 2011; 76:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/33\">",
"      Brieva-Ru&iacute;z L, Diaz-Hurtado M, Matias-Guiu X, et al. Anti-Ri-associated paraneoplastic cerebellar degeneration and breast cancer: an autopsy case study. Clin Neurol Neurosurg 2008; 110:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/34\">",
"      de Andr&eacute;s C, Esquivel A, de Villoria JG, et al. Unusual magnetic resonance imaging and cerebrospinal fluid findings in paraneoplastic cerebellar degeneration: a sequential study. J Neurol Neurosurg Psychiatry 2006; 77:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/35\">",
"      Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/36\">",
"      Dalmau J, Gultekin SH, Voltz R, et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999; 122 ( Pt 1):27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/37\">",
"      Rosenfeld MR, Eichen JG, Wade DF, et al. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001; 50:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/38\">",
"      Sabater L, Bataller L, Su&aacute;rez-Calvet M, et al. ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. J Neuroimmunol 2008; 201-202:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/39\">",
"      Marignier R, Chenevier F, Rogemond V, et al. Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol 2010; 67:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/40\">",
"      Sabater L, Bataller L, Carpentier AF, et al. Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer. J Neurol Neurosurg Psychiatry 2006; 77:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/41\">",
"      Greenlee JE, Clawson SA, Hill KE, et al. Antineuronal autoantibodies in paraneoplastic cerebellar degeneration associated with adenocarcinoma of the prostate. J Neurol Sci 2010; 291:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/42\">",
"      Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000; 47:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/43\">",
"      Aye MM, Kasai T, Tashiro Y, et al. CD8 positive T-cell infiltration in the dentate nucleus of paraneoplastic cerebellar degeneration. J Neuroimmunol 2009; 208:136.",
"     </a>",
"    </li>",
"    <li>",
"     Henson, RA, Urich, H. Cancer and the Nervous System. Blackwell Scientific, Oxford 1982. p.314.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/45\">",
"      Dalmau J, Gonzalez RG, Lerwill MF. Case records of the Massachusetts General Hospital. Case 4-2007. A 56-year-old woman with rapidly progressive vertigo and ataxia. N Engl J Med 2007; 356:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/46\">",
"      Choi KD, Kim JS, Park SH, et al. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 2006; 77:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/47\">",
"      Scheid R, Voltz R, Briest S, et al. Clinical insights into paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 2006; 77:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/48\">",
"      Saiz A, Graus F, Dalmau J, et al. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann Neurol 1999; 46:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/49\">",
"      Marchand V, Graveleau J, Lanctin-Garcia C, et al. A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET. Gynecol Oncol 2007; 105:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/50\">",
"      Cao Y, Abbas J, Wu X, et al. Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: case report and review of the literature. Gynecol Oncol 1999; 75:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/51\">",
"      Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/52\">",
"      Shams'ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006; 253:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/53\">",
"      Esposito M, Penza P, Orefice G, et al. Successful treatment of paraneoplastic cerebellar degeneration with Rituximab. J Neurooncol 2008; 86:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/54\">",
"      David YB, Warner E, Levitan M, et al. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer 1996; 78:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/55\">",
"      Blaes F, Strittmatter M, Merkelbach S, et al. Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J Neurol 1999; 246:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/56\">",
"      Taniguchi Y, Tanji C, Kawai T, et al. A case report of plasmapheresis in paraneoplastic cerebellar ataxia associated with anti-Tr antibody. Ther Apher Dial 2006; 10:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/57\">",
"      Mowzoon N, Bradley WG. Successful immunosuppressant therapy of severe progressive cerebellar degeneration and sensory neuropathy: a case report. J Neurol Sci 2000; 178:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/58\">",
"      Counsell CE, McLeod M, Grant R. Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology 1994; 44:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/59\">",
"      Th&ouml;ne J, Hohaus A, Lamprecht S, et al. Effective immunosuppressant therapy with cyclophosphamide and corticosteroids in paraneoplastic cerebellar degeneration. J Neurol Sci 2008; 272:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/60\">",
"      Phuphanich S, Brock C. Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody. J Neurooncol 2007; 81:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/61\">",
"      Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol 2003; 63:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/62\">",
"      Graus F, Dalmau J, Valldeoriola F, et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol 1997; 74:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26983/abstract/63\">",
"      Honnorat J, Cartalat-Carel S, Ricard D, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009; 80:412.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15822 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-AE2128909E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26983=[""].join("\n");
var outline_f26_22_26983=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15807562\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15807611\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15805935\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15807251\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15807258\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15807265\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15807406\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15807413\">",
"      TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15807562\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/15822\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/15822|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/22/43367\" title=\"picture 1\">",
"      Anti Yo cerebellar degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/56/32647\" title=\"picture 2\">",
"      Sensory neuronopathy histopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/15822|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/60/32717\" title=\"table 1\">",
"      Paraneoplastic antibodies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=related_link\">",
"      Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/12/9417?source=related_link\">",
"      Gait disorders of elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=related_link\">",
"      Paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=related_link\">",
"      Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_22_26984="Treatment of coronary heart disease in end-stage renal disease (dialysis)";
var content_f26_22_26984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of coronary heart disease in end-stage renal disease (dialysis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/22/26984/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26984/contributors\">",
"     Alfred K Cheung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26984/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/22/26984/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26984/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26984/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26984/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/22/26984/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26984/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/22/26984/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease (CVD) is the single best predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent of deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Of the cardiovascular deaths, approximately 20 percent can be attributed to the consequences of coronary heart disease (CHD). Patients with varying degrees of chronic kidney disease (CKD) but not yet dialysis-dependent also have a markedly increased risk of morbidity and mortality from CVD, including CHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the issues relating to CHD are similar in patients with and without renal failure. This topic review will emphasize those features of the treatment of CHD that distinguish the dialysis patient from those without kidney disease. Related issues, such as secondary prevention and diagnosis of CHD in dialysis patients, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33559?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29703?source=see_link\">",
"     \"Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of angina resulting from CHD, stable and unstable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stable angina refers to chest discomfort that occurs predictably and reproducibly at a certain level of exertion and is relieved with rest or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Unstable angina is an acute coronary syndrome that encompasses a variety of clinical conditions, including the new onset of angina, rest angina, an accelerating pattern of previously stable angina, post-myocardial infarction (MI) angina, and angina after a revascularization procedure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=see_link\">",
"       \"Classification of unstable angina and non-ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC TREATMENT OF STABLE CORONARY HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis of angina has an extremely high predictive accuracy for the presence of coronary artery disease. The management of stable angina involves pharmacologic intervention to prevent or minimize ischemia, reduction of risk factors for CHD, and revascularization in some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following sections will review the pharmacologic management of stable CHD. The invasive management of this disorder is presented below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Invasive management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antianginal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with coronary artery disease in patients without kidney disease, the optimal choice of antianginal agent in dialysis patients varies with the presence or absence of comorbid conditions, such as heart failure, diabetes, hypertension, and peripheral vascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the care of patients with stable ischemic heart disease\", section on 'Antianginal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among those with end-stage renal disease, dosing and choice of anti-ischemic agent depends upon both its principal route of elimination and effect upon systemic blood pressure, particularly in patients prone to hypotension during hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Specific issues for dialysis patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The administration of nitrates must be cautious when preload is relatively low, such as the end of a hemodialysis session; this may result in a significant decrease in blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To minimize blood pressure effects during hemodialysis sessions in the daytime, medications may be dosed nocturnally [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anemia therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia should be partially corrected with erythropoiesis stimulating agent and iron therapy, with the goal hemoglobin level being 10 to 11",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Targeting higher hemoglobin levels in those with coronary artery disease or heart failure is paradoxically associated with a trend toward higher mortality. We recommend NOT targeting hemoglobin levels above 12",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    The evidence for these recommendations and a detailed discussion of these issues are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Blood pressure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension should be controlled by removal of excess fluid to maintain hemodynamic dry weight and, if necessary, antihypertensive medications. Beta-blockers, which reduce cardiac work, and calcium channel blockers, which may dilate the coronary vessels, are preferred in patients with symptomatic angina. Nitrates are also an important therapeutic modality in these patients. Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers may also be indicated. Drug doses must be adjusted for kidney function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=see_link\">",
"     \"Hypertension in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data examining the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in dialysis patients. We agree with the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines that suggest that individual treatment decisions should be based upon consideration of patients' individual risks, potential benefits, and preferences. The prescription of low-dose aspirin is probably safe in most patients with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. The dose of aspirin is 81",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues surrounding the use of combination antiplatelet therapy, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , are discussed below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Choice of intracoronary stent'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Risk factor reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of secondary prevention in dialysis patients with coronary heart disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC TREATMENT OF UNSTABLE CORONARY HEART DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the pharmacologic agents available to manage patients with an acute coronary syndrome, such as unstable angina and acute myocardial infarction (ST elevation [Q wave] and non-ST elevation [non-Q wave]), can be utilized in patients with and without renal failure. Thus, if there are no contraindications,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta blockers, ACE",
"    <span class=\"nowrap\">",
"     inhibitors/ARBs,",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    should be given, if indicated and appropriately dosed, in the dialysis patient with acute coronary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, the use of fibrinolytic agents, high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and platelet glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors for acute coronary syndrome is less clear because of the markedly increased risk of bleeding in dialysis patients. Many of the large trials evaluating the efficacy of these agents excluded those with kidney function impairment, even patients with only mild elevations in the serum creatinine concentration. In addition, trials that included patients with kidney dysfunction frequently failed to specifically analyze their outcomes as a unique subgroup [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, fibrinolytic and antithrombolytic agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    platelet glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors should be administered to dialysis patients, if indicated and there are no obvious contraindications. Drug doses must be adjusted for kidney function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Particular issues among dialysis patients include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Glycoprotein IIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the potential increased risk of bleeding, patients with elevations in the serum creatinine concentration were excluded from many of the clinical trials evaluating platelet glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/5\">",
"     5",
"    </a>",
"    ]. A number of observational studies have evaluated adverse effects (particularly bleeding) associated with these agents, with conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. A single center study of 56 dialysis patients and 524 patients without renal dysfunction reported no increase in bleeding complications of the 32 dialysis patients who received glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors compared to those without kidney dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/12\">",
"     12",
"    </a>",
"    ]. By comparison, other studies have reported increased bleeding complications with such agents in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These agents should be administered when indicated and there are no contraindications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       Abciximab",
"      </a>",
"      may be the preferred agent in dialysis patients with renal insufficiency, since it does not require any dose adjustment.",
"     </li>",
"     <li>",
"      Marked dose adjustment of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      is required in dialysis patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By comparison,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    is contraindicated in patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     Enoxaparin",
"    </a>",
"    , a low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , is also contraindicated in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Timing and performance of hemodialysis session",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing of a hemodialysis session after acute coronary syndrome is unclear and has not been adequately studied [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Important considerations include measures aimed at promoting hemodynamic stability, lowering bleeding risk, and minimizing electrolyte disturbances in the attempt to decrease the risk of hypotension and arrhythmias during this period. Alterations in the hemodialysis prescription should also be made to lower the risk of intradialytic hypotension that may further impair coronary perfusion and aggravate ischemia. Rapid changes in serum electrolyte concentrations may precipitate or aggravate arrhythmia, especially in the acute coronary syndrome setting. Postponing hemodialysis to the next day is generally preferred after an acute coronary event, if there is no urgent indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INVASIVE MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;In non-dialysis patients with either stable or unstable coronary artery disease, coronary revascularization can be performed either with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). Based upon observational studies, both the mortality after CABG and the complication rate after PCI are increased in patients with end-stage renal disease compared with nondialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/16-24\">",
"     16-24",
"    </a>",
"    ]. The relative efficacy, indications, advantages, and disadvantages of CABG and PCI with stenting (most commonly with drug-eluting stents) in the general population with CHD are discussed in different topic reviews.",
"   </p>",
"   <p>",
"    The ability to extend the results of CABG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PCI with stenting in the general population to dialysis patients is difficult. This is due in part to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dialysis patients were excluded from practically all well-designed studies that assessed the efficacy of coronary revascularization procedures in patients with coronary heart disease.",
"     </li>",
"     <li>",
"      There is a paucity of studies that have examined the relative efficacy and long-term outcomes in dialysis patients of drug-eluting stents, which are currently the most commonly used stents in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these limitations, we generally suggest that the approach to the invasive management of dialysis patients should follow that used in the general population.",
"   </p>",
"   <p>",
"    The following are some issues that are relatively unique to dialysis patients:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Optimal method of coronary revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of data exists concerning the optimal method of coronary revascularization in patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/27\">",
"     27",
"    </a>",
"    ]. There are no published randomized studies that have directly compared the efficacy of the different techniques. Only retrospective cohort studies have examined this issue, suggesting that drug-eluting stents are associated with lower early mortality than CABG in the first three months but higher mortality than CABG after this period. In general, evidence suggests that the long-term risk of cardiac events",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death in dialysis patients is generally higher following PCI than after CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/16,17,19,21,24,28\">",
"     16,17,19,21,24,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For these reasons, we and others generally favor CABG rather than PCI in the treatment of severe coronary disease in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], unless the immediate peri-operative mortality associated with CABG is deemed to be too high in a particular patient. There is an acceptable morbidity and mortality, excellent symptomatic relief, and improved functional status with CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/29\">",
"     29",
"    </a>",
"    ]. Nevertheless, either CABG or PCI with stenting can be used for coronary revascularization based upon individual patient characteristics and center preferences. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Choice of intracoronary stent",
"    </span>",
"    &nbsp;&mdash;&nbsp;If PCI is used, the type of intracoronary stent associated with optimal outcomes in dialysis patients is unclear. Although no randomized prospective studies have been performed, there is increasing evidence in dialysis patients that drug-eluting stents, compared with bare metal stents, are associated with reduced restenosis rates and a decreased requirement for repeat revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/25,26,31,32\">",
"     25,26,31,32",
"    </a>",
"    ]. We therefore suggest the use of drug-eluting stents rather than other stents because of these findings as well as the relative benefits observed in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients without kidney dysfunction, combined antiplatelet therapy appears to reduce the risk of stent thrombosis. As a result, patients are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other antiplatelet agents for prolonged periods. Dialysis patients have increased risk for bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, the combination of aspirin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    for the prevention of arteriovenous graft stenosis has been shown to be associated with increased bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/35\">",
"     35",
"    </a>",
"    ]. Nonetheless, dialysis patients who undergo coronary stent placement should receive combination therapy with aspirin and another antiplatelet agent, if there are no other contraindications and they are appropriately dosed. Careful monitoring for bleeding should be conducted in such patients, and consideration should be made for a decreased",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    dose during dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=see_link\">",
"     \"General principles of the use of intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Follow-up issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical detection of restenosis after initially successful coronary artery intervention may be more difficult in the dialysis patient because symptoms (such as chest pain or dyspnea) induced by increased",
"    <strong>",
"     fluid",
"    </strong>",
"    volume, particularly increased left ventricular preload, can mimic those resulting from recurrent ischemic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, in some centers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography is performed in all dialysis patients who have undergone angioplasty or stenting, most commonly at 12 to 16 weeks post-procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/7,36\">",
"     7,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to patients without kidney disease, those with ESRD appeared to have enhanced mortality from the clinical consequences of coronary artery disease, particularly acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among those with non-ST elevation MI who underwent PCI from 1999 to 2007, an approximately three to fourfold increased mortality risk was noted in dialysis patients versus those with estimated glomerular filtration rates greater than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 and similar TIMI risk scores [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The long-term survival after a first acute myocardial infarction (MI) was evaluated in one report of over 34,000 patients undergoing chronic dialysis who were hospitalized between the years 1977 and 1995 for MI [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/37\">",
"       37",
"      </a>",
"      ]. At one, two, and five years after an acute myocardial infarction, overall mortality was 59, 73, and 90 percent, respectively, while mortality from cardiac causes alone was 41, 52, and 70 percent. In comparison, mortality at one and two years after an acute MI in the general population is 10 and 15 percent, respectively.",
"     </li>",
"     <li>",
"      A retrospective cohort study evaluated outcomes associated with acute MI occurring between 1998 and 2000 in dialysis patients (data from over 1 million patients in the United States Renal Data System) and 537,444 non-dialysis patients (noted in the third National Registry of Myocardial Infarction) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26984/abstract/40\">",
"       40",
"      </a>",
"      ]. There was an increased risk of in-hospital death for dialysis compared with nondialysis patients (odds ratio 1.5, 95% CI 1.3-1.7).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of stable angina involves pharmacologic intervention to prevent or minimize ischemia, reduction of risk factors for coronary artery disease, and revascularization in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pharmacologic treatment of stable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among dialysis patients, the pharmacologic management of stable coronary heart disease is based upon antianginal therapy, partial correction of anemia, adequate blood pressure control, antiplatelet therapy, and risk factor reduction. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pharmacologic treatment of stable coronary heart disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As with coronary artery disease in patients without kidney disease, the optimal choice of antianginal agent in dialysis patients varies with the presence or absence of comorbid conditions. Specific issues for dialysis patients include appropriate dosing (with adjustment of antianginal medications based on their altered pharmacokinetics due to kidney failure and dialytic removal, as well as their effects upon blood pressure, particularly during dialysis). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antianginal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In dialysis patients being treated with erythropoietic stimulating agents for the anemia of CKD, we suggest targeting hemoglobin levels in the range of 10 to 11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We recommend NOT targeting Hgb levels above 12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Anemia therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypertension should be controlled by removal of excess fluid to maintain dry weight and, if necessary, antihypertensive medications. Drug doses must be adjusted for kidney function. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Blood pressure control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the administration of low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in dialysis patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The dose of aspirin is 81",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      Dialysis patients who would prefer to avoid the increased risk of bleeding for an unproven cardiovascular benefit may reasonably choose to forgo aspirin therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Antiplatelet therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An overview of secondary prevention in dialysis patients with CHD is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pharmacologic treatment of unstable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the pharmacologic agents available to manage patients with an acute coronary syndrome can be utilized in patients with and without kidney disease. Thus, if there are no contraindications,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta blockers, ACE",
"    <span class=\"nowrap\">",
"     inhibitors/ARBs,",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    should be given, if indicated and appropriately dosed, in the dialysis patient with acute coronary syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, the optimal use of fibrinolytic agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and platelet glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors is less clear because of the markedly increased risk of bleeding in dialysis patients. Particular issues among dialysis patients include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelet glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitors should be administered when indicated and there are no contraindications after the increased bleeding risk has been taken into account.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       Abciximab",
"      </a>",
"      may be the preferred agent in patients with impaired kidney function since it does not require any dose adjustment. Marked dose adjustment of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      is required in dialysis patients. By comparison,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      is contraindicated. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Glycoprotein IIb/IIIa inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In an attempt to decrease the risk of hypotension and arrhythmias, the timing and performance of a hemodialysis session should focus upon attempts to promote hemodynamic stability, lower bleeding risk, and minimize electrolyte disturbances. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Timing and performance of hemodialysis session'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Invasive management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among non-dialysis patients with either stable or unstable coronary artery disease, coronary revascularization can be performed either with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) plus stenting. We generally suggest that the approach to the invasive management of dialysis patients follow that used in the general population.",
"   </p>",
"   <p>",
"    The following are some issues that are relatively unique to dialysis patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In dialysis patients, we suggest CABG rather than PCI plus stenting for the treatment of severe coronary disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). It is reasonable for PCI plus stenting to be used over CABG based upon individual patient characteristics and center preferences.",
"     </li>",
"     <li>",
"      If PCI is used, we suggest the use of drug-eluting stents rather than other stents (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Dialysis patients who undergo stent placement should receive appropriate antiplatelet therapy, if there are no contraindications after taking increased bleeding risk into consideration, and agents are appropriately dosed. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Choice of intracoronary stent'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=see_link\">",
"       \"General principles of the use of intracoronary stents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to patients without kidney disease, those with end-stage renal disease appeared to have enhanced mortality from the clinical consequences of coronary artery disease, particularly acute myocardial infarction. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/1\">",
"      Wanner C, Krane V, M&auml;rz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/2\">",
"      Herzog CA. How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 2003; 14:2556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/3\">",
"      Afzali B, Haydar AA, Vinen K, Goldsmith DJ. From Finland to fatland: beneficial effects of statins for patients with chronic kidney disease. J Am Soc Nephrol 2004; 15:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/4\">",
"      Habib AN, Baird BC, Leypoldt JK, et al. The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2006; 21:2881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/5\">",
"      Sorrell VL. Diagnostic tools and management strategies for coronary artery disease in patients with end-stage renal disease. Semin Nephrol 2001; 21:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/6\">",
"      Cice G, Di Benedetto A, D'Andrea A, et al. Sustained-release diltiazem reduces myocardial ischemic episodes in end-stage renal disease: a double-blind, randomized, crossover, placebo-controlled trial. J Am Soc Nephrol 2003; 14:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/7\">",
"      K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/8\">",
"      Jeremias A, Bhatt DL, Chew DP, et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol 2002; 89:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/9\">",
"      Best PJ, Lennon R, Gersh BJ, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 2003; 146:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/10\">",
"      Frilling B, Zahn R, Fraiture B, et al. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol 2002; 89:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/11\">",
"      Freeman RV, Mehta RH, Al Badr W, et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003; 41:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/12\">",
"      Khaja A, Garg R, Govindarajan G, et al. Percutaneous coronary intervention and the use of glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease on dialysis: a single center experience. Hemodial Int 2008; 12 Suppl 2:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/13\">",
"      Tsai, TT, Maddox, TM, Roe, MT, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention JAMA 2009; 302:2458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/14\">",
"      Coritsidis G, Sutariya D, Stern A, et al. Does timing of dialysis in patients with ESRD and acute myocardial infarcts affect morbidity or mortality? Clin J Am Soc Nephrol 2009; 4:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/15\">",
"      Ifudu O, Miles AM, Friedman EA. Hemodialysis immediately after acute myocardial infarction. Nephron 1996; 74:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/16\">",
"      Herzog CA, Ma JZ, Collins AJ. Long-term outcome of dialysis patients in the United States with coronary revascularization procedures. Kidney Int 1999; 56:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/17\">",
"      Rinehart AL, Herzog CA, Collins AJ, et al. A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. Am J Kidney Dis 1995; 25:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/18\">",
"      Kahn JK, Rutherford BD, McConahay DR, et al. Short- and long-term outcome of percutaneous transluminal coronary angioplasty in chronic dialysis patients. Am Heart J 1990; 119:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/19\">",
"      Reusser LM, Osborn LA, White HJ, et al. Increased morbidity after coronary angioplasty in patients on chronic hemodialysis. Am J Cardiol 1994; 73:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/20\">",
"      Jahangiri M, Wright J, Edmondson S, Magee P. Coronary artery bypass graft surgery in dialysis patients. Heart 1997; 78:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/21\">",
"      Hemmelgarn BR, Southern D, Culleton BF, et al. Survival after coronary revascularization among patients with kidney disease. Circulation 2004; 110:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/22\">",
"      Witczak B, Hartmann A, Svennevig JL. Multiple risk assessment of cardiovascular surgery in chronic renal failure patients. Ann Thorac Surg 2005; 79:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/23\">",
"      Charytan DM, Kuntz RE. Risks of coronary artery bypass surgery in dialysis-dependent patients--analysis of the 2001 National Inpatient Sample. Nephrol Dial Transplant 2007; 22:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/24\">",
"      Chang TI, Shilane D, Kazi DS, et al. Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. J Am Soc Nephrol 2012; 23:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/25\">",
"      Aoyama T, Ishii H, Toriyama T, et al. Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J 2008; 72:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/26\">",
"      Halkin A, Selzer F, Marroquin O, et al. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients. J Invasive Cardiol 2006; 18:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/27\">",
"      Nevis IF, Mathew A, Novick RJ, et al. Optimal method of coronary revascularization in patients receiving dialysis: systematic review. Clin J Am Soc Nephrol 2009; 4:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/28\">",
"      Szczech LA, Reddan DN, Owen WF, et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 2001; 60:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/29\">",
"      Owen CH, Cummings RG, Sell TL, et al. Coronary artery bypass grafting in patients with dialysis-dependent renal failure. Ann Thorac Surg 1994; 58:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/30\">",
"      Ahmed, WA, Kirshenbaum, JM. Outcome of coronary artery angioplasty in hemodialysis patients. Semin Dial 1994; 7:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/31\">",
"      Yachi S, Tanabe K, Tanimoto S, et al. Clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents versus bare-metal stents in hemodialysis patients. Am J Kidney Dis 2009; 54:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/32\">",
"      Das P, Moliterno DJ, Charnigo R, et al. Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. J Invasive Cardiol 2006; 18:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/33\">",
"      Weathers LW, Ziada KM. Drug-eluting stents in patients with end-stage renal disease. Minerva Cardioangiol 2008; 56:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/34\">",
"      Hiremath S, Holden RM, Fergusson D, Zimmerman DL. Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates. Clin J Am Soc Nephrol 2009; 4:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/35\">",
"      Kaufman JS, O'Connor TZ, Zhang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003; 14:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/36\">",
"      Herzog CA. The optimal method of coronary revascularization in dialysis patients: choosing between a rock and a hard place. Int J Artif Organs 2000; 23:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/37\">",
"      Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/38\">",
"      Chertow GM, Normand SL, Silva LR, McNeil BJ. Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project. Am J Kidney Dis 2000; 35:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/39\">",
"      Iseki K, Fukiyama K. Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. Am J Kidney Dis 2000; 36:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/40\">",
"      Herzog CA, Littrell K, Arko C, et al. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 2007; 116:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26984/abstract/41\">",
"      Baber U, Kini AS, Sharma SK, et al. Thrombolysis In Myocardial Infarction (TIMI) risk score and mortality in patients with advanced chronic kidney disease and on dialysis. Am J Cardiol 2009; 103:1513.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1921 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26984=[""].join("\n");
var outline_f26_22_26984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGIC TREATMENT OF STABLE CORONARY HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antianginal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anemia therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Blood pressure control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PHARMACOLOGIC TREATMENT OF UNSTABLE CORONARY HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Glycoprotein IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Timing and performance of hemodialysis session",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INVASIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Optimal method of coronary revascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Choice of intracoronary stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Follow-up issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pharmacologic treatment of stable disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pharmacologic treatment of unstable disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Invasive management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=related_link\">",
"      Classification of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33559?source=related_link\">",
"      Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=related_link\">",
"      Hypertension in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=related_link\">",
"      Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29703?source=related_link\">",
"      Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=related_link\">",
"      Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_22_26985="Approach to the infant and child with interstitial lung disease";
var content_f26_22_26985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the infant and child with interstitial lung disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/22/26985/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26985/contributors\">",
"     Leland L Fan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/22/26985/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26985/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/22/26985/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26985/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/22/26985/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial lung disease (ILD), also known as interstitial pneumonitis, consists of a diverse group of rare disorders that involve the pulmonary parenchyma and interfere with gas exchange. ILD occurs less commonly in children than in adults. Although many of the conditions that cause ILD in children and adults are similar, they occur in different proportions in each population. In addition, certain diseases are unique to infants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Interstitial lung disease in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis for a child with chronic tachypnea, hypoxemia, and diffuse pulmonary infiltrates includes many rare and potentially life-threatening conditions (",
"    <a class=\"graphic graphic_table graphicRef71704 \" href=\"UTD.htm?30/32/31245\">",
"     table 1",
"    </a>",
"    ). If a diagnosis can be made, treatment options may be limited, and often include drugs of unproven efficacy with serious side effects. Thus, ILD presents a diagnostic and therapeutic challenge, even to the most experienced pediatric pulmonologist.",
"   </p>",
"   <p>",
"    This topic review provides an approach to the diagnosis and management of ILD in infants and children. The classification of ILD in infants and children is presented separately. Specific disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18775?source=see_link\">",
"     \"Classification of interstitial lung disease in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ILD is rare in childhood. A survey from the United Kingdom and Ireland estimated a prevalence of 3.6 cases per 1 million children &le;16 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/7\">",
"     7",
"    </a>",
"    ]. Sixteen percent of all cases in this report were traced to four families, underlining the importance of a genetic contribution to certain forms of ILD. Many other cases of ILD are the result of infectious or postinfectious processes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Most children with ILD are diagnosed in the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/7,10,11\">",
"     7,10,11",
"    </a>",
"    ]. ILD is slightly more common among boys than girls, particularly in children younger than 2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;ILD comprises a heterogeneous group of disorders that are classified together because of similar clinical, radiographic, physiologic, or pathologic manifestations. However, the term \"interstitial\" is misleading because most of these disorders are associated with extensive alteration of alveolar and airway architecture, in addition to changes in the interstitial compartment. For this reason, the terms \"diffuse infiltrative lung disease\" or \"diffuse parenchymal lung disease\" are sometimes used.",
"   </p>",
"   <p>",
"    There are several potential ways in which to classify ILD in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/9\">",
"     9",
"    </a>",
"    ]. It may be classified according to etiology, if the etiology is known. This classification can be further divided according to whether the ILD is primarily a pulmonary process or whether it is occurs in association with a systemic disorder (",
"    <a class=\"graphic graphic_table graphicRef71704 \" href=\"UTD.htm?30/32/31245\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, many cases of ILD have no recognized cause and are not associated with a systemic disease. These cases may be classified histopathologically (",
"    <a class=\"graphic graphic_table graphicRef71704 \" href=\"UTD.htm?30/32/31245\">",
"     table 1",
"    </a>",
"    ). Finally, ILD may be classified according to age at presentation. This classification scheme is particularly helpful in infants, in whom unique forms of ILD occur (",
"    <a class=\"graphic graphic_table graphicRef71704 \" href=\"UTD.htm?30/32/31245\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/12\">",
"     12",
"    </a>",
"    ]. An overview of the classification of ILD in infants and children is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18775?source=see_link\">",
"     \"Classification of interstitial lung disease in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;ILD should be considered in any infant with a normal birth history who presents with tachypnea, crackles, hypoxemia, chronic cough, or diffuse infiltrates of unknown etiology. ILD syndromes unique to infants should be considered in any term or late preterm infant who develops respiratory distress and either fails to respond adequately to respiratory support or cannot be weaned from respiratory support [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This is particularly true if there is a family history of a similarly affected sibling [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18775?source=see_link&amp;anchor=H10#H10\">",
"     \"Classification of interstitial lung disease in infants and children\", section on 'ILD syndromes unique to infants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;ILD should be considered in any child with a normal birth history who presents with cough, dyspnea, inspiratory crackles, tachypnea, chest wall retractions, and exercise limitation for more than three months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of ILD in infants and children varies depending upon the clinical setting (",
"    <a class=\"graphic graphic_table graphicRef71704 \" href=\"UTD.htm?30/32/31245\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the more common diagnoses to consider include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection in the immunocompromised patient",
"     </li>",
"     <li>",
"      Recurrent aspiration (eg, gastroesophageal reflux, incoordinate swallowing, anatomic abnormalities of the larynx, trachea, or esophagus)",
"     </li>",
"     <li>",
"      Congestive changes related to cardiovascular disease",
"     </li>",
"     <li>",
"      Abnormalities of the pulmonary vasculature",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important step in diagnosis is recognizing when ILD is present, since early identification may lead to arrest or even reversal of deteriorating lung function. Unfortunately, a substantial interval often occurs between onset of symptoms and eventual diagnosis, so that complications frequently develop. More than 25 percent of children with ILD have pulmonary hypertension at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/14\">",
"     14",
"    </a>",
"    ], and 35 percent have been treated for asthma before undergoing a definitive evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic studies are used to identify the extent and severity of disease, predisposing disorders, and the primary disease (",
"    <a class=\"graphic graphic_table graphicRef76496 \" href=\"UTD.htm?36/55/37757\">",
"     table 2",
"    </a>",
"    ). The most useful approach to diagnosis is obtaining a history and physical examination, followed by noninvasive tests and invasive studies.",
"   </p>",
"   <p>",
"    However, even with a thorough evaluation, identifying a specific disorder may not be possible. In a prospective evaluation of 51 children with ILD, this staged approach provided a specific diagnosis in approximately 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/8\">",
"     8",
"    </a>",
"    ]. Diagnosis was based upon history and physical examination alone, noninvasive tests, and invasive studies (including lung biopsy) in 1, 8, and 26 patients, respectively. Of the remaining patients, eight had a suggestive diagnosis and eight had no specific diagnosis. Similarly in a multi-center survey regarding the diagnostic evaluation of 131 children with ILD, an etiologic or histologic diagnosis was achieved in 89 percent; only 4 percent of patients were diagnosed with noninvasive techniques alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and children with ILD typically present with symptoms of restrictive lung disease: tachypnea and dyspnea, exercise intolerance, dry cough, and rarely cyanosis.",
"   </p>",
"   <p>",
"    The European Respiratory Society Task Force (ERSTF) retrospectively reviewed 185 cases of ILD in immunocompetent children, including 58 cases in children younger than 2 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/10\">",
"     10",
"    </a>",
"    ]. The most common symptoms of chronic ILD included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cough (78 percent, overall; 73 percent of those &lt;2 years)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Tachypnea/dyspnea",
"      </span>",
"      (76 percent, overall; 84 percent of those &lt;2 years)",
"     </li>",
"     <li>",
"      Failure to thrive (37 percent, overall; 62 percent of those &lt;2 years)",
"     </li>",
"     <li>",
"      Fever (20 percent, overall; 29 percent of those &lt;2 years)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The onset of these symptoms usually is insidious, and their duration before presentation often is substantial. In a retrospective study of 48 children with ILD, 44 percent were symptomatic for more than one year before diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/15\">",
"     15",
"    </a>",
"    ]. In the ERSTF study, the mean duration of symptoms before diagnosis was 6.6 &plusmn; 0.5 months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wheezing is reported in one-half of affected children, and documented by physical examination in one-fifth. This finding may account for the large proportion of ILD patients who were initially thought to have asthma. Episodic wheezing and a positive response to bronchodilators favor the diagnosis of asthma over ILD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=see_link\">",
"     \"Approach to wheezing in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The history may suggest a specific diagnosis. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Feeding difficulties &mdash; aspiration",
"     </li>",
"     <li>",
"      Hemoptysis &mdash; pulmonary hemorrhage",
"     </li>",
"     <li>",
"      Febrile or acute respiratory illness &mdash; infection",
"     </li>",
"     <li>",
"      Exposure to birds or organic dusts &mdash; hypersensitivity pneumonitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Review of systems may detect an underlying immune deficiency or autoimmune disease. A family history of chronic lung disease may reveal an inherited form of ILD, including familial DIP or pulmonary alveolar proteinosis. In the ERSTF study, 10 percent of children with chronic ILD had affected siblings. Parental consanguinity was present in 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/10\">",
"     10",
"    </a>",
"    ]. Absent surfactant protein C (SP-C) and decreased levels of SP-A and SP-B may contribute to chronic lung injury in familial ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination in patients with ILD frequently is abnormal, but the findings are nonspecific. Tachypnea and retractions typically are present. Failure to thrive signifies advanced disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Crackles or \"velcro rales\" are common in most forms of ILD; in the ERSTF study, they were present in 44 percent of patients overall, but only 9 percent of those &lt;2 years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Wheezing is present in approximately 20 percent of children with ILD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The cardiac examination usually is normal except in the middle or late stages of pulmonary fibrosis, when findings of pulmonary hypertension and cor pulmonale (augmented P2, right-sided lift, right-sided gallop) may become evident.",
"     </li>",
"     <li>",
"      Cyanosis is indicative of severe disease; in the ERSTF study it was present in 28 percent of patients overall, and 54 percent of those &lt;2 years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clubbing of the digits (ie, the distal part of the finger is enlarged compared with the proximal part) is a late manifestation suggesting advanced fibrosis of the lung (",
"      <a class=\"graphic graphic_figure graphicRef52839 \" href=\"UTD.htm?42/58/43951\">",
"       figure 1",
"      </a>",
"      ). In the ERSTF study it was present in 13 percent of patients overall, and 9 percent of those &lt;2 years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Extrapulmonary manifestations may be helpful in narrowing the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef73094 \" href=\"UTD.htm?2/24/2445\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine laboratory evaluation often is not helpful. Nonetheless, it should include biochemical tests to evaluate hepatic and renal function, and hematologic tests to evaluate the presence of anemia, polycythemia, or leukocytosis. A single laboratory test rarely is diagnostic of a specific ILD but can provide supportive evidence in the context of the clinical presentation (",
"    <a class=\"graphic graphic_table graphicRef55597 \" href=\"UTD.htm?26/12/26828\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Decreased neutrophil or lymphocyte counts on a complete blood count suggest the possibility of underlying immunodeficiency. If immunodeficiency is suspected in a child who has unexplained chronic diffuse infiltrates, a full immune evaluation should be performed in any child with unexplained chronic diffuse infiltrates. This includes: HIV antibody titer; immunoglobulin levels (including IgE); T-cell and B-cell subsets; and lymphocyte functional studies (skin tests for delayed hypersensitivity, response to immunizations).",
"   </p>",
"   <p>",
"    Serologic studies should be obtained if clinically indicated by features suggestive of an underlying disorder. Antinuclear antibody (ANA) and C3 levels provide useful screening tests for suspected autoimmune disease. Serum angiotensin converting enzyme (ACE) levels may be markedly elevated in sarcoidosis.",
"   </p>",
"   <p>",
"    An elevated antineutrophil cytoplasmic antibody (ANCA) level in patients with pulmonary hemorrhage suggests vasculitic syndromes, including granulomatosis with polyangiitis (Wegener granulomatosis). Elevated antiglomerular basement membrane (GBM) antibodies suggest pulmonary anti-GBM (Goodpasture) disease. Finding either a positive ANCA or an anti-GBM antibody should prompt a urine examination for blood or red cell casts to identify a pulmonary-renal syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33383?source=see_link\">",
"     \"Approach to evaluating childhood vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H14577579#H14577579\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Acute glomerulonephritis and pulmonary hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When an environmental exposure is noted, demonstration of immunoprecipitins specific to a species of bird or a particular organic dust can confirm the diagnosis of hypersensitivity pneumonitis. Without this history, a screening test for reaction to common antigens and environmental contaminants may still be useful, although the interpretation of positive results is more difficult to make. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=see_link\">",
"     \"Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibody titers can suggest a specific infectious etiology, particularly viral or mycoplasma infection. Cultures as well as rapid tests of nasopharyngeal secretions may be diagnostic of viral, pertussis, or chlamydia infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33062?source=see_link\">",
"     \"Pneumonia caused by Chlamydophila (Chlamydia) species in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H101019906#H101019906\">",
"     \"Mycoplasma pneumoniae infection in children\", section on 'Approach to diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Analysis of blood can identify the common genetic mutations that cause surfactant dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete lung function testing (spirometry, lung volumes, diffusing capacity) should be obtained if possible, depending upon the age and cooperation of the child.",
"   </p>",
"   <p>",
"    Pulmonary function tests (PFTs) are most helpful in assessing severity of illness and in differentiating restrictive from obstructive lung disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"     \"Overview of pulmonary function testing in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spirometry, which includes measurement of forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), usually will be consistent with restrictive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/10,15\">",
"       10,15",
"      </a>",
"      ]. Affected children typically have a decrease in FVC and FEV1 with normal or increased",
"      <span class=\"nowrap\">",
"       FEV1/FVC",
"      </span>",
"      ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lung volume measurements reveal a normal to decreased total lung capacity (TLC) and an increase in residual volume",
"      <span class=\"nowrap\">",
"       (RV)/TLC.",
"      </span>",
"      This increased",
"      <span class=\"nowrap\">",
"       RV/TLC",
"      </span>",
"      ratio may reflect the relative decrease in TLC or a real increase in RV (true hyperinflation) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/17-19\">",
"       17-19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The single-breath diffusing capacity for carbon monoxide (DLCO) is below normal in absolute terms but usually corrects when adjusted for lung volume [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/10,17-19\">",
"       10,17-19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"       \"Overview of pulmonary function testing in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"       \"Diffusing capacity for carbon monoxide\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Resting room air arterial blood gases should be measured. However, pulse oximetry correlates well with arterial blood gas measurements, and the noninvasive measurement may be preferred. Oxygen saturation is normal with mild disease, but progressive illness leads to desaturation during sleep and exercise and, eventually, hypoxemia at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/6\">",
"     6",
"    </a>",
"    ]. Hypercarbia typically is absent until the disease is very advanced.",
"   </p>",
"   <p>",
"    With advanced disease, hypoxemia and structural changes in the lung contribute to increased pulmonary artery pressure, which can be detected by electrocardiogram and monitored with serial echocardiography. The extent of hypoxemia and pulmonary hypertension form the basis of the Severity of Illness Score, which may be of value in predicting survival [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diagnostic imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph, an important modality in diagnosis, is typically is abnormal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73783 graphicRef55956 graphicRef82288 \" href=\"UTD.htm?25/8/25738\">",
"     image 1A-C",
"    </a>",
"    ). In a retrospective series of 48 children with ILD, chest radiographs were abnormal in every case. Infiltrates were predominantly interstitial, alveolar, and mixed in 75, 8, and 13 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/15\">",
"     15",
"    </a>",
"    ]. Interstitial lung infiltrates typically are described as reticular, nodular, reticulonodular, or honeycombed. These descriptions may help to narrow the differential diagnosis, but they do not identify a specific disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     High resolution CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-resolution computed tomography (HRCT) correlates better with the extent, distribution, and severity of disease than does a chest radiograph and provides guidance for biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/6,20-22\">",
"     6,20-22",
"    </a>",
"    ]. However, the use of HRCT is somewhat limited in infants because their rapid breathing causes motion artifacts that make interpretation difficult. A new technique, controlled ventilation HRCT (CV-HRCT), uses noninvasive positive pressure ventilation in the sedated child to allow a brief respiratory pause at full inflation or end expiration, during which HRCT images can be obtained with minimal artifact [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Helical or spiral CT reduces the scanning time and improves the resolution of studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17032?source=see_link\">",
"     \"Principles of computed tomography of the chest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 20 children with biopsy-proven ILD, two experienced radiologists made a diagnosis with a high degree of confidence more often with HRCT than chest radiographs (63 versus 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/25\">",
"     25",
"    </a>",
"    ]. Of the confident first-choice diagnoses made on HRCT, 56 percent were correct. The dominant HRCT features were correlated with biopsy-proven diagnoses as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Geographic hyperlucency &mdash; bronchiolitis obliterans, bronchocentric granulomatosis",
"     </li>",
"     <li>",
"      Septal thickening &mdash; lymphangiomatosis, hemangiomatosis, microlithiasis",
"     </li>",
"     <li>",
"      Ground glass opacification &mdash; lymphocytic interstitial pneumonitis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis",
"     </li>",
"     <li>",
"      Lung cysts and nodules &mdash; pulmonary Langerhans cell histiocytosis",
"     </li>",
"     <li>",
"      Consolidation &mdash; aspiration, cryptogenic organizing pneumonia (formerly called bronchiolitis obliterans organizing pneumonia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent, similarly designed study confirmed the diagnostic accuracy of HRCT in pediatric ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoalveolar lavage (BAL) is used mainly to diagnose infection, detect aspiration and hemorrhage, diagnose certain specific conditions (eg, Langerhans cell histiocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/27\">",
"     27",
"    </a>",
"    ], pulmonary alveolar proteinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/28\">",
"     28",
"    </a>",
"    ], lysosomal storage disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], and surfactant protein deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]), and study disease mechanisms (eg, sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], hypersensitivity pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/35\">",
"     35",
"    </a>",
"    ]). In adults, BAL may help define the stage of disease and allow for the assessment of disease progression or response to therapy. However, the utility of BAL in the clinical assessment and management of pediatric patients with ILD remains to be established.",
"   </p>",
"   <p>",
"    BAL fluid usually is obtained via direct visualization using a \"wedged\" flexible bronchoscope. In small, intubated children, the procedure can be performed blindly with a suction catheter. The volume of saline used for lavage is controversial. Some experts recommend a fixed amount [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/36\">",
"     36",
"    </a>",
"    ], whereas others adjust for body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/37\">",
"     37",
"    </a>",
"    ]. Most favor the latter approach and recommend three aliquots of one",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    which is equal to 10 percent of functional residual capacity (FRC) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/38\">",
"     38",
"    </a>",
"    ]. Reference ranges for BAL constituents are similar to adult values. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link&amp;anchor=H2#H2\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\", section on 'Constituents of BAL in ILD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although BAL provides some useful information, it has limited ability to determine the primary cause of ILD, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of immunocompetent children presenting with diffuse infiltrates, BAL diagnosed a primary disorder in only 5 of 29 patients; three had aspiration and two had infection [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/39\">",
"       39",
"      </a>",
"      ]. The differential diagnosis was narrowed in 15 patients by the presence of lymphocytosis, neutrophilia, or eosinophilia, and a secondary disorder was uncovered in eight.",
"     </li>",
"     <li>",
"      When infectious organisms are recovered, it is uncertain whether they represent true pathogens, airway colonizers, or contaminants. In one study, aspirates obtained through an endotracheal tube in 30 of 31 healthy children who underwent minor surgical procedures grew potentially pathogenic microorganisms [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/40\">",
"       40",
"      </a>",
"      ]. This uncertainty is not an issue when the recovered organism is always pathogenic (eg, Mycoplasma tuberculosis).",
"     </li>",
"     <li>",
"      In immunocompromised children, BAL identified a specific organism in 47 percent without human immunodeficiency virus (HIV) and 77 percent with HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The detection of characteristic cell types in BAL may be helpful in narrowing the differential diagnosis, but usually is not specific for a disorder. Examples include lipid-laden macrophages, which occur in aspiration pneumonia but also are seen in endogenous lipoid pneumonia and fat embolism, and hemosiderin-laden macrophages, which are seen in pulmonary hemosiderosis as well as other hemorrhagic lung diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung biopsy is the most reliable diagnostic procedure because diagnoses of ILD are based upon histopathologic description. HRCT should be used to identify affected areas for biopsy. The tissue should be processed quickly, using standard methods, and interpreted by a pathologist experienced with pediatric lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Video-assisted thoracoscopy (VATS) is the procedure of choice in children requiring lung biopsy because morbidity is less than with open lung biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/41\">",
"     41",
"    </a>",
"    ]. In a prospective study of 30 children with ILD, VATS and open lung biopsy had similar diagnostic yield (60 and 53 percent), but VATS resulted in shorter durations of surgery, hospitalization, and chest tube drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/42\">",
"     42",
"    </a>",
"    ]. Biopsies of multiple lobes did not increase the diagnostic yield, although the numbers were small. Newborns were more likely to have a nondiagnostic biopsy than were older children; however, persistent tachypnea of infancy or other forms of ILD seen only in young children were detected in some. The diagnostic yield is likely to be higher at present because this study was performed before the identification of several ILD syndromes unique to infants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18775?source=see_link\">",
"     \"Classification of interstitial lung disease in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transbronchial biopsy (TBB) is used routinely to detect infection or rejection in children with heart-lung and lung transplantation. However, TBB has limited diagnostic value in children with diffuse infiltrates, except for sarcoidosis. This is due to the small size of these biopsy specimens, which are rarely able to provide sufficient architectural detail to allow definitive histologic diagnosis. Percutaneous fine needle aspiration under CT scan guidance has been used to diagnose diffuse infiltrates, but its role remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment consists of supportive therapy and specific pharmacologic interventions. In most cases, treatment is based upon anecdotal evidence. Because ILD encompasses a heterogeneous group of rare disorders, it is difficult to find enough patients to perform prospective, randomized controlled trials, even with multicenter collaboration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Supportive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive therapy should focus on:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Limiting exposure to cigarette smoke and other inhaled irritants",
"     </li>",
"     <li>",
"      Nutritional support as needed",
"     </li>",
"     <li>",
"      Oxygen therapy for hypoxemia",
"     </li>",
"     <li>",
"      Supervised exercise (for older children)",
"     </li>",
"     <li>",
"      Bronchodilators for reversible airway obstruction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to standard vaccination, annual influenza vaccines and aggressive treatment of intercurrent infection are important therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H2#H2\">",
"     \"Standard immunizations for children and adolescents\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Specific treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific treatment is available for some ILD disorders. Examples include antimicrobials for certain infections, antacids and prokinetic agents for reflux resulting in aspiration, avoidance of the offending antigen in hypersensitivity pneumonitis, interferon alpha for pulmonary hemangiomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/44\">",
"     44",
"    </a>",
"    ], and whole lung lavage for older children with alveolar proteinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/45\">",
"     45",
"    </a>",
"    ]. Granulocyte-macrophage colony-stimulating factor (GM-CSF), which is required for normal surfactant homeostasis, may be an alternative to lung lavage in acquired alveolar proteinosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/360?source=see_link\">",
"     \"Pulmonary alveolar proteinosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids are the mainstay of therapy for most children with ILD because inflammation leading to fibrosis is thought to play an important role in pathogenesis. Treatment consists of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or an equivalent corticosteroid for six to eight weeks, although this recommendation is not based upon results of clinical trials. Pulse therapy with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [maximum 1000 mg], administered over one hour, for three consecutive days each month) is an alternative to daily therapy and may be equally or more effective with fewer side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/6,46\">",
"     6,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who respond favorably to treatment have decreased severity of symptoms, better oxygenation, increased exercise capacity, and improved pulmonary function tests. Improvements may also be seen on chest radiograph or HRCT scan, but these tend to occur over a much longer period of time (eg, two to four years) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/10\">",
"     10",
"    </a>",
"    ]. In one series of 30 children, corticosteroids were effective in 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/15\">",
"     15",
"    </a>",
"    ]. Conditions that are considered variably responsive to corticosteroid therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypersensitivity pneumonitis",
"     </li>",
"     <li>",
"      Nonspecific interstitial pneumonitis",
"     </li>",
"     <li>",
"      Desquamative interstitial pneumonitis",
"     </li>",
"     <li>",
"      Lymphocytic interstitial pneumonitis",
"     </li>",
"     <li>",
"      Cryptogenic organizing pneumonia (bronchiolitis obliterans organizing pneumonia)",
"     </li>",
"     <li>",
"      Eosinophilic pneumonia",
"     </li>",
"     <li>",
"      Sarcoidosis",
"     </li>",
"     <li>",
"      Pulmonary hemosiderosis",
"     </li>",
"     <li>",
"      ILD associated with connective tissue disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment decisions in children with ILD should be individualized based upon the relative risks of disease and treatment. Treatment with corticosteroids or corticosteroid-sparing agents may be justified in many cases because of the considerable morbidity and mortality associated with many of these disorders (",
"    <a class=\"graphic graphic_table graphicRef57718 \" href=\"UTD.htm?6/44/6861\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/47\">",
"     47",
"    </a>",
"    ]. However, the long-term use of corticosteroids, particularly in the developing infant, must be considered with caution because of the potential adverse effects on neuromotor and cognitive function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27880?source=see_link\">",
"     \"Prevention of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternative immunosuppressive agents are considered when corticosteroids fail or result in significant side effects, although their efficacy is uncertain. In these circumstances, a second drug is started and the corticosteroids are weaned.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) is used most frequently. In case reports,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/53/40790?source=see_link\">",
"     chloroquine",
"    </a>",
"    has been effective in desquamative interstitial pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], lymphocytic interstitial pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], nonspecific interstitial pneumonitis, and pulmonary hemosiderosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/53\">",
"     53",
"    </a>",
"    ]. In many cases, hydroxychloroquine had a steroid-sparing effect. Retinal toxicity is a rare but serious complication.",
"   </p>",
"   <p>",
"    Some clinicians use",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    instead of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    .",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     Methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and high-dose intravenous immunoglobulin also have been used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplantation is an option for children who have severe and progressive disease and no response to therapy. Timely referral based upon DLCO measurements and HRCT fibrosis scores may improve outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The survival rate for children with ILD is similar to that of pediatric lung transplantation for all indications, approximately 50 percent at five years. However, mortality from obliterative bronchiolitis after heart-lung transplantation is higher in children than in adults (38 versus 17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3480?source=see_link\">",
"     \"Lung transplantation: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lung transplantation is the only effective treatment for some highly lethal diseases such as surfactant protein B and ABCA3 mutations, and alveolar capillary dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/6\">",
"     6",
"    </a>",
"    ]. However, proper diagnosis must be made as soon as possible after birth to give these patients a chance to undergo transplant. Recurrence of the primary ILD in transplanted lungs of children has not been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/360?source=see_link\">",
"     \"Pulmonary alveolar proteinosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis in ILD depends upon the underlying disorder. As an example, infants with neuroendocrine cell hyperplasia of infancy or pulmonary interstitial glycogenosis generally do well, although they may be symptomatic and require supplemental oxygen for years. In contrast, patients with extensive fibrosis and pulmonary hypertension and SP-B and ABCA3 mutations do poorly.",
"   </p>",
"   <p>",
"    One study reported outcomes of 99 children with chronic ILD seen in Denver, Colorado, over a 15-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26985/abstract/14\">",
"     14",
"    </a>",
"    ]. A variety of disorders, including infection, bronchiolitis obliterans, hypersensitivity pneumonitis, and pulmonary vascular disease, were encountered; 15 patients died (",
"    <a class=\"graphic graphic_table graphicRef57718 \" href=\"UTD.htm?6/44/6861\">",
"     table 5",
"    </a>",
"    ). After the onset of symptoms, the probability of survival was 83, 72, and 64 percent at 24, 48, and 60 months, respectively.",
"   </p>",
"   <p>",
"    Clinical features present at the time of initial evaluation, including duration of symptoms, weight below 5th percentile, crackles, clubbing, and family history of ILD, were",
"    <strong>",
"     not",
"    </strong>",
"    associated with decreased survival. However, an increasing severity of illness score, based upon hypoxemia and pulmonary hypertension, was significantly associated with decreasing survival (",
"    <a class=\"graphic graphic_table graphicRef51188 \" href=\"UTD.htm?10/17/10523\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/9/14483?source=see_link\">",
"       \"Patient information: Interstitial lung disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infant or child with persistent tachypnea, dyspnea, exercise intolerance, dry cough, or hypoxemia should be evaluated by a pediatric pulmonologist. Following a thorough history and physical examination, a chest radiograph should be obtained. The appearance of diffuse pulmonary infiltrates consistent with ILD should prompt additional step-wise testing, including (",
"    <a class=\"graphic graphic_table graphicRef76496 \" href=\"UTD.htm?36/55/37757\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Laboratory studies &mdash; immune work-up, ACE levels, ANA, ANCA, C3 levels, anti-GBM antibody, cultures or antigen testing if indicated, hypersensitivity pneumonitis screen, ECG, echocardiogram",
"     </li>",
"     <li>",
"      Pulmonary function tests &mdash; FVC and FEV1, RV and TLC, DLCO, pulse oximetry",
"     </li>",
"     <li>",
"      Additional diagnostic imaging &mdash; HRCT",
"     </li>",
"     <li>",
"      Bronchoalveolar lavage",
"     </li>",
"     <li>",
"      Lung biopsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General supportive measures are recommended in all patients. If available, specific treatment should be instituted for a particular disorder. If no specific therapy is available, corticosteroids should be considered.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/1\">",
"      Fan LL, Langston C. Chronic interstitial lung disease in children. Pediatr Pulmonol 1993; 16:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/2\">",
"      Fan LL. Evaluation and therapy of chronic interstitial pneumonitis in children. Curr Opin Pediatr 1994; 6:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/3\">",
"      Bokulic RE, Hilman BC. Interstitial lung disease in children. Pediatr Clin North Am 1994; 41:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/4\">",
"      Diaz, RP, Bowman, CM. Childhood interstitial lung disease. Semin Respir Med 1990; 11:253.",
"     </a>",
"    </li>",
"    <li>",
"     Interstitial lung disease in children, Laraya-Cuasay LR, Hughes WT (Eds) (Eds), CRC Press, Inc, CRC Press, Inc 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/6\">",
"      Fan LL, Deterding RR, Langston C. Pediatric interstitial lung disease revisited. Pediatr Pulmonol 2004; 38:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/7\">",
"      Dinwiddie R, Sharief N, Crawford O. Idiopathic interstitial pneumonitis in children: a national survey in the United Kingdom and Ireland. Pediatr Pulmonol 2002; 34:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/8\">",
"      Fan LL, Kozinetz CA, Deterding RR, Brugman SM. Evaluation of a diagnostic approach to pediatric interstitial lung disease. Pediatrics 1998; 101:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/9\">",
"      Langston C, Fan LL. The spectrum of interstitial lung disease in childhood. Pediatr Pulmonol 2001; Suppl 23:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/10\">",
"      Clement A, ERS Task Force. Task force on chronic interstitial lung disease in immunocompetent children. Eur Respir J 2004; 24:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/11\">",
"      Barbato A, Panizzolo C, Cracco A, et al. Interstitial lung disease in children: a multicentre survey on diagnostic approach. Eur Respir J 2000; 16:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/12\">",
"      Langston C, Fan LL. Diffuse interstitial lung disease in infants. Pediatr Pulmonol 2001; Suppl 23:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/13\">",
"      Brasch F, Schimanski S, M&uuml;hlfeld C, et al. Alteration of the pulmonary surfactant system in full-term infants with hereditary ABCA3 deficiency. Am J Respir Crit Care Med 2006; 174:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/14\">",
"      Fan LL, Kozinetz CA. Factors influencing survival in children with chronic interstitial lung disease. Am J Respir Crit Care Med 1997; 156:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/15\">",
"      Fan LL, Mullen AL, Brugman SM, et al. Clinical spectrum of chronic interstitial lung disease in children. J Pediatr 1992; 121:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/16\">",
"      Amin RS, Wert SE, Baughman RP, et al. Surfactant protein deficiency in familial interstitial lung disease. J Pediatr 2001; 139:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/17\">",
"      Zapletal A, Houst��k J, Sam&aacute;nek M, et al. Lung function in children and adolescents with idiopathic interstitial pulmonary fibrosis. Pediatr Pulmonol 1985; 1:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/18\">",
"      Steinkamp G, M&uuml;ller KM, Schirg E, von der Hardt H. Fibrosing alveolitis in childhood. A long-term follow-up. Acta Paediatr Scand 1990; 79:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/19\">",
"      Gaultier C, Chaussain M, Boul&eacute; M, et al. Lung function in interstitial lung diseases in children. Bull Eur Physiopathol Respir 1980; 16:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/20\">",
"      Lynch DA, Brasch RC, Hardy KA, Webb WR. Pediatric pulmonary disease: assessment with high-resolution ultrafast CT. Radiology 1990; 176:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/21\">",
"      Kuhn JP. High-resolution computed tomography of pediatric pulmonary parenchymal disorders. Radiol Clin North Am 1993; 31:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/22\">",
"      Koh DM, Hansell DM. Computed tomography of diffuse interstitial lung disease in children. Clin Radiol 2000; 55:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/23\">",
"      Long FR, Castile RG, Brody AS, et al. Lungs in infants and young children: improved thin-section CT with a noninvasive controlled-ventilation technique--initial experience. Radiology 1999; 212:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/24\">",
"      Long FR, Castile RG. Technique and clinical applications of full-inflation and end-exhalation controlled-ventilation chest CT in infants and young children. Pediatr Radiol 2001; 31:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/25\">",
"      Lynch DA, Hay T, Newell JD Jr, et al. Pediatric diffuse lung disease: diagnosis and classification using high-resolution CT. AJR Am J Roentgenol 1999; 173:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/26\">",
"      Copley SJ, Coren M, Nicholson AG, et al. Diagnostic accuracy of thin-section CT and chest radiography of pediatric interstitial lung disease. AJR Am J Roentgenol 2000; 174:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/27\">",
"      R&eacute;fabert L, Rambaud C, Mamou-Mani T, et al. Cd1a-positive cells in bronchoalveolar lavage samples from children with Langerhans cell histiocytosis. J Pediatr 1996; 129:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/28\">",
"      Mahut B, Delacourt C, Scheinmann P, et al. Pulmonary alveolar proteinosis: experience with eight pediatric cases and a review. Pediatrics 1996; 97:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/29\">",
"      Niggemann B, Rebien W, Rahn W, Wahn U. Asymptomatic pulmonary involvement in 2 children with Niemann-Pick disease type B. Respiration 1994; 61:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/30\">",
"      Carson KF, Williams CA, Rosenthal DL, et al. Bronchoalveolar lavage in a girl with Gaucher's disease. A case report. Acta Cytol 1994; 38:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/31\">",
"      Herting E, Schiffmann H, Roth C, Johansson J. Surfactant lavage demonstrates protein fibrils in a neonate with congenital surfactant protein b deficiency. Am J Respir Crit Care Med 2002; 166:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/32\">",
"      deMello DE, Nogee LM, Heyman S, et al. Molecular and phenotypic variability in the congenital alveolar proteinosis syndrome associated with inherited surfactant protein B deficiency. J Pediatr 1994; 125:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/33\">",
"      Chadelat K, Baculard A, Grimfeld A, et al. Pulmonary sarcoidosis in children: serial evaluation of bronchoalveolar lavage cells during corticosteroid treatment. Pediatr Pulmonol 1993; 16:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/34\">",
"      Tessier V, Chadelat K, Baculard A, et al. BAL in children: a controlled study of differential cytology and cytokine expression profiles by alveolar cells in pediatric sarcoidosis. Chest 1996; 109:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/35\">",
"      Ratjen F, Costabel U, Griese M, Paul K. Bronchoalveolar lavage fluid findings in children with hypersensitivity pneumonitis. Eur Respir J 2003; 21:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/36\">",
"      Midulla F, Villani A, Merolla R, et al. Bronchoalveolar lavage studies in children without parenchymal lung disease: cellular constituents and protein levels. Pediatr Pulmonol 1995; 20:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/37\">",
"      Ratjen F, Bruch J. Adjustment of bronchoalveolar lavage volume to body weight in children. Pediatr Pulmonol 1996; 21:184.",
"     </a>",
"    </li>",
"    <li>",
"     Fan LL. Pediatric interstitial lung disease. In: Interstitial Lung Disease, 4th ed, King TE Jr, Schwarz MI (Eds) (Eds), BC Decker, Hamilton, ON, Canada 2003. p.134.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/39\">",
"      Fan LL, Lung MC, Wagener JS. The diagnostic value of bronchoalveolar lavage in immunocompetent children with chronic diffuse pulmonary infiltrates. Pediatr Pulmonol 1997; 23:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/40\">",
"      Hjuler IM, Hansen MB, Olsen B, Renneberg J. Bacterial colonization of the larynx and trachea in healthy children. Acta Paediatr 1995; 84:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/41\">",
"      Rothenberg SS, Wagner JS, Chang JH, Fan LL. The safety and efficacy of thoracoscopic lung biopsy for diagnosis and treatment in infants and children. J Pediatr Surg 1996; 31:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/42\">",
"      Fan LL, Kozinetz CA, Wojtczak HA, et al. Diagnostic value of transbronchial, thoracoscopic, and open lung biopsy in immunocompetent children with chronic interstitial lung disease. J Pediatr 1997; 131:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/43\">",
"      Spencer DA, Alton HM, Raafat F, Weller PH. Combined percutaneous lung biopsy and high-resolution computed tomography in the diagnosis and management of lung disease in children. Pediatr Pulmonol 1996; 22:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/44\">",
"      White CW, Sondheimer HM, Crouch EC, et al. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989; 320:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/45\">",
"      de Blic J. Pulmonary alveolar proteinosis in children. Paediatr Respir Rev 2004; 5:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/46\">",
"      Desmarquest P, Tamalet A, Fauroux B, et al. Chronic interstitial lung disease in children: response to high-dose intravenous methylprednisolone pulses. Pediatr Pulmonol 1998; 26:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/47\">",
"      de Benedictis FM, Canny GJ, Levison H. The role of corticosteroids in respiratory diseases of children. Pediatr Pulmonol 1996; 22:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/48\">",
"      Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004; 350:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/49\">",
"      Springer C, Maayan C, Katzir Z, et al. Chloroquine treatment in desquamative interstitial pneumonia. Arch Dis Child 1987; 62:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/50\">",
"      Leahy F, Pasterkamp H, Tal A. Desquamative interstitial pneumonia responsive to chloroquine. Clin Pediatr 1984; 24:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/51\">",
"      Waters KA, Bale P, Isaacs D, Mellis C. Successful chloroquine therapy in a child with lymphoid interstitial pneumonitis. J Pediatr 1991; 119:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/52\">",
"      Campos JM, Simonetti JP. Treatment of lymphoid interstitial pneumonia with chloroquine. J Pediatr 1993; 122:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/53\">",
"      Bush A, Sheppard MN, Warner JO. Chloroquine in idiopathic pulmonary haemosiderosis. Arch Dis Child 1992; 67:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/54\">",
"      Mogulkoc N, Brutsche MH, Bishop PW, et al. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001; 164:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26985/abstract/55\">",
"      Scott JP, Whitehead B, de Leval M, et al. Paediatric incidence of acute rejection and obliterative bronchiolitis: a comparison with adults. Transpl Int 1994; 7 Suppl 1:S404.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6374 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-99C72D4C66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26985=[""].join("\n");
var outline_f26_22_26985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diagnostic imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - High resolution CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Supportive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Specific treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6374\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6374|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/46/30432\" title=\"diagnostic image 1A\">",
"      DIP plain radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/42/32421\" title=\"diagnostic image 1B\">",
"      NSIP CXR and HRCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/14/31973\" title=\"diagnostic image 1C\">",
"      LIP CXR and HRCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6374|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/58/43951\" title=\"figure 1\">",
"      Clubbing of the fingers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6374|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/32/31245\" title=\"table 1\">",
"      Classification pediatric ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/55/37757\" title=\"table 2\">",
"      Diagnostic evaluation ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/24/2445\" title=\"table 3\">",
"      Physical findings in ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/12/26828\" title=\"table 4\">",
"      Laboratory findings in ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/44/6861\" title=\"table 5\">",
"      ILD diagnosis and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/17/10523\" title=\"table 6\">",
"      Severity of illness score PILD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33383?source=related_link\">",
"      Approach to evaluating childhood vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=related_link\">",
"      Approach to wheezing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18775?source=related_link\">",
"      Classification of interstitial lung disease in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=related_link\">",
"      Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=related_link\">",
"      Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=related_link\">",
"      Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=related_link\">",
"      Diffusing capacity for carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3480?source=related_link\">",
"      Lung transplantation: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=related_link\">",
"      Overview of pulmonary function testing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/9/14483?source=related_link\">",
"      Patient information: Interstitial lung disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33062?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) species in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27880?source=related_link\">",
"      Prevention of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17032?source=related_link\">",
"      Principles of computed tomography of the chest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/360?source=related_link\">",
"      Pulmonary alveolar proteinosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_22_26986="Zoonoses from pets other than dogs and cats";
var content_f26_22_26986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Zoonoses from pets other than dogs and cats",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/22/26986/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26986/contributors\">",
"     Camille N Kotton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/22/26986/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26986/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/22/26986/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/22/26986/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/22/26986/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pets serve valuable social roles in society [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Pets may lower blood pressure, reduce cholesterol and triglyceride levels, and improve feelings of loneliness, while increasing opportunities for exercise, outdoor activities, and socialization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these benefits, pets present zoonotic risks, especially for immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. In addition to infection from pets, there have been multiple outbreaks of enteric disease associated with animal exposure in public settings, such as county fairs, farms, and petting zoos [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/8\">",
"     8",
"    </a>",
"    ]. In a review of 55 such outbreaks, most were due to Escherichia coli O157 (58 percent) and Salmonella species (22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18745?source=see_link&amp;anchor=H4450953#H4450953\">",
"     \"Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)\", section on 'Animal contact'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology of zoonoses from pets other than dogs and cats will be reviewed here. The epidemiology of dog- and cat-related zoonoses is presented separately and the clinical management of specific zoonotic diseases is discussed in the appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29065?source=see_link\">",
"     \"Zoonoses from dogs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31401?source=see_link\">",
"     \"Zoonoses from cats\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A zoonosis is an animal disease that is transmissible to humans. Humans are usually an accidental host that acquires disease through close contact with an infected animal, who may or may not be symptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Veterinary Medical Association's 2005 to 2006 survey of United States pet owners found that 63 percent of all United States households have at least one pet (",
"    <a class=\"external\" href=\"file://www.avma.org/\">",
"     www.avma.org",
"    </a>",
"    ). The most common route of infection related to pet contact, is through bites, especially in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"     \"Soft tissue infections due to dog and cat bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should ask about pets when taking a medical history and formulating a differential diagnosis. Many of the risks posed by pet ownership can be reduced by good hygiene after handling pets, careful pet selection, and proper pet care. New pets can pose more of a health risk. Adult pets are generally safer than younger animals, since they are less likely to be involved in playful activities that include scratching and biting. Children are at highest risk for infection because they are more likely to have close contact with pets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission of an extensive array of bacterial, viral, and parasitic zoonotic pathogens can occur from pets. Many different routes of transmission can cause infections related to pets including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infectious saliva that contaminate bite wounds, skin abrasions, or mucous membranes",
"     </li>",
"     <li>",
"      Hand-to-mouth transfer of microorganisms, cysts, or oocysts (eggs) from feces of an infected animal",
"     </li>",
"     <li>",
"      Insect bites when these vectors are carried into the home by pets or when bites transmit disease from a pet, acting as a disease reservoir, to humans",
"     </li>",
"     <li>",
"      Aerosol from body fluids (eg, respiratory secretions, placenta)",
"     </li>",
"     <li>",
"      Scratches",
"     </li>",
"     <li>",
"      Contamination of water or the environment with pathogen containing animal urine",
"     </li>",
"     <li>",
"      Contamination of an object that is subsequently put into the mouth (eg, pacifier) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HORSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fecal transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common zoonotic pathogens causing equine gastroenteritis include Salmonella, Campylobacter, Cryptosporidium and Giardia. Although horses are not the usual source for human gastrointestinal infection, these pathogens should be considered in a patient who presents with compatible symptoms who has had contact with a horse with diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Salmonella",
"    </span>",
"    &nbsp;&mdash;&nbsp;An outbreak of salmonellosis in a population of hospitalized horses resulted in the closure of a veterinary teaching hospital for a period of 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/11\">",
"     11",
"    </a>",
"    ]. Fecal samples were collected from suspected cases and cultured for Salmonella. Thirty-three cases of infection by a multidrug-resistant strain of S. typhimurium were detected. S. typhimurium might have been introduced into the hospital environment by a foal presenting with diarrhea.",
"   </p>",
"   <p>",
"    Salmonella spp infections transmitted to humans usually result in a mild, self-limited gastroenteritis. However, severe invasive illness, such as septicemia or meningitis, can occur especially in infants and immunocompromised persons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=see_link\">",
"     \"Approach to the patient with nontyphoidal Salmonella in a stool culture\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Campylobacter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter enteritis in humans presents after an incubation period of one to seven days as a syndrome most commonly characterized by prominent abdominal pain and profuse diarrhea that is often bloody. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of Campylobacter infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cryptosporidium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptosporidium is an intracellular protozoan parasite that is associated with gastrointestinal diseases in all classes of vertebrates including horses. Cryptosporidial oocyst shedding is primarily found in immunocompromised or immature horses and rarely from healthy mature horses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryptosporidium infection in immunocompetent individuals has a variable presentation, it can be asymptomatic, cause a self-limited gastroenteritis (usually resolving in 10 to 14 days without treatment), or can cause more severe diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/13\">",
"     13",
"    </a>",
"    ]. In immunocompromised hosts, the illness is more frequently protracted and severe, and can lead to significant malabsorption and weight loss. Cryptosporidium parvum and C. hominis are the usual pathogens in humans; immunocompromised hosts can also be infected by other Cryptosporidium spp [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Giardia lamblia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giardia lamblia (also known as G. duodenalis or G. intestinalis) is a flagellated protozoan parasite and one of the most common gastrointestinal parasites in the United States. There is evidence supporting the zoonotic transmission of Giardia; horses may constitute a potential source for human infection of Giardia either directly or via contamination of watersheds [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The spectrum of clinical disease in humans includes asymptomatic infection, self-limited acute giardiasis, and chronic infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Clostridium difficile",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. difficile infection occurs in foals and horses following treatment with antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/16\">",
"     16",
"    </a>",
"    ]. Outbreaks may occur in veterinary hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/17\">",
"     17",
"    </a>",
"    ]. However, no case of horse to human transmission has been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Aerosol",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Rhodococcus equi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhodococcus equi is a gram-positive pleomorphic organism that appears coccoid on solid media but forms long rods or short filaments in liquid media. The organisms can be acid fast with the Ziehl-Neelsen stain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37814?source=see_link\">",
"     \"Microbiology; pathogenesis; and epidemiology of Rhodococcus equi infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    R. equi is a soil organism carried in the gut of many herbivores and widespread in their environment. On horse farms, progressive environmental contamination with R. equi has been related to the length of time that animals were present [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/18\">",
"     18",
"    </a>",
"    ]. The highest numbers of organisms have been found in the surface soil on horse farms with endemic disease. Exposure to soil contaminated with herbivore manure is likely the major route of acquisition for both animal and human infection.",
"   </p>",
"   <p>",
"    Foals less than six months old are uniquely susceptible to the development of a chronic suppurative bronchopneumonia that can lead to lung and bronchial lymph node abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/19\">",
"     19",
"    </a>",
"    ]. Ulcerative colitis and mesenteric adenitis may also occur, usually associated with pulmonary infection.",
"   </p>",
"   <p>",
"    Most human infections have been associated with immune system dysfunction (eg, HIV, solid organ transplant recipients). Pulmonary infections are the most common form of human disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18791?source=see_link\">",
"     \"Clinical features; diagnosis; therapy; and prevention of Rhodococcus equi infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Brucella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brucella spp infection in horses appears to have a worldwide distribution, but human infections transmitted by horses are uncommon. The Brucella spp that are frequently associated with horses are B. suis and B. abortus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Humans may become infected when they are exposed to body fluids from a B. suis or B. abortus infected horse. Most cases of human transmission from horses are in developing countries.",
"   </p>",
"   <p>",
"    Human brucellosis is a well-documented cause of fever of unknown origin with varied and nonspecific symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of brucellosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Coxiella burnetii",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coxiella burnetii, the etiologic agent of Q fever, is a worldwide zoonosis. The most common animal reservoirs are goats, cattle, sheep, cats, and occasionally dogs or horses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Infected mammals shed C. burnetii in urine, feces, milk, and birth products.",
"   </p>",
"   <p>",
"    In humans, exposure results from inhalation of contaminated aerosols from parturient fluids of infected mammals, which can be present in the environment, on the coats of newborn animals, or from the placenta. A serosurvey of horses in Uruguay found a positive rate of 5.5 percent in 1979 and 21.7 percent in 1985 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/23\">",
"     23",
"    </a>",
"    ]. Outbreaks in humans in Uruguay have occurred in workers at meat-processing plants, no Q fever cases are reported that implicated transmission from pet horses to human [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22357?source=see_link\">",
"     \"Microbiology and epidemiology of Q fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical signs of Q fever are often extremely mild or absent. Patients may be asymptomatic or can present acutely with one of three clinical presentations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A self-limited flu-like illness",
"     </li>",
"     <li>",
"      Pneumonia",
"     </li>",
"     <li>",
"      Hepatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic infection most commonly involves the heart as endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12502?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Q fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mosquito-borne disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Horses can be infected by Eastern, Western, or Venezuelan equine encephalitis virus or West Nile virus. However, although both human and horses may develop encephalitis from each of these agents, infection with Eastern and Western equine encephalitis (EEE and WEE) and West Nile virus results in low or undetectable levels of viremia, thus these hosts do not serve as reservoirs for further spread of the virus. The horse, however, acts as a reservoir of disease for Venezuelan equine encephalitis (VEE) virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Equine encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large outbreaks of Western equine encephalitis in humans and horses occurred in the western United States in the 1950s and 1960s. However, a declining horse population, equine vaccination, and improved vector control have reduced the incidence of the disease. Infection of avian species results in a viremia of sufficient magnitude and frequency to maintain a reservoir of infected mosquitoes. Infection of horses causes low level viremia and thus the horse is not a reservoir of WEE or EEE virus.",
"   </p>",
"   <p>",
"    In contrast, horses serve as the primary amplification hosts for Venezuelan equine encephalitis (VEE) virus without which there would be little human disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/24\">",
"     24",
"    </a>",
"    ]. Effective prevention of both human and equine disease can be accomplished by immunizing equines. Mosquitoes are required as a vector for human transmission. VEE has a widespread geographic distribution from Florida to South America.",
"   </p>",
"   <p>",
"    Human disease occurs after an incubation period of one to six days, and is heralded by a brief febrile illness of sudden onset, accompanied by malaise, nausea or vomiting, headache, and myalgia. Less than 0.5 percent of adults and less than 4 percent of children develop encephalitis, characterized by nuchal rigidity, seizures, coma, and paralysis. Long-term sequelae and fatalities are uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=see_link\">",
"     \"Arthropod-borne encephalitides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Infected saliva",
"    </span>",
"    &nbsp;&mdash;&nbsp;Saliva can transmit and contaminate bite wounds, skin abrasions, or mucous membranes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Rabies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, horses can become infected with rabies and die [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Human rabies is rare in the United States, with only 47 cases reported between 1990 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/27\">",
"     27",
"    </a>",
"    ]. However, rabies should be considered in the differential diagnosis of patients presenting with acute progressive encephalitis regardless of a history of an animal bite. Because of the nonspecific early symptoms, other more common infectious and noninfectious disorders (eg, encephalitis caused by arboviruses or enterovirus and Guillain-Barr&eacute; syndrome or vasculitis) should be ruled out. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29624?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rabies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RABBITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections related to domestic pet rabbits are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/28\">",
"     28",
"    </a>",
"    ]. Although they can contract and potentially transmit a variety of zoonotic pathogens, infection with any one of these pathogens is unusual. The following zoonotic pathogens have been reported in pet rabbits:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salmonella spp, Yersinia pseudotuberculosis, and Cryptosporidium infection may be transmitted to humans through contaminated rabbit feces [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Respiratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pasteurella multocida can colonize and cause a respiratory disease (snuffles) or eye infections in rabbits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/30\">",
"     30",
"    </a>",
"    ]. Although P. multocida has been found in the oropharynx of animal breeders and antibodies to P. multocida have been detected in their sera, occupational disease has not been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bordetella bronchiseptica was isolated four times over 2.5 years from a 79-year old bronchopneumonia patient who lived on a farm and had contact with rabbits [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/32\">",
"       32",
"      </a>",
"      ]. Epidemiologic investigation found that the rabbits had clinical symptoms consistent with B. bronchiseptica respiratory infection and sacrifice of one symptomatic rabbit led to the isolation of the organism from the lower respiratory tract.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabies virus infection was confirmed in seven pet rabbits in New York State [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/33\">",
"     33",
"    </a>",
"    ]. The animals had been caged outside and had probably contracted the disease from a wild animal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatophytes such as Trichophyton (ringworm) are prevalent in rabbits on farms and the skin infection can be transmitted to humans through direct contact with the skin lesions of rabbits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cheyletiellosis (caused by the rabbit fur mite) can cause a papular, pruritic eruption in humans, although the human infection is limited by the inability of the mite to reproduce on human skin [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Zoonoses from wild rabbits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zoonotic infections in wild rabbits are more likely to cause human disease. Infections related to contact with wild rabbits include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tularemia, a zoonotic disease caused by Francisella tularensis, infects rabbits. Handling infected rabbits is one of the most common modes of tularemia transmission in the United States. During 2001 to 2003, an outbreak of human tularemia in Wyoming was temporally associated with an outbreak among rabbits [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wild cottontail rabbits on Nantucket Island, Massachusetts, have been found to harbor a Babesia spp that was identical to that causing human babesiosis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. In addition, cottontail rabbits on Nantucket Island also harbor Anaplasma phagocytophilum (the agent of human granulocytic anaplasmosis, HGA), although the impact of this reservoir on human disease is unknown [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42248?source=see_link\">",
"       \"Epidemiology and pathogenesis of babesiosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=see_link\">",
"       \"Human ehrlichiosis and anaplasmosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7012451\">",
"    <span class=\"h1\">",
"     DEER, SHEEP, CATTLE AND GOATS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parapoxvirus infections can be transmitted from deer, sheep, cattle and goats to humans. People with parapoxvirus infections can present with an erythematous maculopapular lesion after an incubation period of three to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/41\">",
"     41",
"    </a>",
"    ]. Lesions usually occur at the site of inoculation (often fingers or hands) and evolve slowly over the course of four to eight weeks from a papule to a vesicle and then to an ulcer with subsequent crusting. Recurrent lesions can occur since infection does not confer immunity.",
"   </p>",
"   <p>",
"    The specific type of parapoxvirus varies by host; for example, orf virus infection occurs in sheep and goats while bovine papular stomatitis virus occurs in cattle:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 2009, parapoxvirus infection was diagnosed in two deer hunters in the eastern United States after the hunters had field-dressed white-tailed deer [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/42\">",
"       42",
"      </a>",
"      ]. DNA sequence analysis suggested that the virus infecting the hunters was a unique parapoxvirus strain. One patient had resolution of a papulonodular cutaneous lesion on his finger without medical intervention; the other patient was treated with antibiotics.",
"     </li>",
"     <li>",
"      In 2012, four cases of orf were reported in the United States in association with the slaughter of goats and lambs for religious observances [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/43\">",
"       43",
"      </a>",
"      ]. All incurred puncture wounds resulting in cutaneous lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On histology, these lesions are characterized by epidermal hyperplasia with occasional cytoplasmic inclusions, prominent vascular proliferation, and mixed inflammatory-cell infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/44\">",
"     44",
"    </a>",
"    ]. The diagnosis can be confirmed through polymerase chain reaction (PCR) testing, which is available through the United States Centers for Disease Control and Prevention (CDC) (404-639-4129).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     RODENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rodents, including hamsters, gerbils, guinea pigs, mice, rats, and prairie dogs, are becoming more common pets. Transmission of infectious disease from rodent to man usually results from bites or exposure to potentially infectious feces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Transmission by feces",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pet rodents are a potential source of salmonellosis. During 2004, the Minnesota Department of Health (MDH) Public Health Laboratory reported the isolation of multidrug-resistant Salmonella enterica serotype Typhimurium from patients and their ill hamsters purchased from a Minnesota pet distributor; this was the first documented human salmonellosis outbreak associated with pet rodents [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=see_link&amp;anchor=H7#H7\">",
"       \"Microbiology and epidemiology of salmonellosis\", section on 'Other methods of transmission'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Information related to the transmission of hantaviruses from rodent feces is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13848?source=see_link\">",
"     \"Epidemiology and diagnosis of hantavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Transmission by infected saliva (bites)",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A three-year-old boy was diagnosed with tularemia associated with a pet hamster bite in 2004 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/47\">",
"       47",
"      </a>",
"      ]. A pet prairie dog was also linked to transmission of tularemia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rat bite fever, a rare disease caused by Streptobacillus moniliformis or Spirillum minus, can be transmitted by rats, mice, and squirrels. A fatal case of rat bite fever in a pet shop employee occurred following a superficial finger wound on a contaminated rat cage [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1413?source=see_link\">",
"       \"Rat bite fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rabies very rarely is reported from rodents, a report in 2005 confirmed rabies in a pet guinea pig in New York State [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/33\">",
"       33",
"      </a>",
"      ]. The animal was housed outside and probably came in contact with wild animals. Rabies prophylaxis is rarely indicated following rodent bites. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=see_link\">",
"       \"Rabies immune globulin and vaccine\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Direct contact or aerosol",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wild house mice are the primary reservoir for lymphocytic choriomeningitis virus (LCMV) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/50\">",
"       50",
"      </a>",
"      ]. Pet rodents, such as hamsters and guinea pigs, become infected after contact with infected mice [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/51\">",
"       51",
"      </a>",
"      ]. Human acquisition of LCMV occurs by direct contact with fomites contaminated with infectious virus or inhalation of aerosolized virus. A large outbreak of LCMV infection associated with pet hamsters sold by a single distributor was reported in 1974, when 181 human cases were identified in 12 states; no deaths occurred [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/52\">",
"       52",
"      </a>",
"      ]. The outbreak was controlled by voluntary cessation of the sale of pet hamsters and subsequent destruction of the infected breeding stock.",
"      <br/>",
"      <br/>",
"      A report of LCV infection in organ transplant recipients was traced back to asymptomatic infection in the donor who had a pet hamster from whom LCV was subsequently isolated [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/50\">",
"       50",
"      </a>",
"      ]. The asymptomatic organ donor, who died of a stroke, was the source of organs to five recipients, four of whom died. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link&amp;anchor=H8#H8\">",
"       \"Infection in the solid organ transplant recipient\", section on 'Donor-derived infections'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ill pet prairie dogs imported from West Africa were responsible for an outbreak of monkeypox infection in the Midwestern United States in 2003 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16439?source=see_link\">",
"       \"Monkeypox\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A case report describes transmission of cowpox to a young boy from a sick pet rat in the United Kingdom [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/54\">",
"       54",
"      </a>",
"      ]. Human cowpox infection primarily occurs in Europe.",
"     </li>",
"     <li>",
"      Ringworm, a Trichophyton species, is the most common zoonotic disease transmitted from rodents to people [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/28,55\">",
"       28,55",
"      </a>",
"      ]. Parasitic diseases transmitted by rodents occur mostly in children and include teniasis (Hymenolepis nana and Hymenolepis diminuta), which can cause nausea, vomiting, and diarrhea, as well as sarcoptic mange (Trixacarus caviae) from guinea pigs (usually asymptomatic), but causes pruritic skin lesions in humans [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Zoonoses by wild rodents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hantavirus infection has been commonly associated with wild mice, there are no published reports related to transmission from pets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     BIRDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pet birds are associated with transmission to man of both bacterial and fungal infections.",
"   </p>",
"   <p>",
"    The most common pet-related avian bacterial zoonosis is infection due to Chlamydophila psittaci (formerly known as Chlamydia psittaci) (psittacosis). Birds may also carry Mycobacterium avium and Salmonella spp in their gastrointestinal tracts, but there is no evidence that pet birds transmit M. avium or Salmonella to man [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/56\">",
"     56",
"    </a>",
"    ]. In 2006, there were three outbreaks of salmonellosis that resulted from contact with chicks and other baby poultry (ducklings, goslings, and baby turkeys) purchased at agricultural feed stores in the springtime [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/57\">",
"     57",
"    </a>",
"    ]. From 2004 through 2011, there was also a prolonged, multistate outbreak of more than 300 cases of salmonellosis due to S. montevideo, where a mail-order hatchery for young poultry was identified as the source [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Transmission by bodily fluids",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psittacosis, also known as parrot fever and ornithosis, is a bacterial infection caused by Chlamydophila psittaci. Virtually all pet birds can carry C. psittaci, but psittacine birds are the most likely to be infected. Infected birds shed the bacteria through feces and nasal discharge, and humans become infected from exposure to these materials.",
"      <br/>",
"      <br/>",
"      From 1988 through 2003, 935 human cases of psittacosis were reported to the CDC, most resulted from exposure to infected pet birds, usually cockatiels, parakeets, parrots, and macaws [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/59\">",
"       59",
"      </a>",
"      ]. A case report of psittacosis in both members of an elderly couple who ran a pet shop serves as a classic example of environmental exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/14/8425?source=see_link\">",
"       \"Psittacosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cryptococcus neoformans has been found in soil samples from around the world in areas frequented by birds, especially pigeons and chickens. It colonizes the bird's gastrointestinal tract and is found in their excreta [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/61\">",
"       61",
"      </a>",
"      ]. Human cryptococcal disease (pneumonia or meningitis) associated with pet bird contact (eg, cockatoo, cockatiel) primarily is seen in immunocompromised hosts [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. Screening healthy birds for Cryptococcus neoformans is not recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/64\">",
"       64",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=see_link\">",
"       \"Cryptococcal infection outside the central nervous system\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Transmission by the avian environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histoplasma capsulatum is not transmitted from pet birds to man, as birds are not carriers of the fungus. H. capsulatum is found in areas such as bird roosts, as growth of the fungus is stimulated in bird droppings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis and clinical features of pulmonary histoplasmosis\", section on 'Reservoir'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Zoonoses from wild birds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wild birds, but not pet birds, have been associated with two avian viral zoonoses, avian influenza and West Nile virus infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14090?source=see_link\">",
"     \"Epidemiology, transmission, and pathogenesis of avian influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22264?source=see_link\">",
"     \"Clinical manifestations and diagnosis of West Nile virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     FISH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pet fish are very rarely associated with human infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/4\">",
"     4",
"    </a>",
"    ]. Most cases of fish-related human illness stems from the consumption of fish, rather than pet ownership.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Mycobacterium marinum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacterium marinum, causes fish tuberculosis and contaminates the water of aquaria housing infected fish. Humans develop M. marinum infection, \"fish tank granuloma\", when they sustain a minor skin injury while cleaning a fish tank [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/65\">",
"     65",
"    </a>",
"    ]. Other atypical Mycobacteria species, primarily M. fortuitum and M. chelonae, cause a similar disease both in fish and man [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human M. marinum infection presents as a cutaneous infection characterized by chronic skin papules, pustules, and ulcers that develop weeks following the injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=see_link\">",
"     \"Soft tissue infections following water exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Occupational exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional fish zoonoses are usually associated with occupational exposure (eg, fishermen) through spine puncture or open wounds and include Aeromonas hydrophila, Edwardsiella tarda, and Erysipelothrix rhusiopathiae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=see_link\">",
"     \"Soft tissue infections following water exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a case report, a woman with diabetes mellitus developed a thigh infection that drained foul-smelling pus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/67\">",
"     67",
"    </a>",
"    ]. Necrotizing fasciitis was diagnosed surgically and histopathologically and Erysipelothrix rhusiopathiae was isolated from the drainage. A pet goldfish might have been the source. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1478?source=see_link\">",
"     \"Erysipelothrix infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     REPTILES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estimated three percent of households in the United States own at least one reptile (turtles, snakes, iguanas, or other lizards) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Salmonella and other gastrointestinal pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common zoonoses related to pet reptiles is salmonellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/69\">",
"     69",
"    </a>",
"    ]. Seventy-four to &gt;90 percent of reptiles are colonized with Salmonella spp and shed the organism intermittently in their feces [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. Contact with reptiles and amphibians accounts for an estimated 74,000 (6 percent) of the approximately 1.2 million sporadic human Salmonella infections that occur annually in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/74\">",
"     74",
"    </a>",
"    ]. In a case controlled study of the epidemiology of sporadic Salmonella infection in infants, infants with Salmonella infection were most likely to have had reptile exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/75\">",
"     75",
"    </a>",
"    ]. In addition to salmonellosis, transmission of Yersinia, Campylobacter, and Aeromonas infection to humans has been associated with reptiles [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sale of turtles with a carapace of less than four inches was banned in the United States by the United States Food and Drug Administration (FDA) in 1975; this ban prevented an estimated 100,000 cases of salmonellosis annually in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/76\">",
"     76",
"    </a>",
"    ]. Nonetheless, a large multistate outbreak of Salmonella infections in 2007-2008, in part from small turtle exposure, resulted in over 100 cases of Salmonella paratyphi B var. Java infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/77\">",
"     77",
"    </a>",
"    ]. An illegal resurgence in the sale of small turtles resulted in at least six human cases of salmonellosis in Wisconsin and Wyoming [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/78\">",
"     78",
"    </a>",
"    ]. Several cases of salmonellosis related to small turtles, including a death in a three week old infant, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/79\">",
"     79",
"    </a>",
"    ]. A survey of fecal samples from reptiles (18 turtles, 71 lizards and 23 snakes) in a pet shop in Japan, found Salmonella spp were isolated from 83 (74.1 percent) of 112 samples [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/70\">",
"     70",
"    </a>",
"    ]. The predominant serovars were S. Bardo, S. Newport, and S. Panama, all capable of causing human salmonellosis.",
"   </p>",
"   <p>",
"    Contact with pet turtles has also been associated with Edwardsiella tarda gastroenteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/80\">",
"     80",
"    </a>",
"    ]. Lizards and snakes can transmit enteric pathogens such as Salmonella and Plesiomonas [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. The risk of salmonellosis from snakes is illustrated by a case of salmonellosis in a three month old infant whose father was a biology teacher [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/69\">",
"     69",
"    </a>",
"    ]. The infant presented with fever and bloody diarrhea, and stool culture grew Salmonella serotype Nima. The father handled a boa constrictor during biology class that he often draped over his shoulder. A stool culture from the snake grew the same Salmonella serotype. Although the father was careful to wash his hands after handling the snake, he did not change his clothing when he came home from work before holding his child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Wild reptile zoonoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parasitic and fungal infections may be transmitted by wild reptiles, although there are no reported cases associated with pet-reptile transmission. Pentastomiasis (Armillifer species) is a parasitic disease caused by worm-like arthropods that inhabit the respiratory system of the snake. Although usually asymptomatic in humans, the encapsulated larvae are sometimes found during laparotomies or are diagnosed by radiographic examination. Infection in North Americans is very rare with only eight cases reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/84\">",
"     84",
"    </a>",
"    ]. Most cases occur in people from West Africa and Congo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/85\">",
"     85",
"    </a>",
"    ]. Hypersensitivity or toxin release can cause neurologic findings and very rarely death [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fungal infection has not been described as a reptilian zoonosis. In a surveillance study of common garden lizards in Nigeria for pathogenic fungi, the most important pathogenic fungus isolated was Basidiobolus haptosporus, the agent of subcutaneous zygomycosis, which was found in the intestinal contents of 112 (56 percent) lizards [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/86\">",
"     86",
"    </a>",
"    ]. Other fungi isolated from lizards included Aspergillus spp in 24 (12 percent), Candida spp, Penicillium spp, and Fusarium spp each in 12 (six percent), and Mucor spp in eight (four percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/86\">",
"     86",
"    </a>",
"    ]. Although transmission from reptiles has not been directly linked to human disease, these fungi could cause serious disease in immunocompromised hosts. In 1995, a new species of Trichinella (Trichinella zimbabwensis) was discovered in farmed Nile crocodiles (Crocodylus niloticus) in Zimbabwe; further spread into wild reptiles has been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/87\">",
"     87",
"    </a>",
"    ]. Contact with exotic animals may allow for zoonotic spread of previously unknown parasites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     EXOTIC PETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zoonotic risks from exotic pets and wildlife used as pets are probably underestimated, since they may be traded illegally (thus, escaping standard surveillance systems), be fed exotic diets that may contain unusual pathogens, and harbor under-recognized pathogens. Public education about the risks from exotic pet trades, bushmeat, and wildlife should be augmented [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Ferrets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ferrets have been associated with Salmonella and Campylobacter, and less commonly with cryptosporidiosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/89\">",
"     89",
"    </a>",
"    ], toxocariasis, tuberculosis, leptospirosis and listeriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/28,90,91\">",
"     28,90,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Influenza is the most common zoonotic disease in ferrets [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/92\">",
"       92",
"      </a>",
"      ]. The ferret can develop influenza, but the course is usually benign. Human cases of influenza have occurred from contamination by aerosols from infected ferrets [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/93\">",
"       93",
"      </a>",
"      ]. The ferret has been used as an animal model for influenza research [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Giardia has recently been isolated from a ferret in a pet shop; the genotype suggested it could be a causative agent of human giardiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mycobacterium microti, known as vole tuberculosis and more commonly found in wild rodents than in pets, was isolated from a man with an illness featuring anorexia, weight loss, and malaise [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/95\">",
"       95",
"      </a>",
"      ]. M. microti was subsequently isolated from the man's pet ferret.",
"     </li>",
"     <li>",
"      Although rabies transmission from ferrets to humans has not been documented, rabies should be considered with any ferret that has acute onset of paralysis or behavioral changes and a condition that rapidly deteriorates despite veterinarian intervention; need for prophylaxis of contacts should be evaluated. Pet ferrets should be immunized for rabies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Hedgehogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hedgehogs are small, nocturnal, spiny-coated insectivores that have become popular as exotic pets [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/96\">",
"     96",
"    </a>",
"    ]. Hedgehogs pose a risk for a number of potential zoonotic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/97\">",
"     97",
"    </a>",
"    ]. The most common zoonosis is salmonellosis, several reports document transmission of Salmonella Tilene from hedgehog to humans, most cases occurring in children less than three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/98-100\">",
"     98-100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several reports document transmission of dermatophytes from hedgehogs to humans. Trichophyton mentagrophytes causes a pruritic eruption, which resolves spontaneously within two to three weeks after onset [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/101-103\">",
"     101-103",
"    </a>",
"    ]. In addition, human ringworm cases have been associated with persons handling hedgehogs, some for only one to two minutes in a pet store [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/102,103\">",
"     102,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other potential zoonoses associated with sick hedgehogs include, Yersinia pseudotuberculosis, Yersinia pestis, and Mycobacterium marinum, although no human infection directly related to hedgehog exposure due to these pathogens has been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/104-106\">",
"     104-106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Flying squirrels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flying squirrels have been reported to harbor Toxoplasma gondii, Staphylococci, as well as Rickettsia prowazekii (etiologic agent of epidemic typhus) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/19\">",
"     19",
"    </a>",
"    ]. There have been many reports of human typhus after contact with wild flying squirrels or their nests, but no reports of transmission from pet flying squirrels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Chinchillas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chinchillas can harbor agents of dermatophytoses, including Trichophyton and Microsporum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/108\">",
"     108",
"    </a>",
"    ], human pathogenic fungi, Aspergillus niger and Cladosporium species [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/13\">",
"     13",
"    </a>",
"    ], as well as the bacterial pathogens, Klebsiella pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/14\">",
"     14",
"    </a>",
"    ] and Pseudomonas aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/109\">",
"     109",
"    </a>",
"    ]. However, there are no reports of transmission of these potential zoonoses from pet chinchillas to man.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Monkeys",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monkeys can carry many diseases that infect humans, and monkey-human cross-species transmission could theoretically occur quite easily given the genetic similarity. However, very few reports of human infections related to pet monkey transmission exists in the published literature. Transmission can occur through contact with feces and secretions or through bites. A rare report documents transmission of both Shigella and Salmonella from asymptomatic pet spider monkeys to their owners [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     B virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most worrisome monkey-related zoonosis is B-virus (Cercopithecine herpesvirus 1) infection, which is transmitted directly from macaques through bites or scratches or from their tissues and fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/111\">",
"     111",
"    </a>",
"    ]. B virus infection is highly prevalent (80 to 90 percent) in adult macaques, with most animals showing no sign of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/112\">",
"     112",
"    </a>",
"    ]. Human disease, however, usually results in fatal encephalomyelitis or severe neurologic impairment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32583?source=see_link\">",
"     \"B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Simple precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures against the acquisition of infection from animals will generally include good hand-washing practices [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/50\">",
"     50",
"    </a>",
"    ]. In a study using systematic unannounced observations of behaviors at petting zoos, compliance with hand-washing ranged from 0 through 77 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/10\">",
"     10",
"    </a>",
"    ]. Predictors for increased hand hygiene compliance included simple measures, such as the availability of hand hygiene stations at the exit from the petting zoo area.",
"   </p>",
"   <p>",
"    Although pets have been implicated in transmission of zoonoses to their owners, risk of transmission from contact with pets is low and may be further reduced by simple precautions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pets should be seen by a veterinarian on a regular basis, treated promptly for diarrhea and dermatoses and, where appropriate, should be vaccinated for rabies.",
"     </li>",
"     <li>",
"      Pets should be fed high quality commercial food and should not eat raw meat or eggs. They should not be allowed to eat garbage, feces, or hunt [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/53\">",
"       53",
"      </a>",
"      ]. They should not be allowed to drink non-potable water (eg, surface water or toilet water).",
"     </li>",
"     <li>",
"      Young pets present a greater risk for disease than older pets, as they are more likely to engage in playful nipping and biting, behavior which may transmit zoonotic pathogens.",
"     </li>",
"     <li>",
"      Owners should wash their hands following contact with their pet or cleaning of their cages.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Measures to prevent disease in public settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC recommends that organizers of public venues (eg, state fairs, pet stores, circuses, child care facilities) should [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/113\">",
"     113",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prohibit food in animal areas",
"     </li>",
"     <li>",
"      Provide a transition between animal areas and nonanimal areas",
"     </li>",
"     <li>",
"      Share information about disease risk and prevention with attendees",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts and pets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Groups at high risk for serious infection from pets include persons with waning immunity (eg, older adults); children less than five years old; and people who are pregnant, immunocompromised (eg, persons with human immunodeficiency",
"    <span class=\"nowrap\">",
"     virus/acquired",
"    </span>",
"    immunodeficiency syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/114\">",
"     114",
"    </a>",
"    ], without a functioning spleen, or on immunosuppressive therapy), or cognitively impaired. To avoid infections, people at higher risk should take particular precautions with any animal contact. In addition to thorough and frequent hand washing, these precautions might include avoiding contact with animals and their environment (eg, pens, bedding, and manure). For children, risk for exposure might be reduced if they are closely supervised by adults, carried by adults in animal areas, or have animal contact only over a barrier. These measures discourage animals from jumping on or nuzzling children and minimize contact with feces and soiled bedding.",
"   </p>",
"   <p>",
"    Numerous reports exist of the transmission of zoonoses to humans during and after solid organ and hematopoietic stem cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/115\">",
"     115",
"    </a>",
"    ]. Donor-derived infections from West Nile virus infection, Chagas disease, toxoplasmosis, rabies, lymphocytic choriomeningitis virus infection, and infection due to Brucella species have all been reported. Most zoonoses present as a primary infection in the post-transplant period; immunocompromised patients are more likely to experience significant morbidity and mortality from these infections. Risks of zoonotic infection in transplant recipients could be reduced by patient education.",
"   </p>",
"   <p>",
"    The United States Public Health Service and the Infectious Diseases Society of America have issued formal recommendation for HIV positive people who desire pet contact [",
"    <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/64\">",
"     64",
"    </a>",
"    ]. The guidelines specify:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When obtaining a new pet, HIV-infected persons should avoid animals aged &lt;6 months (or &lt;1 year for cats) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/22/26986/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HIV-infected persons should be cautious when obtaining a pet from pet-breeding facilities, pet stores, and animal shelters, because of highly variable hygienic and sanitary conditions. Stray animals should be avoided.",
"     </li>",
"     <li>",
"      HIV-infected persons should avoid contact with any animal that has diarrhea. HIV-infected pet owners should seek veterinary care for animals with diarrheal illness, and a fecal sample from such animals should be examined for Cryptosporidium, Salmonella, and Campylobacter.",
"     </li>",
"     <li>",
"      HIV-infected persons should wash their hands after handling pets, including before eating, and should avoid contact with pets' feces.",
"     </li>",
"     <li>",
"      HIV-infected persons should avoid contact with reptiles (eg, snakes, lizards, iguanas, and turtles) as well as chicks and ducklings because of the risk for salmonellosis.",
"     </li>",
"     <li>",
"      Gloves should be used during aquarium cleaning to reduce the risk for infection with Mycobacterium marinum.",
"     </li>",
"     <li>",
"      Contact with exotic pets (eg, nonhuman primates) should be avoided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Centers for Disease Control offer a \"Pet-Scription\" at",
"    <a class=\"external\" href=\"file://www.cdc.gov/healthypets/health_prof.htm\">",
"     file://www.cdc.gov/healthypets/health_prof.htm#petscription",
"    </a>",
"    , which provides patients with more information about pet and infection risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"     Tetanus immune globulin",
"    </a>",
"    and tetanus toxoid should be administered to all bite patients who have had two or fewer primary immunizations. Tetanus toxoid alone can be given to those who have completed a primary immunization series but who have not received a booster for more than five years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/61/11217?source=see_link\">",
"       \"Patient information: Psittacosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=see_link\">",
"       \"Patient information: Animal bites (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A zoonosis is an animal disease that is transmissible to humans. Humans are usually an accidental host that acquires disease through close contact with an infected animal, who may or may not be symptomatic. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children are at highest risk for infection because they are more likely to have close contact with pets. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pets are responsible for transmission of an extensive array of bacterial, fungal, and parasitic zoonotic pathogens. The route of transmission can be through the saliva (eg, bites or contaminated scratches), feces, respiratory secretions, direct contact, or by the animal acting as a vehicle and source of tick or flea exposure. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although pets have been implicated in transmission of zoonoses to their owners, risk of transmission from contact with pets is low and may be further reduced by simple precautions. (See",
"      <a class=\"local\" href=\"#H49\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/1\">",
"      Anderson WP, Reid CM, Jennings GL. Pet ownership and risk factors for cardiovascular disease. Med J Aust 1992; 157:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/2\">",
"      Parslow RA, Jorm AF. Pet ownership and risk factors for cardiovascular disease: another look. Med J Aust 2003; 179:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/3\">",
"      Stasi MF, Amati D, Costa C, et al. Pet-therapy: a trial for institutionalized frail elderly patients. Arch Gerontol Geriatr Suppl 2004; :407.",
"     </a>",
"    </li>",
"    <li>",
"     Bisseru B. Disease of Man Acquired from His Pets, J. B. Lippincott Company, Philadelphia 1967.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/5\">",
"      Elliot DL, Tolle SW, Goldberg L, Miller JB. Pet-associated illness. N Engl J Med 1985; 313:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/6\">",
"      Trevejo RT, Barr MC, Robinson RA. Important emerging bacterial zoonotic infections affecting the immunocompromised. Vet Res 2005; 36:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/7\">",
"      Pickering LK, Marano N, Bocchini JA, et al. Exposure to nontraditional pets at home and to animals in public settings: risks to children. Pediatrics 2008; 122:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/8\">",
"      National Association of State Public Health Veterinarians, Inc. (NASPHV), Centers for Disease Control and Prevention (CDC), Council of State and Territorial Epidemiologists, American Veterinary Medical Association. Compendium of measures to prevent disease associated with animals in public settings, 2007: National Association of State Public Health Veterinarians, Inc. (NASPHV). MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/9\">",
"      Steinmuller N, Demma L, Bender JB, et al. Outbreaks of enteric disease associated with animal contact: not just a foodborne problem anymore. Clin Infect Dis 2006; 43:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/10\">",
"      Weese JS, McCarthy L, Mossop M, et al. Observation of practices at petting zoos and the potential impact on zoonotic disease transmission. Clin Infect Dis 2007; 45:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/11\">",
"      Ward MP, Brady TH, Cou&euml;til LL, et al. Investigation and control of an outbreak of salmonellosis caused by multidrug-resistant Salmonella typhimurium in a population of hospitalized horses. Vet Microbiol 2005; 107:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/12\">",
"      McKenzie DM, Diffay BC. Diarrhoea associated with cryptosporidial oocyst shedding in a quarterhorse stallion. Aust Vet J 2000; 78:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/13\">",
"      Aho R. Saprophytic fungi isolated from the hair of domestic and laboratory animals with suspected dermatophytosis. Mycopathologia 1983; 83:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/14\">",
"      Bartoszcze M, Matras J, Palec S, et al. Klebsiella pneumoniae infection in chinchillas. Vet Rec 1990; 127:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/15\">",
"      Traub R, Wade S, Read C, et al. Molecular characterization of potentially zoonotic isolates of Giardia duodenalis in horses. Vet Parasitol 2005; 130:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/16\">",
"      Olson ME, Thorlakson CL, Deselliers L, et al. Giardia and Cryptosporidium in Canadian farm animals. Vet Parasitol 1997; 68:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/17\">",
"      Madewell BR, Tang YJ, Jang S, et al. Apparent outbreaks of Clostridium difficile-associated diarrhea in horses in a veterinary medical teaching hospital. J Vet Diagn Invest 1995; 7:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/18\">",
"      Cohen ND, O'Conor MS, Chaffin MK, Martens RJ. Farm characteristics and management practices associated with development of Rhodococcus equi pneumonia in foals. J Am Vet Med Assoc 2005; 226:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/19\">",
"      Rosen T, Jablon J. Infectious threats from exotic pets: dermatological implications. Dermatol Clin 2003; 21:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/20\">",
"      Cvetnic Z, Spicic S, Curic S, et al. Isolation of Brucella suis biovar 3 from horses in Croatia. Vet Rec 2005; 156:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/21\">",
"      Carrigan MJ, Cockram FA, Nash GV. Brucella abortus biotype 1 arthritis in a horse. Aust Vet J 1987; 64:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/22\">",
"      Marrie TJ. Coxiella burnetii pneumonia. Eur Respir J 2003; 21:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/23\">",
"      Somma-Moreira RE, Caffarena RM, Somma S, et al. Analysis of Q fever in Uruguay. Rev Infect Dis 1987; 9:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/24\">",
"      Gibbs EP. Equine viral encephalitis. Equine Vet J 1976; 8:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/25\">",
"      Krebs JW, Mandel EJ, Swerdlow DL, Rupprecht CE. Rabies surveillance in the United States during 2004. J Am Vet Med Assoc 2005; 227:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/26\">",
"      Feder HM, Nelson RS, Cartter ML, Sadre I. Rabies prophylaxis following the feeding of a rabid pony. Clin Pediatr (Phila) 1998; 37:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Human rabies--Florida, 2004. MMWR Morb Mortal Wkly Rep 2005; 54:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/28\">",
"      Chomel BB. Zoonoses of house pets other than dogs, cats and birds. Pediatr Infect Dis J 1992; 11:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/29\">",
"      Shiibashi T, Imai T, Sato Y, et al. Cryptosporidium infection in juvenile pet rabbits. J Vet Med Sci 2006; 68:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/30\">",
"      Rougier S, Galland D, Boucher S, et al. Epidemiology and susceptibility of pathogenic bacteria responsible for upper respiratory tract infections in pet rabbits. Vet Microbiol 2006; 115:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/31\">",
"      Donnio PY, Le Goff C, Avril JL, et al. Pasteurella multocida: oropharyngeal carriage and antibody response in breeders. Vet Res 1994; 25:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/32\">",
"      Gueirard P, Weber C, Le Coustumier A, Guiso N. Human Bordetella bronchiseptica infection related to contact with infected animals: persistence of bacteria in host. J Clin Microbiol 1995; 33:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/33\">",
"      Eidson M, Matthews SD, Willsey AL, et al. Rabies virus infection in a pet guinea pig and seven pet rabbits. J Am Vet Med Assoc 2005; 227:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/34\">",
"      Torres-Rodr&iacute;guez JM, Dronda MA, Rossell J, Madrenys N. Incidence of dermatophytoses in rabbit farms in Catalonia, Spain, and its repercussion on human health. Eur J Epidemiol 1992; 8:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/35\">",
"      Skorepov&aacute; M, Stork J, Hrab&aacute;kov&aacute; J. Case reports. Tinea gladiatorum due to Trichophyton mentagrophytes. Mycoses 2002; 45:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/36\">",
"      Parish LC, Schwartzman RM. Zoonoses of dermatological interest. Semin Dermatol 1993; 12:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/37\">",
"      Centers for Disease Control and Prevention (CDC). Tularemia transmitted by insect bites--Wyoming, 2001-2003. MMWR Morb Mortal Wkly Rep 2005; 54:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/38\">",
"      Holman PJ, Spencer AM, Droleskey RE, et al. In vitro cultivation of a zoonotic Babesia sp. isolated from eastern cottontail rabbits (Sylvilagus floridanus) on Nantucket Island, Massachusetts. J Clin Microbiol 2005; 43:3995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/39\">",
"      Goethert HK, Telford SR 3rd. Enzootic transmission of Babesia divergens among cottontail rabbits on Nantucket Island, Massachusetts. Am J Trop Med Hyg 2003; 69:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/40\">",
"      Goethert HK, Telford SR 3rd. Enzootic transmission of Anaplasma bovis in Nantucket cottontail rabbits. J Clin Microbiol 2003; 41:3744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/41\">",
"      Leavell UW Jr, McNamara MJ, Muelling R, et al. Orf. Report of 19 human cases with clinical and pathological observations. JAMA 1968; 204:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/42\">",
"      Roess AA, Galan A, Kitces E, et al. Novel deer-associated parapoxvirus infection in deer hunters. N Engl J Med 2010; 363:2621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/43\">",
"      Centers for Disease Control and Prevention (CDC). Human Orf virus infection from household exposures - United States, 2009-2011. MMWR Morb Mortal Wkly Rep 2012; 61:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/44\">",
"      Groves RW, Wilson-Jones E, MacDonald DM. Human orf and milkers' nodule: a clinicopathologic study. J Am Acad Dermatol 1991; 25:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/45\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of multidrug-resistant Salmonella typhimurium associated with rodents purchased at retail pet stores--United States, December 2003-October 2004. MMWR Morb Mortal Wkly Rep 2005; 54:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/46\">",
"      Swanson SJ, Snider C, Braden CR, et al. Multidrug-resistant Salmonella enterica serotype Typhimurium associated with pet rodents. N Engl J Med 2007; 356:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/47\">",
"      Centers for Disease Control and Prevention (CDC). Tularemia associated with a hamster bite--Colorado, 2004. MMWR Morb Mortal Wkly Rep 2005; 53:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/48\">",
"      Avashia SB, Petersen JM, Lindley CM, et al. First reported prairie dog-to-human tularemia transmission, Texas, 2002. Emerg Infect Dis 2004; 10:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/49\">",
"      Shvartsblat S, Kochie M, Harber P, Howard J. Fatal rat bite fever in a pet shop employee. Am J Ind Med 2004; 45:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/50\">",
"      Centers for Disease Control and Prevention (CDC). Lymphocytic choriomeningitis virus infection in organ transplant recipients--Massachusetts, Rhode Island, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/51\">",
"      Barton LL, Mets MB. Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. Clin Infect Dis 2001; 33:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/52\">",
"      Gregg MB. Recent outbreaks of lymphocytic choriomeningitis in the United States of America. Bull World Health Organ 1975; 52:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/53\">",
"      Reed KD, Melski JW, Graham MB, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 2004; 350:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/54\">",
"      H&ouml;nlinger B, Huemer HP, Romani N, et al. Generalized cowpox infection probably transmitted from a rat. Br J Dermatol 2005; 153:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/55\">",
"      Pollock C. Fungal diseases of laboratory rodents. Vet Clin North Am Exot Anim Pract 2003; 6:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/56\">",
"      Thegerstr&ouml;m J, Marklund BI, Hoffner S, et al. Mycobacterium avium with the bird type IS1245 RFLP profile is commonly found in wild and domestic animals, but rarely in humans. Scand J Infect Dis 2005; 37:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/57\">",
"      Centers for Disease Control and Prevention (CDC). Three outbreaks of salmonellosis associated with baby poultry from three hatcheries--United States, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/58\">",
"      Gaffga NH, Barton Behravesh C, Ettestad PJ, et al. Outbreak of salmonellosis linked to live poultry from a mail-order hatchery. N Engl J Med 2012; 366:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/59\">",
"      Smith KA, Bradley KK, Stobierski MG, et al. Compendium of measures to control Chlamydophila psittaci (formerly Chlamydia psittaci) infection among humans (psittacosis) and pet birds, 2005. J Am Vet Med Assoc 2005; 226:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/60\">",
"      Saito T, Ohnishi J, Mori Y, et al. Infection by Chlamydophilia avium in an elderly couple working in a pet shop. J Clin Microbiol 2005; 43:3011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/61\">",
"      Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 1991; 13:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/62\">",
"      Nosanchuk JD, Shoham S, Fries BC, et al. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med 2000; 132:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/63\">",
"      Shrestha RK, Stoller JK, Honari G, et al. Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel. Respir Care 2004; 49:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/64\">",
"      Kaplan JE, Masur H, Holmes KK, et al. Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/65\">",
"      Decostere A, Hermans K, Haesebrouck F. Piscine mycobacteriosis: a literature review covering the agent and the disease it causes in fish and humans. Vet Microbiol 2004; 99:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/66\">",
"      Kern W, Vanek E, Jungbluth H. [Fish breeder granuloma: infection caused by Mycobacterium marinum and other atypical mycobacteria in the human. Analysis of 8 cases and review of the literature]. Med Klin (Munich) 1989; 84:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/67\">",
"      Simionescu R, Grover S, Shekar R, West BC. Necrotizing fasciitis caused by Erysipelothrix rhusiopathiae. South Med J 2003; 96:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/68\">",
"      Wise JK, Heathcott BL, Gonzalez ML. Results of the AVMA survey on companion animal ownership in US pet-owning households. American Veterinary Medical Association. J Am Vet Med Assoc 2002; 221:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/69\">",
"      Centers for Disease Control and Prevention (CDC). Reptile-associated salmonellosis--selected states, 1998-2002. MMWR Morb Mortal Wkly Rep 2003; 52:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/70\">",
"      Nakadai A, Kuroki T, Kato Y, et al. Prevalence of Salmonella spp. in pet reptiles in Japan. J Vet Med Sci 2005; 67:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/71\">",
"      Chiodini RJ, Sundberg JP. Salmonellosis in reptiles: a review. Am J Epidemiol 1981; 113:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/72\">",
"      Centers for Disease Control and Prevention (CDC). Reptile-associated salmonellosis--selected states, 1996-1998. MMWR Morb Mortal Wkly Rep 1999; 48:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/73\">",
"      Burnham BR, Atchley DH, DeFusco RP, et al. Prevalence of fecal shedding of Salmonella organisms among captive green iguanas and potential public health implications. J Am Vet Med Assoc 1998; 213:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/74\">",
"      Mermin J, Hoar B, Angulo FJ. Iguanas and Salmonella marina infection in children: a reflection of the increasing incidence of reptile-associated salmonellosis in the United States. Pediatrics 1997; 99:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/75\">",
"      Jones TF, Ingram LA, Fullerton KE, et al. A case-control study of the epidemiology of sporadic Salmonella infection in infants. Pediatrics 2006; 118:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/76\">",
"      Cohen ML, Potter M, Pollard R, Feldman RA. Turtle-associated salmonellosis in the United States. Effect of Public Health Action, 1970 to 1976. JAMA 1980; 243:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/77\">",
"      Centers for Disease Control and Prevention (CDC). Multistate outbreak of human Salmonella infections associated with exposure to turtles--United States, 2007-2008. MMWR Morb Mortal Wkly Rep 2008; 57:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/78\">",
"      Centers for Disease Control and Prevention (CDC). Salmonellosis associated with pet turtles--Wisconsin and Wyoming, 2004. MMWR Morb Mortal Wkly Rep 2005; 54:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/79\">",
"      Centers for Disease Control and Prevention (CDC). Turtle-associated salmonellosis in humans--United States, 2006-2007. MMWR Morb Mortal Wkly Rep 2007; 56:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/80\">",
"      Nagel P, Serritella A, Layden TJ. Edwardsiella tarda gastroenteritis associated with a pet turtle. Gastroenterology 1982; 82:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/81\">",
"      Wells EV, Boulton M, Hall W, Bidol SA. Reptile-associated salmonellosis in preschool-aged children in Michigan, January 2001-June 2003. Clin Infect Dis 2004; 39:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/82\">",
"      Pasmans F, Martel A, Boyen F, et al. Characterization of Salmonella isolates from captive lizards. Vet Microbiol 2005; 110:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/83\">",
"      Davis WA 2nd, Chretien JH, Garagusi VF, Goldstein MA. Snake-to-human transmission of Aeromonas (Pl) shigelloides resulting in gastroenteritis. South Med J 1978; 71:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/84\">",
"      Guardia SN, Sepp H, Scholten T, Morava-Protzner I. Pentastomiasis in Canada. Arch Pathol Lab Med 1991; 115:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/85\">",
"      Lavarde V, Fornes P. Lethal infection due to Armillifer armillatus (Porocephalida): A snake-related parasitic disease. Clin Infect Dis 1999; 29:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/86\">",
"      Enweani IB, Uwajeh JC, Bello CS, Ndip RN. Fungal carriage in lizards. Mycoses 1997; 40:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/87\">",
"      Pozio E, Foggin CM, Gelanew T, et al. Trichinella zimbabwensis in wild reptiles of Zimbabwe and Mozambique and farmed reptiles of Ethiopia. Vet Parasitol 2007; 143:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/88\">",
"      Chomel BB, Belotto A, Meslin FX. Wildlife, exotic pets, and emerging zoonoses. Emerg Infect Dis 2007; 13:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/89\">",
"      Rehg JE, Gigliotti F, Stokes DC. Cryptosporidiosis in ferrets. Lab Anim Sci 1988; 38:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/90\">",
"      MORRIS JA, COBURN DR. The isolation of Salmonella typhi-murium from ferrets. J Bacteriol 1948; 55:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/91\">",
"      MORRIS JA, NORMAN MC. The isolation of Listeria monocytogenes from ferrets. J Bacteriol 1950; 59:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/92\">",
"      Langlois I. Viral diseases of ferrets. Vet Clin North Am Exot Anim Pract 2005; 8:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/93\">",
"      Marini RP, Adkins JA, Fox JG. Proven or potential zoonotic diseases of ferrets. J Am Vet Med Assoc 1989; 195:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/94\">",
"      Abe N, Read C, Thompson RC, Iseki M. Zoonotic genotype of Giardia intestinalis detected in a ferret. J Parasitol 2005; 91:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/95\">",
"      Cavanagh R, Begon M, Bennett M, et al. Mycobacterium microti infection (vole tuberculosis) in wild rodent populations. J Clin Microbiol 2002; 40:3281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/96\">",
"      Hoefer HL. Hedgehogs. Vet Clin North Am Small Anim Pract 1994; 24:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/97\">",
"      Riley PY, Chomel BB. Hedgehog zoonoses. Emerg Infect Dis 2005; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/98\">",
"      Woodward DL, Khakhria R, Johnson WM. Human salmonellosis associated with exotic pets. J Clin Microbiol 1997; 35:2786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/99\">",
"      Centers for Disease Control and Prevention (CDC). African pygmy hedgehog-associated salmonellosis--Washington, 1994. MMWR Morb Mortal Wkly Rep 1995; 44:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/100\">",
"      Craig C, Styliadis S, Woodward D, Werker D. African pygmy hedgehog--associated Salmonella tilene in Canada. Can Commun Dis Rep 1997; 23:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/101\">",
"      Gregory MW, English MP. Arthroderma benhamiae infection in the Central African hedgehog Erinaceus albiventris, and a report of a human case. Mycopathologia 1975; 55:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/102\">",
"      Philpot CM, Bowen RG. Hazards from hedgehogs: two case reports with a survey of the epidemiology of hedgehog ringworm. Clin Exp Dermatol 1992; 17:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/103\">",
"      Rosen T. Hazardous hedgehogs. South Med J 2000; 93:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/104\">",
"      Keymer IF, Gibson EA, Reynolds DJ. Zoonoses and other findings in hedgehogs (Erinaceus europaeus): a survey of mortality and review of the literature. Vet Rec 1991; 128:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/105\">",
"      Tappe JP, Weitzman I, Liu S, et al. Systemic Mycobacterium marinum infection in a European hedgehog. J Am Vet Med Assoc 1983; 183:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/106\">",
"      Duplantier JM, Duchemin JB, Chanteau S, Carniel E. From the recent lessons of the Malagasy foci towards a global understanding of the factors involved in plague reemergence. Vet Res 2005; 36:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/107\">",
"      Reynolds MG, Krebs JS, Comer JA, et al. Flying squirrel-associated typhus, United States. Emerg Infect Dis 2003; 9:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/108\">",
"      Marshall KL. Fungal diseases in small mammals: therapeutic trends and zoonotic considerations. Vet Clin North Am Exot Anim Pract 2003; 6:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/109\">",
"      Doerning BJ, Brammer DW, Rush HG. Pseudomonas aeruginosa infection in a Chinchilla lanigera. Lab Anim 1993; 27:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/110\">",
"      Fox JG. Transmissible drug resistance in Shigella and Salmonella isolated from pet monkeys and their owners. J Med Primatol 1975; 4:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/111\">",
"      Huff JL, Barry PA. B-virus (Cercopithecine herpesvirus 1) infection in humans and macaques: potential for zoonotic disease. Emerg Infect Dis 2003; 9:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/112\">",
"      Ostrowski SR, Leslie MJ, Parrott T, et al. B-virus from pet macaque monkeys: an emerging threat in the United States? Emerg Infect Dis 1998; 4:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/113\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/114\">",
"      Glaser CA, Angulo FJ, Rooney JA. Animal-associated opportunistic infections among persons infected with the human immunodeficiency virus. Clin Infect Dis 1994; 18:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/115\">",
"      Kotton CN. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. Clin Infect Dis 2007; 44:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/22/26986/abstract/116\">",
"      Robinson RA, Pugh RN. Dogs, zoonoses and immunosuppression. J R Soc Promot Health 2002; 122:95.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5531 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26986=[""].join("\n");
var outline_f26_22_26986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H55\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HORSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fecal transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Salmonella",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Campylobacter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cryptosporidium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Giardia lamblia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Clostridium difficile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Aerosol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Rhodococcus equi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Brucella",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Coxiella burnetii",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mosquito-borne disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Equine encephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Infected saliva",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Rabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RABBITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Respiratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cutaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Zoonoses from wild rabbits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7012451\">",
"      DEER, SHEEP, CATTLE AND GOATS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      RODENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Transmission by feces",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Transmission by infected saliva (bites)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Direct contact or aerosol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Zoonoses by wild rodents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      BIRDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Transmission by bodily fluids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Transmission by the avian environment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Zoonoses from wild birds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      FISH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Mycobacterium marinum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Occupational exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      REPTILES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Salmonella and other gastrointestinal pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Wild reptile zoonoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      EXOTIC PETS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Ferrets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Hedgehogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Flying squirrels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Chinchillas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Monkeys",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - B virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Simple precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Measures to prevent disease in public settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Immunocompromised hosts and pets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=related_link\">",
"      Approach to the patient with nontyphoidal Salmonella in a stool culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=related_link\">",
"      Arthropod-borne encephalitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32583?source=related_link\">",
"      B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18791?source=related_link\">",
"      Clinical features; diagnosis; therapy; and prevention of Rhodococcus equi infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12502?source=related_link\">",
"      Clinical manifestations and diagnosis of Q fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22264?source=related_link\">",
"      Clinical manifestations and diagnosis of West Nile virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=related_link\">",
"      Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29624?source=related_link\">",
"      Clinical manifestations and diagnosis of rabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of Campylobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of brucellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=related_link\">",
"      Cryptococcal infection outside the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13848?source=related_link\">",
"      Epidemiology and diagnosis of hantavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42248?source=related_link\">",
"      Epidemiology and pathogenesis of babesiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14090?source=related_link\">",
"      Epidemiology, transmission, and pathogenesis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1478?source=related_link\">",
"      Erysipelothrix infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=related_link\">",
"      Human ehrlichiosis and anaplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22357?source=related_link\">",
"      Microbiology and epidemiology of Q fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=related_link\">",
"      Microbiology and epidemiology of salmonellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18745?source=related_link\">",
"      Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37814?source=related_link\">",
"      Microbiology; pathogenesis; and epidemiology of Rhodococcus equi infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16439?source=related_link\">",
"      Monkeypox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=related_link\">",
"      Pathogenesis and clinical features of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=related_link\">",
"      Patient information: Animal bites (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/61/11217?source=related_link\">",
"      Patient information: Psittacosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/14/8425?source=related_link\">",
"      Psittacosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=related_link\">",
"      Rabies immune globulin and vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1413?source=related_link\">",
"      Rat bite fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=related_link\">",
"      Soft tissue infections due to dog and cat bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=related_link\">",
"      Soft tissue infections following water exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31401?source=related_link\">",
"      Zoonoses from cats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29065?source=related_link\">",
"      Zoonoses from dogs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_22_26987="DCIS versus LCIS";
var content_f26_22_26987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparative features of ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        DCIS",
"       </td>",
"       <td class=\"subtitle1\">",
"        LCIS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presentation",
"       </td>",
"       <td>",
"        Incidental finding, mammographic abnormality, occasionally palpable, unifocal",
"       </td>",
"       <td>",
"        Incidental finding, often multifocal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Predominant location",
"       </td>",
"       <td>",
"        Ducts",
"       </td>",
"       <td>",
"        Lobules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cell size",
"       </td>",
"       <td>",
"        Medium or large",
"       </td>",
"       <td>",
"        Small",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pattern",
"       </td>",
"       <td>",
"        Comedo, cribriform, micropapillary, papillary, solid",
"       </td>",
"       <td>",
"        Solid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcifications",
"       </td>",
"       <td>",
"        Yes or no",
"       </td>",
"       <td>",
"        Usually no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk of subsequent invasive cancer",
"       </td>",
"       <td>",
"        Higher",
"       </td>",
"       <td>",
"        Lower",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Location of subsequent invasive cancer",
"       </td>",
"       <td>",
"        Ipsilateral",
"       </td>",
"       <td>",
"        Ipsilateral or contraleteral",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26987=[""].join("\n");
var outline_f26_22_26987=null;
var title_f26_22_26988="Inotropic drugs";
var content_f26_22_26988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Inotropic infusions used for management of a potential pediatric organ donor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Milrinone",
"         </strong>",
"        </p>",
"        <p>",
"         (Primacor&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        0.25-0.75 mcg/kg/min IV",
"       </td>",
"       <td>",
"        <p>",
"         Loading dose: 50 mcg/kg",
"        </p>",
"        <p>",
"         Hypotension can occur",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Dopamine",
"        </strong>",
"       </td>",
"       <td>",
"        2-20 mcg/kg/min IV",
"       </td>",
"       <td>",
"        Titrate to desired blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Dobutamine",
"         </strong>",
"        </p>",
"        <p>",
"         (Dobutrex&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        2-20 mcg/kg/min IV",
"       </td>",
"       <td>",
"        Titrate to desired blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Epinephrine",
"        </strong>",
"       </td>",
"       <td>",
"        0.1-1 mcg/kg/min IV",
"       </td>",
"       <td>",
"        Titrate to desired blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Norepinephrine",
"         </strong>",
"        </p>",
"        <p>",
"         (Levophed&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        0.05-2 mcg/kg/min IV",
"       </td>",
"       <td>",
"        Titrate to desired blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Phenylephrine",
"         </strong>",
"        </p>",
"        <p>",
"         (Neo-Synephrine&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        0.1-0.5 mcg/kg/min IV",
"       </td>",
"       <td>",
"        <p>",
"         Bolus: 5-20 mcg/kg",
"        </p>",
"        <p>",
"         Titrate to desired blood pressure",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Vasopressin",
"         </strong>",
"        </p>",
"        <p>",
"         (Pitressin&reg;)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0.3-2 milli-units/kg/min IV",
"        </p>",
"        <p>",
"         <strong>",
"          Note: Dosing is different for treatment of diabetes insipidus",
"         </strong>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Limited data in children",
"        </p>",
"        <p>",
"         Not recommended as first line therapy",
"        </p>",
"        <p>",
"         Titrate to desired blood pressure",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        Inotropic agents are used for low cardiac output states to improve end organ perfusion. These agents should be titrated to maintain a normal blood pressure for age. Blood pressure alone does not indicate adequate tissue perfusion. Serum biomarkers such as lactate should be followed as inotropic support is titrated.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nakagawa, TA. Pediatric donor management guidelines. NATCO, The Organization for Transplant Professionals, 2008. p.5.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26988=[""].join("\n");
var outline_f26_22_26988=null;
var title_f26_22_26989="Osmolytes and hyponatremia";
var content_f26_22_26989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Cerebral osmotic adaptation to severe hyponatremia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 222px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in brain water, sodium plus potassium content, and three organic solutes - inositol, glutamine, and taurine - two and seven days after the onset of severe hyponatremia (plasma sodium concentration less than 110 meq/L). The numbers at the bottom represent the baseline values. The return of brain water toward normal at day 7 is due to loss of sodium, potassium, and the organic solutes (called osmolytes). Although the absolute osmolyte loss is less than that of sodium plus potassium, the fractional loss is much greater - 36 of 60 or 60 percent versus 60 of 670 or less than 10 percent. Preferential osmolyte loss has the added advantage of not interfering with protein function within the cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Verbalis, JG, Gullans, SR, Brain Res 1991; 567:274.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26989=[""].join("\n");
var outline_f26_22_26989=null;
var title_f26_22_26990="Tibial bowing in osteomalacia";
var content_f26_22_26990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tibial bowing in osteomalacia: Radiographic findings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 230px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tibial shortening and bowing in a man with vitamin D resistant rickets. A surgical osteotomy was performed to correct the tibial bending (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of CJ Menkes, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26990=[""].join("\n");
var outline_f26_22_26990=null;
var title_f26_22_26991="Transverse palmar crease";
var content_f26_22_26991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse palmar crease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 271px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clark DA. Atlas of Neonatology, WB Saunders, Philadelphia 2000. Copyright &copy; 2000 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_22_26991=[""].join("\n");
var outline_f26_22_26991=null;
